Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults by Horne, David J et al.
Cochrane Database of Systematic Reviews
Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary
tuberculosis and rifampicin resistance in adults (Review)
Horne DJ, Kohli M, Zifodya JS, Schiller I, Dendukuri N, Tollefson D, Schumacher SG, Ochodo EA,
Pai M, Steingart KR
Horne DJ, Kohli M, Zifodya JS, Schiller I, Dendukuri N, Tollefson D, Schumacher SG, Ochodo EA, Pai M, Steingart KR.
Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.
Cochrane Database of Systematic Reviews 2019, Issue 6. Art. No.: CD009593.
DOI: 10.1002/14651858.CD009593.pub4.
www.cochranelibrary.com
Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
6BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
11OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
17RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Figure 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Figure 7. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
Figure 8. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Figure 9. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
Figure 10. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
Figure 11. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Figure 12. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
Figure 13. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Figure 14. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
Figure 15. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
Figure 16. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Figure 17. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Figure 18. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
Figure 19. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
Figure 20. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
Figure 21. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
46ADDITIONAL SUMMARY OF FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . .
49DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
53AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
53ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
53REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
75CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
277DATA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Test 1. Xpert MTB/RIF for detection of pulmonary tuberculosis (PTB). . . . . . . . . . . . . . . . . 278
Test 2. Xpert Ultra for detection of PTB. . . . . . . . . . . . . . . . . . . . . . . . . . . 281
Test 3. Smear-positive, Xpert MTB/RIF. . . . . . . . . . . . . . . . . . . . . . . . . . . . 281
Test 4. Smear-positive, Xpert MTB/RIF, direct comparison Xpert MTB/RIF vs Xpert Ultra. . . . . . . . . . 283
Test 5. Smear-positive, Xpert Ultra, direct comparison Xpert MTB/RIF vs Xpert Ultra. . . . . . . . . . . 283
Test 6. Smear-negative, Xpert MTB/RIF. . . . . . . . . . . . . . . . . . . . . . . . . . . . 284
Test 7. Smear-negative, Xpert MTB/RIF, direct comparison Xpert MTB/RIF vs Xpert Ultra. . . . . . . . . . 286
Test 8. Smear-negative, Xpert Ultra, direct comparison Xpert MTB/RIF vs Xpert Ultra. . . . . . . . . . . 286
Test 9. HIV-negative, Xpert MTB/RIF. . . . . . . . . . . . . . . . . . . . . . . . . . . . 287
Test 10. HIV-positive, Xpert MTB/RIF. . . . . . . . . . . . . . . . . . . . . . . . . . . . 288
Test 11. HIV-negative, within study comparisons. . . . . . . . . . . . . . . . . . . . . . . . 289
Test 12. HIV-positive, within study comparisons. . . . . . . . . . . . . . . . . . . . . . . . . 290
Test 13. HIV-negative, Xpert MTB/RIF, direct comparison Xpert MTB/RIF vs Xpert Ultra. . . . . . . . . . 290
Test 14. HIV-negative, Xpert Ultra, direct comparison Xpert MTB/RIF vs Xpert Ultra. . . . . . . . . . . 291
Test 15. HIV-positive, Xpert MTB/RIF, direct comparison Xpert MTB/RIF vs Xpert Ultra. . . . . . . . . . 291
iXpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Test 16. HIV-positive, Xpert Ultra, direct comparison Xpert MTB/RIF vs Xpert Ultra. . . . . . . . . . . . 291
Test 17. Xpert MTB/RIF for detection of rifampicin resistance. . . . . . . . . . . . . . . . . . . . 292
Test 18. Xpert Ultra for detection of rifampicin resistance. . . . . . . . . . . . . . . . . . . . . . 294
294ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
299APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 22. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 312
Figure 23. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 313
318FEEDBACK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
319WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
319HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
321CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
321DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
322SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
322DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
322INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iiXpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
[Diagnostic Test Accuracy Review]
Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary
tuberculosis and rifampicin resistance in adults
David J Horne1a , Mikashmi Kohli2b, Jerry S Zifodya3 , Ian Schiller4, Nandini Dendukuri4 , Deanna Tollefson5, Samuel G Schumacher
6, Eleanor A Ochodo7, Madhukar Pai2, Karen R Steingart8
1Department of Medicine, Division of Pulmonary and Critical Care Medicine, and Firland Northwest TB Center, University of
Washington, Seattle, WA, USA. 2Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal,
Canada. 3Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA, USA. 4Division of Clinical Epidemiology,
McGill University Health Centre - Research Institute, Montreal, Canada. 5Department of Global Health, University of Washington,
Seattle, WA, USA. 6FIND, Geneva, Switzerland. 7Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences,
Stellenbosch University, Cape Town, South Africa. 8Honorary Research Fellow, Department of Clinical Sciences, Liverpool School of
Tropical Medicine, Liverpool, UK
aThese authors contributed equally to this work. bThese authors contributed equally to this work
Contact address: KarenRSteingart,Honorary Research Fellow,Department of Clinical Sciences, Liverpool School of TropicalMedicine,
Pembroke Place, Liverpool, UK. karen.steingart@gmail.com.
Editorial group: Cochrane Infectious Diseases Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 6, 2019.
Citation: Horne DJ, Kohli M, Zifodya JS, Schiller I, Dendukuri N, Tollefson D, Schumacher SG, Ochodo EA, Pai M, Steingart
KR. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of
Systematic Reviews 2019, Issue 6. Art. No.: CD009593. DOI: 10.1002/14651858.CD009593.pub4.
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of
The Cochrane Collaboration. This is an open access article under the terms of the Creative Commons Attribution-Non-Commercial
Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used
for commercial purposes.
A B S T R A C T
Background
Xpert MTB/RIF (Xpert MTB/RIF) and Xpert MTB/RIF Ultra (Xpert Ultra), the newest version, are the only World Health Organi-
zation (WHO)-recommended rapid tests that simultaneously detect tuberculosis and rifampicin resistance in persons with signs and
symptoms of tuberculosis, at lower health system levels. A previous Cochrane Review found Xpert MTB/RIF sensitive and specific
for tuberculosis (Steingart 2014). Since the previous review, new studies have been published. We performed a review update for an
upcoming WHO policy review.
Objectives
Todetermine diagnostic accuracy ofXpertMTB/RIF andXpertUltra for tuberculosis in adultswith presumptive pulmonary tuberculosis
(PTB) and for rifampicin resistance in adults with presumptive rifampicin-resistant tuberculosis.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register, MEDLINE, Embase, Science Citation Index, Web of
Science, Latin American Caribbean Health Sciences Literature, Scopus, the WHO International Clinical Trials Registry Platform,
the International Standard Randomized Controlled Trial Number Registry, and ProQuest, to 11 October 2018, without language
restriction.
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Selection criteria
Randomized trials, cross-sectional, and cohort studies using respiratory specimens that evaluated Xpert MTB/RIF, Xpert Ultra, or both
against the reference standard, culture for tuberculosis and culture-based drug susceptibility testing or MTBDRplus for rifampicin
resistance.
Data collection and analysis
Four review authors independently extracted data using a standardized form. When possible, we also extracted data by smear and
HIV status. We assessed study quality using QUADAS-2 and performed meta-analyses to estimate pooled sensitivity and specificity
separately for tuberculosis and rifampicin resistance. We investigated potential sources of heterogeneity. Most analyses used a bivariate
random-effects model. For tuberculosis detection, we first estimated accuracy using all included studies and then only the subset of
studies where participants were unselected, i.e. not selected based on prior microscopy testing.
Main results
We identified in total 95 studies (77 new studies since the previous review): 86 studies (42,091 participants) evaluated Xpert MTB/RIF
for tuberculosis and 57 studies (8287 participants) for rifampicin resistance. One study compared Xpert MTB/RIF and Xpert Ultra
on the same participant specimen.
Tuberculosis detection
Of the total 86 studies, 45 took place in high tuberculosis burden and 50 in high TB/HIV burden countries. Most studies had low risk
of bias.
Xpert MTB/RIF pooled sensitivity and specificity (95% credible Interval (CrI)) were 85% (82% to 88%) and 98% (97% to 98%),
(70 studies, 37,237 unselected participants; high-certainty evidence). We found similar accuracy when we included all studies.
For a population of 1000 people where 100 have tuberculosis on culture, 103 would be Xpert MTB/RIF-positive and 18 (17%) would
not have tuberculosis (false-positives); 897 would be Xpert MTB/RIF-negative and 15 (2%) would have tuberculosis (false-negatives).
Xpert Ultra sensitivity (95% confidence interval (CI)) was 88% (85% to 91%) versus Xpert MTB/RIF 83% (79% to 86%); Xpert
Ultra specificity was 96% (94% to 97%) versus Xpert MTB/RIF 98% (97% to 99%), (1 study, 1439 participants; moderate-certainty
evidence).
Xpert MTB/RIF pooled sensitivity was 98% (97% to 98%) in smear-positive and 67% (62% to 72%) in smear-negative, culture-
positive participants, (45 studies). Xpert MTB/RIF pooled sensitivity was 88% (83% to 92%) in HIV-negative and 81% (75% to
86%) in HIV-positive participants; specificities were similar 98% (97% to 99%), (14 studies).
Rifampicin resistance detection
Xpert MTB/RIF pooled sensitivity and specificity (95% Crl) were 96% (94% to 97%) and 98% (98% to 99%), (48 studies, 8020
participants; high-certainty evidence).
For a population of 1000 people where 100 have rifampicin-resistant tuberculosis, 114 would be positive for rifampicin-resistant
tuberculosis and 18 (16%) would not have rifampicin resistance (false-positives); 886 would be would be negative for rifampicin-
resistant tuberculosis and four (0.4%) would have rifampicin resistance (false-negatives).
Xpert Ultra sensitivity (95% CI) was 95% (90% to 98%) versus Xpert MTB/RIF 95% (91% to 98%); Xpert Ultra specificity was 98%
(97% to 99%) versus Xpert MTB/RIF 98% (96% to 99%), (1 study, 551 participants; moderate-certainty evidence).
Authors’ conclusions
We found Xpert MTB/RIF to be sensitive and specific for diagnosing PTB and rifampicin resistance, consistent with findings reported
previously. Xpert MTB/RIF was more sensitive for tuberculosis in smear-positive than smear-negative participants and HIV-negative
thanHIV-positive participants. Comparedwith XpertMTB/RIF, XpertUltra had higher sensitivity and lower specificity for tuberculosis
and similar sensitivity and specificity for rifampicin resistance (1 study). Xpert MTB/RIF and Xpert Ultra provide accurate results and
can allow rapid initiation of treatment for multidrug-resistant tuberculosis.
P L A I N L A N G U A G E S U M M A R Y
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Xpert MTB/RIF and Xpert Ultra for diagnosing pulmonary tuberculosis and rifampicin resistance in adults
Why is improving the diagnosis of pulmonary tuberculosis important?
Tuberculosis causes more deaths globally than any other infectious disease. When detected early and effectively treated, tuberculosis
is largely curable, but in 2017, around 1.6 million people died of tuberculosis. Xpert MTB/RIF and Xpert Ultra, the newest version,
are World Health Organization-recommended tests that simultaneously detect tuberculosis and rifampicin resistance in persons with
tuberculosis symptoms. Rifampicin is an important anti-tuberculosis drug. Not recognizing tuberculosis early may result in delayed
diagnosis and treatment, severe illness, and death. An incorrect tuberculosis diagnosis may result in anxiety and unnecessary treatment.
What is the aim of this review?
To determine how accurate XpertMTB/RIF and XpertUltra are for diagnosing pulmonary tuberculosis (PTB) and rifampicin resistance
in adults. This is an update of the 2014 Cochrane Review.
What was studied in this review?
Xpert MTB/RIF and Xpert Ultra, with results measured against culture (benchmark).
What are the main results in this review?
95 studies: 86 studies (42,091 participants) evaluated Xpert MTB/RIF for tuberculosis; 57 studies (8287 participants) for rifampicin
resistance. One study compared Xpert Ultra and Xpert MTB/RIF.
For PTB, Xpert MTB/RIF was sensitive (85%), registering positive in people who actually had tuberculosis, and specific (98%), i.e.
it did not register positive in people who were actually negative. Xpert Ultra had higher sensitivity than Xpert MTB/RIF (88% versus
83%) in one study.
For rifampicin resistance, Xpert MTB/RIF was highly sensitive (96%) and specific (98%). Xpert Ultra gave similar results.
Xpert MTB/RIF was better for diagnosing tuberculosis in HIV-negative than in HIV-positive people.
How confident are we in the results of this review?
Confident. We included many studies and used the best reference standards.
Who do the results of this review apply to?
People with presumed PTB or rifampicin resistance.
What are the implications of this review?
In theory, among 1000 people where 100 have tuberculosis on culture, 103 would be Xpert MTB/RIF-positive and 18 (17%) would
not have tuberculosis (false-positives); 897 would be Xpert MTB/RIF-negative and 15 (2%) would have tuberculosis (false-negatives).
Among 1000 people where 100 have rifampicin resistance, 114 would be positive for rifampicin resistance and 18 (16%) would not
have rifampicin resistance (false-positives); 886 would be negative for rifampicin resistance and four (0.4%) would have rifampicin
resistance (false-negatives).
How up-to-date is this review?
To 11 October 2018.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Review question: What is the diagnost ic accuracy of Xpert MTB/ RIF and Xpert Ultra for detect ion of pulmonary tuberculosis (PTB)?
Patients/population: Adults with presumptive PTB. Part icipants were ‘unselected’, meaning they were not enrolled in a study based on microscopy smear results or past
history of tuberculosis
Role: An init ial test
Index tests: Xpert MTB/ RIF and Xpert Ultra
Threshold for index tests: An automated result is provided
Reference standards: Solid or liquid culture
Studies: Cross-sect ional and cohort studies
Setting: Primary care facilit ies and local hospitals
Index test Effect (95% Crl) Number of partici-
pants (studies)
Test result Number of results per 1000 patients tested (95% CrI)1 Certainty of the evidence
(GRADE)
Prevalence 1% Prevalence 10% Prevalence 30%
Xpert MTB/ RIF in
unselected part ici-
pants
Pooled sensit ivity
85% (82 to 88)
10,409 (70 studies) True posit ives 9 (8 to 9) 85 (82 to 88) 255 (246 to 264) ⊕⊕⊕⊕
Higha,b,c
False nega-
t ives
1 (1 to 2) 15 (12 to 18) 45 (36 to 54)
Pooled specif icity
98% (97 to 98)
26,828 (70 studies) True
negat ives
970 (960 to 970) 882 (873 to 882) 686 (679 to 686) ⊕⊕⊕⊕
Higha
False posi-
t ives
20 (20 to 30) 18 (18 to 27) 14 (14 to 21)
Xpert Ultra Sensit ivity 88% (85
to 91)
462 (1 study) True posit ives 9 (9 to 9) 88 (85 to 91) 264 (255 to 273) ⊕⊕⊕©
Moderated,e
False nega-
t ives
1 (1 to 1) 12 (9 to 15) 36 (27 to 45)
Specif icity 96% (94
to 97)
977 (1 study) True
negat ives
950 (931 to 960) 864 (846 to 873) 672 (658 to 679) ⊕⊕⊕©
Moderated,e
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False posi-
t ives
40 (30 to 59) 36 (27 to 54) 28 (21 to 42)
Abbreviat ions: CrI: credible interval; PTB: pulmonary tuberculosis.
Prevalence est imates were suggested by the WHO Global TB Programme. For Xpert MTB/ RIF, the median tuberculosis
prevalence in the included studies was 26%. For Xpert Ultra, the tuberculosis prevalence in the study was 32%.
Credible lim its were est imated based on those around the point est imates for pooled sensit ivity and specif icity; 95%
conf idence intervals were est imated for the single study that evaluated Ultra.
aThe median tuberculosis prevalence in the studies was 26% and thus the results tend to be more applicable to sett ings with
a higher tuberculosis prevalence. For tuberculosis prevalence of 1% and 10%, whether or not to downgrade is unclear. It is
possible the test will perform dif ferent ly at lower tuberculosis prevalences. We did not downgrade for indirectness.
bFor individual studies, sensit ivity est imates ranged f rom 43% to 100%. We thought that dif f erences in enrolment criteria
(dif f erent populat ions targeted), disease severity, and sett ing could in part explain heterogeneity. We did not downgrade for
inconsistency.
cThere were a large number of studies and part icipants in this analysis. The 95%CrI around true posit ives and false negat ives
would probably not lead to dif ferent decisions depending on which credible lim its are assumed. We did not downgrade for
imprecision.
dThe tuberculosis prevalence in the study was 32% and thus the results tend to be more applicable to sett ings with a higher
tuberculosis prevalence. For tuberculosis prevalences of 1% and 10%, whether or not to downgrade is unclear. It is possible
the test will perform dif ferent ly at lower prevalences. We did not downgrade for indirectness.
eAlthough there was only one study on the accuracy of Xpert Ultra for PTB, this was a mult icentre study conducted in
eight countries (South Af rica, Uganda, Kenya, India, China, Georgia, Belarus, and Brazil). We downgraded by one level for
imprecision.
GRADE certainty of the evidence
High: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect,
but there is a possibility that it is substant ially dif f erent.
Low: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the
ef fect.
Very low: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the
est imate of ef fect.
The results presented in this table should not be interpreted in isolat ion f rom results of the individual included studies
contribut ing to each summary test accuracy measure.
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B A C K G R O U N D
Tuberculosis is the world’s leading cause of infectious disease-re-
lated death and is one of the top 10 causes of death worldwide
(WHO Global TB Report 2018). In 2017, 10 million people de-
veloped tuberculosis disease, equivalent to 133 cases per 100,000
population (WHO Global TB Report 2018). Of the 10 million
tuberculosis cases, approximately 9% occurred among people liv-
ing with HIV. Worldwide, for all forms of tuberculosis, a substan-
tial percentage (~ 36%) of patients were not reported to national
treatment programmes (WHO Global TB Report 2018). When
tuberculosis is detected early and is effectively treated, the disease
is largely curable. However, in 2017, 1.6 million people died of
tuberculosis, including 300,000 deaths among people living with
HIV (WHO Global TB Report 2018). Ending the tuberculosis
epidemic by 2030 is among the health targets of the Sustainable
Development Goals.
Drug-resistant tuberculosis is a serious threat to global health
(Zumla 2012). Three groupings for tuberculosis drug resistance are
used for the purpose of surveillance and treatment: rifampicin-re-
sistant tuberculosis, multidrug-resistant tuberculosis (MDR-TB),
and extensively drug-resistant tuberculosis (XDR-TB). MDR-TB
is defined as resistance to at least isoniazid and rifampicin, the two
most important first-line anti-tuberculosis drugs. XDR-TB is de-
fined asMDR-TB plus resistance to at least one drug in the follow-
ing two classes of medicines used in treatment of MDR-TB: fluo-
roquinolones and second-line injectable agents (WHOGlobal TB
Report 2018). In 2017, approximately 558,000 people developed
MDR-TB/rifampicin-resistant tuberculosis. Regarding XDR-TB,
10,800 cases were reported by 77 countries (WHO Global TB
Report 2018). In 2017, 30% of new and previously-treated people
with tuberculosis were tested for rifampicin resistance; while this
is a significant improvement over recent rates, considerable gaps
remain.
Accurate and rapid detection of tuberculosis, including smear-
negative tuberculosis and drug resistant-tuberculosis, is critical for
improving patient outcomes (increased cure and decreased mor-
tality, and prevention of additional drug resistance, treatment fail-
ure, and relapse), and decreasing tuberculosis transmission. My-
cobacterial culture is generally considered the best available refer-
ence standard for tuberculosis diagnosis and is a key step in detect-
ing drug resistance. However, culture is a relatively complex and
slow procedure. Solid culture typically takes between four to eight
weeks for results and liquid culture, although more sensitive and
rapid than solid culture, requires weeks and is more prone to con-
tamination (WHO Policy Framework 2015). In addition, culture
requires specialized laboratories and highly skilled staff. In 2010,
theWorld Health Organization (WHO) recommended the use of
a novel, rapid, automated, cartridge-based, nucleic acid amplifi-
cation (NAA) test, Xpert MTB/RIF (Cepheid, Sunnyvale, USA)
(hereafter referred to as XpertMTB/RIF), that can simultaneously
detect tuberculosis and rifampicin resistance (WHO Policy Xpert
MTB/RIF 2011).
Target condition being diagnosed
Tuberculosis
Tuberculosis is caused by the bacteriumMycobacterium tuberculosis
(M tuberculosis) and is spread from person to person through the
air. Tuberculosis most commonly affects the lungs (pulmonary tu-
berculosis (PTB)), but may affect any organ or tissue outside of the
lungs (extrapulmonary tuberculosis). Signs and symptoms of PTB
include cough, fever, chills, night sweats, weight loss, haemoptysis
(coughing up blood), and fatigue. Signs and symptoms of extra-
pulmonary tuberculosis depend on the site of disease. Tubercu-
losis treatment regimens must contain multiple drugs to which
the organisms are sensitive to cure tuberculosis and avoid selec-
tion for drug resistance. The treatment of MDR-TB is complex,
historically requiring two years or more of therapy, although the
WHO conditionally recommended a nine- to 12-month regimen
in 2016 (WHO 2016b). The drugs used to treat MDR-TB are
less potent and more toxic than the drugs used to treat drug-sus-
ceptible tuberculosis.
Rifampicin resistance
Rifampicin inhibits bacterial DNA-dependent RNA polymerase,
encoded by the RNA polymerase gene (rpoB) (Hartmann 1967).
Resistance to this drug has mainly been associated with mutations
in a limited region of the rpoB gene (Telenti 1993). Rifampicin
resistance may occur alone or in association with resistance to
isoniazid and other drugs. In highMDR-TB settings, the presence
of rifampicin resistance alone may serve as a proxy for MDR-TB
(WHO Rapid Implementation 2011). People with drug-resistant
tuberculosis can transmit the infection to others.
Index test(s)
Xpert MTB/RIF is an automated polymerase chain reaction
(PCR) test (molecular test) using the GeneXpert platform (
Blakemore 2010; Cepheid 2009; Helb 2010). Xpert MTB/RIF
is a single test that can detect both M tuberculosis complex and
rifampicin resistance within two hours after starting the test, with
minimal hands-on technical time.Unlike conventionalNAA tests,
Xpert MTB/RIF is unique because sample processing and PCR
amplification and detection are integrated into a single self-en-
closed test unit, the GeneXpert cartridge. Following sample load-
ing, all steps in the assay are completely automated and self-con-
tained. In addition, the assay’s sample reagent, used to liquefy
sputum, has potent tuberculocidal (the ability to kill tuberculosis
bacteria) properties and so largely eliminates biosafety concerns
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during the test procedure (Banada 2010). These features allow
the technology to be taken out of a reference laboratory and used
nearer to the patient (Small 2011). Xpert MTB/RIF requires an
uninterrupted and stable electrical power supply, temperature con-
trol, and yearly calibration of the cartridge modules (WHORapid
Implementation 2011).
The test procedure may be used directly on clinical specimens,
either raw sputum specimens or sputum pellets created after de-
contaminating and concentrating the sputum (Blakemore 2010).
In both cases, the test material is combined with the assay sample
reagent (sodium hydroxide and isopropanol), mixed by hand or
vortex, and incubated at room temperature for 15 minutes. After
the incubation step, 2 mL of the treated specimen are transferred
to the cartridge and the run is initiated (Helb 2010). According
to the manufacturer, Xpert MTB/RIF may be used with fresh
sputum specimens, which may be either unprocessed sputum or
processed sputum sediments. The sample reagent:sample volume
ratio is 2:1 for unprocessed sputum and 3:1 for sputum pellets.
The manufacturer does not specifically mention the use of Xpert
MTB/RIF with frozen specimens (Cepheid 2009).
Xpert MTB/RIF limit of detection, (the lowest number of colony
forming units per sample that can be reproducibly distinguished
from negative samples with 95% confidence) (Cepheid 2009), is
five genome copies of purified DNA per reaction or 131 colony
forming units (CFUs) per mL in M tuberculosis-spiked sputum
(Helb 2010). In comparison, identification of tuberculosis bacilli
bymicroscopic examination requires at least 10,000 bacilli per mL
of sputum (Toman 2004a). Xpert MTB/RIF detects both live and
dead bacteria (Miotto 2012).
Xpert MTB/RIF uses molecular beacon technology to detect ri-
fampicin resistance. Molecular beacons are nucleic acid probes
that recognize and report the presence or absence of the normal,
rifampicin-susceptible, ‘wild type’ sequence of the rpoB gene of
tuberculosis. Five different-coloured beacons are used, each cov-
ering a separate nucleic acid sequence within the amplified rpoB
gene. When a beacon binds to the matching sequence, it fluo-
resces or ‘lights up’, which indicates the presence of one of the
gene sequences that is characteristic of rifampicin-susceptible tu-
berculosis. Failure of the beacon to bind or delayed binding to
the matching sequence indicates potential rifampicin resistance.
The number and timing of detection (when the fluorescent signal
rises above a predetermined baseline cycle threshold) of positive
beacons as well as results of sample processing controls allow the
test to distinguish among the following results: ‘No tuberculosis’;
‘tuberculosis detected, rifampicin resistance detected’; ‘tuberculo-
sis detected, no rifampicin resistance detected’; and an ‘invalid re-
sult’ (Figure 1). A single Xpert MTB/RIF run will provide both
detection of tuberculosis and detection of rifampicin resistance.
One cannot deselect testing for rifampicin resistance and only run
the assay for tuberculosis detection, although it is possible for the
laboratory to omit results for rifampicin resistance when reporting
to the healthcare provider.
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Figure 1. Readout of Xpert MTB/RIF assay for a tuberculosis positive, rifampicin-susceptible specimen.
Courtesy: Karin Weyer, the WHO Global TB Programme.
Since Xpert MTB/RIF was released, there have been four gener-
ations (G1, G2, G3, and G4) of the test involving different soft-
ware and cartridge combinations. G4 contains modifications that
improved determination of rifampicin resistance detection as pre-
vious Xpert MTB/RIF versions had found that some rifampicin
susceptibility results were falsely resistant. In order to improve on
Xpert MTB/RIF sensitivity, Cepheid developed Xpert MTB/RIF
Ultra (hereafter referred to as Xpert Ultra), a re-engineered assay
that uses a newly developed cartridge but may be run on the same
device after a software upgrade. Xpert Ultra incorporates two dif-
ferent multi-copy amplification targets and a larger DNA reaction
chamber thanXpertMTB/RIF (WHOXpertUltra 2017). A labo-
ratory study reported that the limit of detection using Xpert Ultra
improved to 15.6 CFU/mL of sputum compared to 112.6 CFU/
mL for Xpert MTB/RIF (Chakravorty 2017). Of note, Xpert Ul-
tra has added a new result category, ‘trace call’, that corresponds
to the lowest bacillary burden forM tuberculosis detection (WHO
Xpert Ultra 2017). Although no rifampicin resistance result will
be available for people with trace results, a trace positive result is
sufficient to initiate anti-tuberculosis therapy in children or HIV-
positive people, according to theWHO report. Other people with
a trace result should have a new sputum specimen collected for
XpertUltra testing (WHOXpertUltra 2017). XpertUltra is avail-
able for clinical use and several countries have moved from using
Xpert MTB/RIF to using Xpert Ultra instead. In this Cochrane
Review, we include studies that used any generation of the index
tests.
Clinical pathway
Xpert MTB/RIF and Xpert Ultra are used for the diagnosis of
tuberculosis and rifampicin resistance. Figure 2 shows the clinical
pathway and presents the context in which the index tests might
be used. The target condition is PTB. Persons to be evaluated for
PTB are adults with signs or symptoms suggestive of tuberculosis,
such as cough, fever, night sweats, weight loss, haemoptysis, and
fatigue, or with an abnormal chest x-ray suggestive of tuberculo-
sis. Additionally, people who are known to have tuberculosis and
are at risk for rifampicin-resistant or MDR-TB (e.g. those with a
previous history of tuberculosis treatment or those who have an
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inadequate response to anti-tuberculosis treatment) may undergo
XpertMTB/RIF and XpertUltra testing to evaluate for rifampicin
resistance.
Figure 2. The clinical pathway describes how people might present and the point in the pathway at which
they would be considered for testing with Xpert MTB/RIF or Xpert Ultra. A person with presumptive PTB
may experience cough, chest pain, the coughing up of blood, fever, night sweats, fatigue, loss of appetite, and
weight loss. When she presents to a health facility, she will undergo a health examination (history and physical
examination) and usually a chest x-ray. She will be tested with the index test, either Xpert MTB/RIF or Xpert
Ultra, if available, as this test is recommended as the initial diagnostic test for all adults and children with signs
and symptoms of tuberculosis. Abbreviations: DR-TB: drug-resistant tuberculosis; MDR-TB: multidrug-
resistant tuberculosis; PTB: pulmonary tuberculosis; RIF: rifampicin; SL-LPA: second-line line probe assay;
Xpert: either Xpert MTB/RIF of Xpert Ultra. Figure adapted from GLI 2018.
The index test is performed as an initial test for adults with pre-
sumptive PTB or MDR-TB.
The downstream consequences of testing include the following.
• True-positive (TP): patients would benefit from rapid
diagnosis and appropriate treatment.
• True-negative (TN): patients would be spared unnecessary
treatment and would benefit from reassurance and pursuit of an
alternative diagnosis.
• False-positive (FP): patients would probably experience
anxiety and morbidity caused by additional testing, unnecessary
treatment, and possible adverse events; possible stigma associated
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with a tuberculosis or MDR-TB diagnosis; and the chance that a
false-positive result may halt further diagnostic evaluation.
• False-negative (FN): increased risk of morbidity and
mortality and delayed treatment initiation; risk of ongoing
tuberculosis transmission.
Settings of interest
Wewere interested in how the index test performed in people with
presumptive PTB, who were evaluated as they would be in routine
practice, most often in local hospitals or primary care centres. The
index test may have the greatest impact on health when used in a
setting such as a primary healthcare facility, where treatment can
be started the same day as testing or as soon as possible.
It should be noted that in the original Cochrane Review, we
described the setting of interest as peripheral-level laboratories
based on a classification system previously in use (WHO Policy
Framework 2015).
Role of index test(s)
We were interested in the following roles for testing.
I. Xpert MTB/RIF and Xpert Ultra for detection of
PTB
Index test used as an initial test for the diagnosis of PTB.
II. Xpert MTB/RIF and Xpert Ultra for detection of
rifampicin resistance
Index test used as an initial test for the diagnosis of rifampicin-
resistant tuberculosis or MDR-TB.
As mentioned, in high MDR-TB settings the presence of ri-
fampicin resistance alonemay serve as a proxy forMDR-TB. Xpert
MTB/RIF and Xpert Ultra do not eliminate the need for subse-
quent culture and phenotypic drug susceptibility testing (DST),
which are required to monitor treatment progress and to detect
resistance to drugs other than rifampicin.
Alternative test(s)
In this section, we describe selected alternative tests for detection
of PTB and rifampicin resistance. For a comprehensive review of
alternative tests, we refer the reader to several excellent resources
(Lewinsohn 2017; Unitaid 2017).
Smear microscopy is the examination of smears for acid-fast
bacilli (tuberculosis bacteria) under a microscope. The examina-
tion may be performed by light microscopy (Ziehl-Neelsen), fluo-
rescence microscopy, or light-emitting diode (LED) fluorescence
microscopy. Advantages of smear microscopy include its simplic-
ity, low cost, speed, and high specificity in high tuberculosis bur-
den areas. In addition, smear microscopy identifies the most in-
fectious people with tuberculosis. Smear microscopy can be per-
formed in basic laboratories. Drawbacks of smear microscopy in-
clude the need for specialized training and its relatively low sensi-
tivity, 50% to 60%on average for a direct smear (Steingart 2006b).
Around 5000 to 10,000 organisms per mL must be present in
the specimen for tuberculosis bacteria to be visible by microscopy
(American Thoracic Society 2000). Although the sensitivity of
microscopy can be improved by approximately 10% with fluo-
rescence (Steingart 2006a), a large number of tuberculosis cases
still go undiagnosed. Smear-negative tuberculosis is disproportion-
ately higher in HIV-positive than in HIV-negative individuals,
accounting for 24% to 61% of all pulmonary cases in people liv-
ing with HIV (Getahun 2007; Perkins 2007). Microscopy can-
not distinguish between drug-susceptible tuberculosis and drug-
resistant tuberculosis. The WHO recommends that microscopy
as the initial diagnostic test should be replaced with WHO-rec-
ommended rapid tests that can simultaneously detect tuberculosis
and tuberculosis drug resistance (WHO Compendium 2018).
Mycobacterial culture is a method used to grow bacteria on nutri-
ent-rich media. In comparison with microscopy, a positive culture
requires only around 100 organisms per mL and therefore can de-
tect lower numbers of tuberculosis bacteria (American Thoracic
Society 2000). Additionally, culture is essential for species identi-
fication and DST. However, culture may take up to six to eight
weeks and requires a highly equipped laboratory.
NAA tests are molecular systems that can detect small quantities
of genetic material (DNA or RNA) from micro-organisms, such
as M tuberculosis. The key advantage of NAA tests is that they
are rapid diagnostic tests, potentially providing results in a few
hours. A variety of molecular amplification methods are available,
of which PCR is the most common. NAA tests are available as
commercial kits and in-house tests (based on a protocol developed
in a laboratory) and are used routinely in high-income countries
for tuberculosis detection. In-house PCR is widely used in low-
income countries because these tests are less expensive than com-
mercial kits. However, in-house PCR is known to produce highly
inconsistent results (Flores 2005).
Alternative molecular methods for DST include the com-
mercial line probe assays, GenoType MTBDRplus assay
(MTBDRplus, Hain LifeScience, Nehren, Germany), and the
Nipro NTM+MDRTB detection kit 2 (Nipro, Tokyo, Japan),
which detect the presence of mutations associated with drug
resistance to isoniazid and rifampicin (Nathavitharana 2017).
MTBDRplus is the most widely studied line probe assay. Advan-
tages of line probe assays are that they can provide a result for
detection of tuberculosis and drug resistance in one to two days.
Drawbacks are that line probe assays are expensive and need to
be used in intermediate and central laboratories (Unitaid 2017).
The WHO recommends that for persons with a sputum smear-
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positive specimen or a cultured tuberculosis isolate, commercial
molecular line probe assays may be used as the initial test instead of
phenotypic culture-based DST to detect resistance to rifampicin
and isoniazid (conditional recommendation, moderate certainty
in the evidence for the test’s accuracy) (WHO LPA 2016). Other
molecular assays for detection of tuberculosis and resistance to ri-
fampicin and isoniazid along with instruments are in development
(Walzl 2018).
Alere Determine™ TB LAM Ag (AlereLAM) Alere Inc,
(Waltham, USA) is a commercially available point-of-care test for
tuberculosis disease (PTB and extrapulmonary tuberculosis). The
test detects lipoarabinomannan (LAM), a component of the bac-
terial cell wall, which is present in the urine of some people with
tuberculosis. AlereLAM is performed by placing urine on one end
of a test strip, with results appearing as a band on the strip if tu-
berculosis is present. The test is simple, requires no special equip-
ment, and shows results in 25 minutes (Shah 2016). Of note, the
presence of LAM in the urine of HIV-positive adults undergoing
treatment for tuberculosis has been found to be associated with
increased risk of mortality (Gupta-Wright 2018). In randomized
trials, use of Alere LAM inHIV-positive inpatients has been shown
to reduce mortality (Gupta-Wright 2018; Peter 2016). Based in
part on evidence from a Cochrane Review, Shah 2016, the WHO
recommends that AlereLAM should be used to assist in the diag-
nosis of tuberculosis in adult inpatients, specifically “people liv-
ing with HIV who have signs or symptoms of tuberculosis and
a CD4 cell count less than or equal to 100 cells/µL, and people
living with HIV who are ‘seriously ill’ regardless of CD4 count or
if the CD4 count is unknown. This recommendation also applies
to HIV-positive children with signs and symptoms of tuberculosis
(pulmonary or extrapulmonary, or both) based on the generalisa-
tion of data from adults while acknowledging very limited data
and concern regarding low specificity of the AlereLAM assay in
children” (WHO LAM 2015). The WHO does not recommend
AlereLAM for tuberculosis screening or diagnosis of active tuber-
culosis disease in most population groups (WHO LAM 2015).
Fujifilm SILVAMP TB LAM (FuijiLAM, co-developed by FIND,
Geneva, Switzerland and Fujifilm, Tokyo, Japan) is a new, urine-
based, point-of-care test for tuberculosis diagnosis in people living
with HIV. Using stored (biobanked) urine specimens from hos-
pitalized people in South Africa, FujiLAM was found to have su-
perior sensitivity, 70.4% (95% CI 53.0% to 83.1%) compared to
AlereLAM sensitivity of 42.3% (31.7% to 51.8%) (Broger 2018).
At the time of this writing, a call was open for prospective clinical
trials of FuijiLAM to generate data for an updated WHO policy
review.
Rationale
Xpert MTB/RIF and Xpert Ultra provide obvious benefits for pa-
tients (earlier diagnosis and the opportunity to begin earlier, ap-
propriate treatment) and for public health (opportunities to in-
terrupt tuberculosis transmission), especially in high tuberculosis
burden countries.
Since 2010, the WHO has recommended the use of Xpert MTB/
RIF as the preferred initial diagnostic test for people thought
to have MDR-TB or HIV-associated tuberculosis (strong rec-
ommendation, moderate-certainty evidence) (WHOPolicy Xpert
MTB/RIF 2011). In 2013, theWHOexpanded the recommenda-
tions, stating that Xpert MTB/RIF may be used rather than con-
ventional microscopy and culture as the initial diagnostic test in all
adults suspected of having tuberculosis (conditional recommenda-
tion acknowledging resource implications, high-quality evidence)
(WHO Xpert MTB/RIF Policy Update 2013). In addition, the
WHO recommended that following an Xpert MTB/RIF test that
demonstrates rifampicin resistance, subsequent drug susceptibil-
ity testing (e.g. using a line probe assay to second-line drugs) re-
mains essential to detect resistance to drugs other than rifampicin
(WHO Xpert MTB/RIF Policy Update 2013). In 2017, based
on a non-inferiority analysis of Xpert Ultra compared with Xpert
MTB/RIF, the WHO stated that recommendations on the use of
Xpert MTB/RIF also apply to the use of Xpert Ultra as the initial
diagnostic test for all adults and children with signs and symp-
toms of tuberculosis (WHO Xpert Ultra 2017). We performed
this Cochrane Review to inform an updated WHO policy review
on the use of Xpert MTB/RIF and Xpert Ultra.
O B J E C T I V E S
Primary objectives
To determine the diagnostic accuracy of Xpert MTB/RIF and
Xpert Ultra for tuberculosis in adults with presumptive PTB, and
for rifampicin resistance in adults with presumptive rifampicin-
resistant tuberculosis or MDR-TB.
Secondary objectives
• To compare the diagnostic accuracy of Xpert MTB/RIF
and Xpert Ultra.
• To investigate potential sources of heterogeneity in test
accuracy. For detection of PTB, covariates were smear status;
HIV status; history of tuberculosis; the setting that ran the test;
tuberculosis burden; TB/HIV burden; and prevalence of PTB in
the studies. For detection of rifampicin resistance, covariates
were MDR-TB burden and prevalence of rifampicin resistance in
the studies.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
We include cross-sectional studies and cohort studies that assessed
the diagnostic accuracy of the index test(s) for both PTB and ri-
fampicin resistance, PTB alone, or rifampicin resistance alone.We
also include randomized controlled trials (RCTs) that evaluated
the use of the index(s) test on patient health outcomes, but that
also reported sensitivity and specificity. Although the study design
was a randomized trial for the purpose of determining the impact
of the test on participant outcomes, the study design was a cross-
sectional study for the purpose of determining the diagnostic ac-
curacy of the index tests in this review. We used abstracts to iden-
tify published studies and included these publications when they
met our inclusion criteria. We only included studies that reported
data comparing the index test(s) to an acceptable reference stan-
dard from which we could extract true positive (TP), true nega-
tive (TN), false positive (FP), and false negative (FN) values. The
index tests could be assessed alone or together with other tests.
We included studies that evaluated the index tests in HIV-positive
people irrespective of tuberculosis symptoms, for instance HIV-
positive people being assessed for antiretroviral therapy, as in the
study by Lawn 2011. We included these studies for the following
reasons: the risk of developing tuberculosis is much higher in peo-
ple living with HIV, estimated to be 20 to 37 times higher inHIV-
positive individuals than in HIV-negative individuals (Getahun
2010); signs and symptoms of tuberculosis in people living with
HIV vary, which makes it challenging to determine when to con-
sider a diagnosis of tuberculosis; and many HIV-positive people
in low-income countries develop tuberculosis as the first manifes-
tation of AIDS.
We excluded case reports and studies with a case-control design,
the latter because these types of studies are prone to bias, in partic-
ular, studies enrolling participants with severe disease and healthy
participants without disease.We excluded studies of the index tests
in people with diabetes but without tuberculosis symptoms, and
studies designed to find people with active tuberculosis in com-
munity settings. We excluded drug resistance surveys.
Participants
We included studies that enrolled adults, aged 15 years or
older, with presumptive PTB, rifampicin-resistant tuberculosis, or
MDR-TB. For tuberculosis detection, we were interested in peo-
ple who were not currently on tuberculosis treatment or those on
treatment for less than seven days. Tuberculosis treatment might
interfere with the confirmation of tuberculosis on culture (the ref-
erence standard for this review). If we could not tell the treatment
status of the participants, we contacted primary study authors for
this information. For rifampicin resistance detection, we were in-
terested in people at high risk for MDR-TB and we therefore in-
cluded participants who had received previous treatment, partici-
pants who were receiving tuberculosis treatment because they had
not converted their sputum from positive to negative, and contacts
with participants with known drug-resistant disease, as described
in Boehme 2010.
We included studies that assessed the diagnostic accuracy of Xpert
MTB/RIF (Xpert MTB/RIF) and Xpert MTB/RIF Ultra (Xpert
Ultra) using sputum and other respiratory specimens, such as fluid
obtained from bronchial alveolar lavage and tracheal aspiration,
consistent with the intended use of the manufacturer (Cepheid
2009), and studies from all types of health facilities and all labo-
ratory levels (peripheral, intermediate, and central) from all coun-
tries. Unlike the original Cochrane Reviews, for this review update
if a study included both adults and children and we could not
disaggregate results for adults alone, we excluded the study. We
also excluded studies where the age of participants was unknown.
Index tests
The index tests were Xpert MTB/RIF and Xpert Ultra.
Index test results are automatically generated (i.e. there is a single
threshold), and the user is provided with a printable test result as
follows.
• MTB (M tuberculosis) DETECTED; Rif (rifampicin)
resistance DETECTED.
• MTB DETECTED; Rif resistance NOT DETECTED.
• MTB detected; Rif resistance INDETERMINATE.
• MTB NOT DETECTED.
• INVALID (the presence or absence of MTB cannot be
determined).
• ERROR (the presence or absence of MTB cannot be
determined).
• NO RESULT (the presence or absence of MTB cannot be
determined).
Xpert Ultra incorporates a semi-quantitative classification for re-
sults: trace, very low, low, moderate, and high. ‘Trace’ corresponds
to the lowest bacterial burden for detection of M tuberculosis
(Chakravorty 2017). We considered a trace result to mean MTB
(M tuberculosis) DETECTED. However, no rifampicin-resistance
result was available for participants with trace results (WHO Xpert
Ultra 2017).
Target conditions
The target conditions were active PTB and rifampicin resistance.
Reference standards
For tuberculosis, acceptable reference standards used solid media
(Löwenstein-Jensen, Middlebrook 7H10 or 7H11, or Ogawa me-
dia) or a commercial liquid culture system, (such as BACTEC™
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460TB System or BACTEC™MGIT™ 960 Mycobacterial De-
tection System, BD, USA; BacT/ALERT System, bioMérieux,
France; or VersaTREK Mycobacteria Detection & Susceptibility,
Thermo Fisher Scientific, USA).
For rifampicin resistance, the reference standards were pheno-
typic culture-based DST methods recommended by the WHO
(WHO Policy DST 2008). Acceptable methods were the pro-
portion method performed on solid media (such as Löwenstein-
Jensen, Middlebrook 7H10 or 7H11, or Ogawa media), use of
a commercial liquid culture system, such as MGIT™ 960 My-
cobacterial Detection System, BD, USA, or both. For this review
update, we also included MTBDRplus, a WHO-recommended
test (WHO LPA 2016).
Search methods for identification of studies
We tried to identify all relevant studies regardless of language or
publication status (published, unpublished, in press, and ongo-
ing).
Electronic searches
We searched the following databases up to 18 January 2018, using
the search terms and strategy described in Appendix 1:
• Cochrane Infectious Diseases Group Specialized Register;
• MEDLINE (OVID, from 1966);
• Embase (OVID, from 1974);
• Science Citation Index - Expanded (from 1900),
Conference Proceedings Citation Index - Science (CPCI-S, from
1990), and BIOSIS Previews (from 1926); all three from the
Web of Science;
• Scopus (Elsevier, from 1970);
• Latin American Caribbean Health Sciences Literature
(LILACS) (BIREME, from 1982).
We also searched ClinicalTrials.gov, theWHOInternational Clin-
ical Trials Registry Platform (ICTRP; www.who.int/trialsearch),
and the International Standard Randomized Controlled Trials
Number ( ISRCTN) registry ( www.isrctn.com/) for trials in
progress, and ProQuest Dissertations & Theses A&I (1990 to 7
August 2017) for dissertations. On 11 October 2018, we per-
formed an additional search, specifically for studies that evaluated
Xpert Ultra.
To identify other systematic reviews and meta-analyses, we per-
formed an additional search on 26 March 2018 in MEDLINE
( PubMed), Embase ( OVID) and the Cochrane Library, Issue
7 2018, applying filters for systematic reviews ( www.sign.ac.uk/
search-filters.html) to search terms for Xpert and tuberculosis.
Searching other resources
We reviewed reference lists of included articles and any relevant
review articles identified through the above methods.We also con-
tacted researchers at FIND, the WHO Global TB Programme,
and other experts in the field of tuberculosis diagnostics for infor-
mation on ongoing and unpublished studies.
Data collection and analysis
Selection of studies
We used Covidence to manage the selection of studies (Covidence
2017). Working in pairs, four review authors independently scru-
tinized titles and abstracts identified from literature searching to
identify potentially eligible studies. We retrieved the article of any
citation identified by any review author for full-text review. Then,
again working in pairs, four review authors independently assessed
articles for inclusion using predefined inclusion and exclusion cri-
teria, and resolved any discrepancies by discussion among all re-
view authors. We recorded all studies excluded after full-text as-
sessment and their reasons for exclusion in the Characteristics of
excluded studies table.We illustrated the study selection process in
a PRISMA diagram. We included search results from the original
review and re-evaluated previously included studies to determine
if the studies met the refined inclusion criteria.
In the 2014CochraneReview (Steingart 2014), for themulticentre
studies Boehme 2010 (five study centres) and Boehme 2011 (six
study centres), we entered data separately for each study centre.
We did not repeat this for this updated review and hence we count
Boehme 2010 andBoehme 2011 each as one study and present the
two-by-two data for the total population in each study. Appendix
2 presents the data by individual study centre.
Data extraction and management
We extracted data on the following characteristics.
• Author, publication year, study design, country where study
was located, level of laboratory services, setting (outpatient,
inpatient, or both outpatient and inpatient) and whether the test
was run at point of care.
• Population characteristics: age, gender, smear status, HIV
status.
• Index test(s), Xpert MTB/RIF or Xpert Ultra.
• Reference standard.
• Condition of the specimen (fresh or frozen).
• Quality Assessment of Studies of Diagnostic Accuracy -
Revised (QUADAS-2) items (Whiting 2011).
• Number of TP, FP, FN, and TN (i.e. true positives, false
positives, false negatives, and true negatives, with respect to
culture).
• Number of uninterpretable results for detection of PTB.
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• Number of indeterminate results for detection of rifampicin
resistance.
We classified country income status as either low- and middle-
income or high-income, according to the World Bank List of
Economies (World Bank 2017). In addition, we classified ‘coun-
try’ as being high burden or not high burden for tuberculosis, TB/
HIV, or MDR-TB, according to the post-2015 era classification
by the WHO (WHO Global TB Report 2018). A country could
be classified as high burden for one, two, or all three of the high
burden categories.
We classified the level of laboratory that ran the index tests as be-
ing one of three service levels: peripheral, intermediate, or central
(GLI 2015). Peripheral laboratories may perform Xpert MTB/
RIF or Xpert Ultra testing, but typically perform only smear mi-
croscopy, and will refer specimens or people in need of further
tests, such as rapid molecular testing, culture, or DST, to a higher-
level laboratory. Intermediate laboratories typically perform tests
such as microscopy, rapid molecular tests, culture on solid media
and line probe assays on sputum. Central laboratories run inter-
mediate laboratory tests, as well as culture on liquid media and
DST on solid or liquid media to detect resistance to first- and
second-line anti-tuberculosis drugs, line probe assays on positive
cultures, and rapid speciation tests (GLI 2015).
Whenever possible, we extracted TP, FP, FN, and TN values based
on one Xpert MTB/RIF or Xpert Ultra result for one specimen
provided by one participant. However, in some of the studies,
the number of specimens (and index test results) exceeded the
number of participants, suggesting that a single participant may
have providedmultiple specimens.We therefore compared pooled
sensitivity and specificity for tuberculosis detection in all studies
with pooled sensitivity and specificity in the subset of studies that
provided one index test result based on one specimen provided by
one participant (see Sensitivity analyses).
Concerning the condition of the specimen, although the manu-
facturer recommends use of fresh specimens, we were aware that
several studies had been conducted using frozen specimens so we
extracted this information as well. We investigated the influence
of condition of specimen in a sensitivity analysis.
Concerning the definition of smear positivity, as most included
studies performed the index tests in intermediate-level or central-
level laboratories, we assumed these studies adhered to the revised
definition of a new sputum smear-positive PTB case based on the
presence of at least one acid-fast bacillus in at least one sputum
sample in countries with a well-functioning external quality assur-
ance system (WHO Policy Smear-positive TB Case 2007).
We developed a standardized data extraction form and piloted the
form with 10 studies. Based upon the pilot, we finalized the form.
Four review authors working in pairs independently extracted data
from each study using the final form. We contacted study authors
formissing data and clarifications andmanaged all data with RED-
Cap (Harris 2009). The final data extraction form is in Appendix
3. With regard to the use of REDCap, the content in this review
is solely the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of Health.
We followed Cochrane policy, which states that “authors of pri-
mary studies will not extract data from their own study or studies.
Instead, another author will extract these data, and check the in-
terpretation against the study report and any available study reg-
istration details or protocol”.
Assessment of methodological quality
We used the QUADAS-2 tool, tailored to this review, to assess
the quality of the included studies (Appendix 4) (Whiting 2011).
QUADAS-2 consists of four domains: patient selection, index test,
reference standard, and flow and timing. We assessed all domains
for the potential for risks of bias and the first three domains for
concerns regarding applicability. Four review authors, working in-
dependently in pairs, completed QUADAS-2 and resolved dis-
agreements through discussion. We present the results of this qual-
ity assessment in text, tables, and graphs.
Statistical analysis and data synthesis
We performed descriptive analyses for the results of the included
studies using Stata 15 (Stata 2017).We determined sensitivity and
specificity estimates and 95% confidence intervals (CIs) for indi-
vidual studies and generated forest plots using Review Manager
2014. Whenever possible, we included nontuberculous mycobac-
teria (NTM) as non-tuberculosis for specificity determinations.
We chose to use data that were not subject to discrepant analyses
(unresolved data), since resolved data after discrepant analyses are
a potential for risk of bias (Hadgu 2005).
We carried out meta-analyses to estimate the pooled sensitivity
and specificity of the index tests separately for tuberculosis detec-
tion and rifampicin resistance detection. When possible, we de-
termined pooled estimates using an adaptation of the bivariate
random-effects model of Reitsma 2005, which uses the exact bi-
nomial likelihood for the observed proportions (Chu 2006). We
accounted for the hierarchical structure of two multicentre studies
for which individual centre data were available by adding a ran-
dom effect for each centre (Boehme 2010; Boehme 2011). The bi-
variate random-effects approach allowed us to calculate the pooled
estimates of sensitivity and specificity while dealing with potential
sources of variation caused by (1) imprecision of sensitivity and
specificity estimates within individual studies; (2) correlation be-
tween sensitivity and specificity across studies; and (3) variation
in sensitivity and specificity between studies. For XpertMTB/RIF
and Xpert Ultra for PTB detection among smear-positive individ-
uals (described below), we performed a univariate analysis.
For the primary analysis for Xpert MTB/RIF or Xpert Ultra for
tuberculosis detection, we first estimated accuracy using all studies
meeting our inclusion criteria and then using only the subset of
studies where participants were unselected. In the latter analysis,
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we excluded studies that preselected participants based on prior
microscopy testing or primarily included participants with a his-
tory of previous tuberculosis treatment.
Rifampicin resistance detection
For analysis of Xpert MTB/RIF or Xpert Ultra accuracy for de-
tection of rifampicin resistance, we included participants who
(1) were culture-positive; (2) had a valid phenotypic DST (or
MTBDRplus) result; (3)wereXpertMTB/RIF (orXpertUltra) tu-
berculosis-positive; and (4) had a valid Xpert MTB/RIF (or Xpert
Ultra) Rif result.
• Sensitivity = Xpert MTB/RIF (or Xpert Ultra) Rif resistant/
DST Rif resistant.
• Specificity = Xpert MTB/RIF (or Xpert Ultra) Rif
susceptible/DST Rif susceptible.
For rifampicin resistance detection, we performed bivariate meta-
analyses to determine sensitivity and specificity estimates.
Comparison of Xpert MTB/RIF and Xpert Ultra
We intended to perform meta-analyses of the accuracy of Xpert
MTB/RIF and Xpert Ultra by first including all studies with rel-
evant data, i.e. indirect comparisons, and then by restricting the
analyses to studies that made comparisons between Xpert MTB/
RIF and Xpert Ultra in the same participants, i.e. direct compar-
isons (Takwoingi 2013). However, we identified only one study
using Xpert Ultra and this study compared Xpert MTB/RIF and
Xpert Ultra on the same participant specimens (Dorman 2018).
As in the primary analysis in Dorman 2018, Xpert Ultra trace calls
in this review were considered to be positive for the detection of
M tuberculosis.
We estimated all models using a Bayesian approach with low-in-
formation prior distributions using OpenBUGS software (Ver-
sion 3.2.3) (Lunn 2009), along with R (Version 3.3.2) (R Core
Team 2016). Under the Bayesian approach, all unknown param-
eters must be provided a prior distribution that defines the range
of possible values of the parameter and the likelihood of each of
those values based on information external to the data. In order
to let the observed data determine the final results, we chose to
use low-information prior distributions over the pooled sensitivity
and specificity parameters and their between-study standard devi-
ation parameters. We summarize the model we used in the Statis-
tical Appendix together with the OpenBUGS programme used to
implement it (Appendix 5). It is known that meta-analysis models
can be sensitive to the choice of prior distributions over between-
study standard deviation parameters.We therefore carried out sen-
sitivity analyses and considered alternative prior distributions that
are less informative, allowing a wider range of possible values. To
study the sensitivity of all results to the choice of prior distribu-
tions, we considered alternative prior distributions that were less
informative, allowing a wider range of possible values. We noted
no appreciable change in pooled accuracy parameters but, as ex-
pected, found that the posterior credible intervals and prediction
intervals were slightly wider. Information from the prior distri-
bution is combined with the likelihood of the observed data in
accordance with Bayes theorem to obtain a posterior distribution
for each unknown parameter (Appendix 6).
Using a sample from the posterior distribution, we can obtain
various descriptive statistics of interest. We estimated the median
pooled sensitivity and specificity and their 95% credible intervals
(CrIs). The median or the 50% quantile is the value below which
lies 50% of the posterior sample.We reported the median because
the posterior distributions of some parameters may be skewed and
the median would be considered a better point estimate of the
unknown parameter than the mean in such cases. The 95% CrI
is the Bayesian equivalent of the classical (frequentist) 95% CI.
(We have indicated 95% CI for individual study estimates and
95% CrI for pooled study estimates, as appropriate). The 95%
CrI may be interpreted as an interval that has a 95% probability
of capturing the true value of the unknown parameter, given the
observed data and the prior information.
We also estimated the ‘predicted’ sensitivity and specificity in a
future study together with their 95% CrIs. The predicted estimate
is our best guess for the estimate in a future study and is the same
as the pooled estimate. The CrIs, however,may be different. These
values are derived from the predicted region typically reported in
a bivariate meta-analysis plot. If there is no heterogeneity at all
between studies, the CI (or CrI) around the predicted estimate
will be the same as the CI around the pooled estimate. On the
other hand, if there is considerable heterogeneity between studies,
the CI around the predicted estimate will be much wider than the
CI around the pooled estimate. We generated the plots using R
(version 3.3.2) (R Core Team 2016).
Approach to uninterpretable index test results
The index tests report an uninterpretable test result for unexpected
results with any of the internal control measures of the assay. The
uninterpretable rate for detection of PTB was the number of tests
classified as ‘invalid’, ‘error’, or ‘no result’ divided by the total
number of index tests performed. The uninterpretable rate for de-
tection of rifampicin resistance (referred to as indeterminate rate)
was the number of tests classified as ‘MTB detected; Rif resistance
INDETERMINATE’ divided by the total number of index test-
positive results. As we found very few uninterpretable results re-
ported, we excluded these results from the quantitative analysis.
We used a Bayesian hierarchical model for a single proportion to
estimate the pooled proportion of uninterpretable index test re-
sults.
Investigations of heterogeneity
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Detection of PTB
Effect of smear status and HIV status
We investigated heterogeneity by performing subgroup analyses
to determine sensitivity and specificity estimates for participants
grouped by smear or HIV status. We analysed the data in two
ways: 1) we performedmeta-analyses where we included all studies
with available data, and 2) we performedmeta-analyses restricting
the analysis to studies that provided data for both smear-positive
and smear-negative individuals (or both HIV-negative and HIV-
positive individuals) within the same study. In the latter compari-
son, we hoped to achieve a similar distribution of other participant
characteristics and manner of test execution in the subgroups.
For smear-positive tuberculosis, we performed a univariate anal-
ysis for sensitivity. We did this because in many studies the value
for true negatives was zero (tuberculosis was not detected when
defined by a positive culture), and we considered all participants
to be true positives. It has been observed among individuals with
presumptive tuberculosis that when a sputum specimen is found
to be positive by smear microscopy, the probability of a culture
being negative is low (Toman 2004b).
Effect of other covariates
To study the impact of additional covariates of interest, we per-
formed subgroup analyses with the following covariates.
PTB detection
• High tuberculosis burden, yes or no.
• High TB/HIV burden, yes or no.
• Percentage of participants with a history of tuberculosis,
greater than the median value versus less than or equal to the
median value.
• Setting that ran the test, point of care or peripheral setting
versus intermediate or central laboratory.
• Prevalence of PTB in the studies, greater than the median
value versus less than or equal to the median value.
All the aforementioned covariates were categorical, study-level co-
variates. For these analyses, we restricted the studies to those that
included unselected participants, i.e. we excluded studies that pre-
selected participants on the basis of a prior smear microscopy re-
sult or primarily included participants with a history of previous
tuberculosis treatment.
Detection of rifampicin resistance
For rifampicin resistance detection, we performed subgroup anal-
yses with the following covariates.
• High MDR-TB burden, yes or no.
• Studies involving participants who had received previous
tuberculosis treatment, yes or no.
• Prevalence of rifampicin resistance in the studies, greater
than the median value versus less than or equal to the median
value.
All the aforementioned covariates were categorical, study-level co-
variates.
Sensitivity analyses
For detectionof PTB,we performed sensitivity analyses by limiting
inclusion in the meta-analysis based on the following criteria.
• Studies that explicitly represented the use of the index tests
for the diagnosis of individuals with signs and symptoms of
tuberculosis (presumptive tuberculosis). We excluded studies
that involved HIV-positive participants irrespective of
tuberculosis symptoms.
• Studies where a single specimen yielded a single Xpert
MTB/RIF result for a given participant. We excluded studies
that included more specimens than participants.
• Studies that included only untreated participants. We
excluded studies that did not explicitly state they included only
untreated participants.
• Studies that used liquid culture as the reference standard.
• Studies where a consecutive or random sample of
participants were enrolled.
• Studies where the reference standard was blinded.
• Studies that only used fresh specimens.
• Studies that accounted for all participants in the analysis.
We excluded studies where we answered ‘no’ or ‘unclear’ to the
QUADAS-2 Flow and Timing signalling question: Were all
patients included in the analysis?
In addition, in order to assess the influence of two largemulticentre
manufacturer-supported studies on the summary estimates, we
performed an analysis excluding these studies (Boehme 2010;
Boehme 2011).
For the sensitivity analyses, we restricted the studies to those that
included unselected participants; i.e. we excluded studies that pre-
selected participants on the basis of a prior smear microscopy re-
sult or previous tuberculosis treatment.
Assessment of reporting bias
We chose not to carry out formal assessment of publication bias
using methods such as funnel plots or regression tests, because
such techniques have not been helpful for diagnostic test accuracy
studies (Macaskill 2010). However, Xpert MTB/RIF and Xpert
Ultra are produced by only one manufacturer and, as tests for
which there has been considerable attention and scrutiny, we be-
lieve reporting bias was minimal.
16Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Other analyses
Nontuberculous mycobacteria (NTM)
NTM, such asM avium complex andM intracellulare, comprise a
multi-species group of humanpathogens that are ubiquitous inwa-
ter and soil. NTMs can cause severe pulmonary and other diseases
that share clinical signs with tuberculosis but are treated differ-
ently. People living with HIV with severe immunosuppression are
particularly vulnerable to infections caused by NTM (Gopinath
2010). We summarized separately data for NTM by determining
the percent of false-positive Xpert MTB/RIF results (data were
only reported for Xpert MTB/RIF) in samples that grew NTMs
(see Results: Other analyses: NTM).
Assessment of certainty of the evidence
Four review authors assessed the certainty of the evidence (also
called quality of the evidence) using the GRADE approach
(Balshem 2011; Schünemann 2008; Schünemann 2016), and
GRADEpro Guideline Development Tool (GDT) software (
GRADEpro GDT 2015). In the context of a systematic review,
ratings of the certainty of the evidence reflect the extent of our
confidence that the estimates of effect (including test accuracy and
associations) are correct. As recommended, we rated the certainty
of the evidence as either high (not downgraded), moderate (down-
graded by one level), low (downgraded by two levels), or very
low (downgraded by more than two levels) for five domains: risk
of bias, indirectness, inconsistency, imprecision, and publication
bias.
For each outcome, we considered the certainty of the evidence
to begin as high when high-quality observational studies (cross-
sectional or cohort studies) enrolled participants with diagnostic
uncertainty. If we had a reason for downgrading, we used our
judgement to classify the reason as serious (downgraded by one
level) or very serious (downgraded by two levels). We summarized
this information in the ‘Summary of findings’ tables (Summary of
findings 1; Summary of findings 2).
We applied GRADE in the following ways.
• Risk of bias: we used QUADAS-2 to assess risk of bias.
• Indirectness: we used QUADAS-2 for concerns of
applicability and looked for important differences between the
populations studied (for example, the spectrum of disease), the
setting, index test, and outcomes, and asked whether differences
were sufficient to lower certainty in results.
• Inconsistency: GRADE recommends downgrading for
unexplained inconsistency in sensitivity and specificity estimates.
We carried out prespecified analyses to investigate potential
sources of heterogeneity and did not downgrade when we
believed we could explain inconsistency in the accuracy estimates.
• Imprecision: we considered a precise estimate to be one that
would allow a clinically meaningful decision. We considered the
width of the CrI and asked ourselves, ‘Would we make a different
decision if the lower or upper boundary of the CrI represented
the truth?’. In addition, we worked out projected ranges for TP,
FN, TN, and FP for a given prevalence of tuberculosis and made
judgements on imprecision from these calculations. We also
considered whether the number of participants included in the
analysis was less than the number generated by a conventional
sample size calculation for a single adequately-powered study.
• Publication bias: we rated publication bias as undetected
(not serious) because of the comprehensiveness of the literature
search and following extensive outreach to tuberculosis
researchers to identify studies. As we included a large number of
studies, we thought that had we missed several small studies, the
results would probably not be different.
R E S U L T S
Results of the search
We identified 95 unique studies, integrating 77 new studies since
publication of the Cochrane Review (Steingart 2014). All stud-
ies but one (Huang 2015 in Chinese) were written in English.
For PTB detection, rifampicin resistance detection, or both PTB
and rifampicin resistance detection, all 95 studies evaluated Xpert
MTB/RIF (Xpert MTB/RIF) and one study compared Xpert
MTB/RIF and Xpert MTB/RIF Ultra (Xpert Ultra) (Dorman
2018). Of the total 86 studies for PTB detection, 48 studies eval-
uated the test for detection of both PTB and rifampicin resistance
and 38 studies for PTB alone.Of the total 57 studies for rifampicin
resistance detection, nine studies evaluated the test for rifampicin
resistance alone. Figure 3 shows the flow of studies in the review.
We recorded the excluded studies, including those listed in the
previous Cochrane Review (Steingart 2014), and the reasons for
their exclusion in the Characteristics of excluded studies table.
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Figure 3. Flow diagram of studies in the review. To identify other systematic reviews, we performed an
additional literature search on 26 March 2018 (Table 5).
Methodological quality of included studies
Studies evaluating Xpert MTB/RIF and Xpert Ultra
for detection of PTB
Figure 4, Figure 5, and Figure 6 show risk of bias and applicability
concerns for 86 studies evaluating Xpert MTB/RIF and Xpert
Ultra for tuberculosis detection.
Figure 4. Risk of bias and applicability concerns graph for pulmonary tuberculosis detection: review
authors’ judgements about each domain presented as percentages across included studies.
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Figure 5. Risk of bias and applicability concerns summary for pulmonary tuberculosis detection: review
authors’ judgements about each domain for each included study, studies A through K.
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Figure 6. Risk of bias and applicability concerns summary for pulmonary tuberculosis detection: review
authors’ judgements about each domain for each included study, studies L through Z.
20Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
In the Patient Selection domain, we considered 55 studies (64%)
to have low risk of bias because the study enrolled a consecutive or
random sample of eligible participants and avoided inappropriate
exclusions. We considered 16 studies (19%) to have high risk of
bias because the study did not avoid inappropriate exclusions: 13
studies enrolled participants whose sputum specimens were pri-
marily or exclusively smear-positive or smear-negative (Barnard
2015; Friedrich 2011; Jo 2016; Lee 2013; Le Palud 2014; Meyer
2017; Mok 2016; Moure 2011; Tadesse 2016; Theron 2013; Van
Rie 2013; Walusimbi 2013a; Williamson 2012) and three stud-
ies exclusively enrolled participants who had previously received
tuberculosis treatment (Meawed 2016; Metcalfe 2015; Pimkina
2015). In addition, we considered 15 studies (17%) to have un-
clear risk of bias because the manner of participant selection
was not stated (Atwebembeire 2016; Barmankulova 2015; Bates
2013a; Boum 2016; Chen 2017; Huang 2015; Kim CH 2015;
Luetkemeyer 2016; Mbelele 2017; Moussa 2016; Mutingwende
2015; Nosova 2013a; Reechaipichitkul 2017; Shao 2017; Shenai
2016). With respect to applicability, we considered 46 studies
(53%) to have low concern because participants in these stud-
ies were evaluated in primary care facilities, local hospitals, or
both settings (Adelman 2015; Al-Darraji 2013; Balcells 2012;
Balcha 2014; Barmankulova 2015; Bjerrum 2016; Boehme 2010;
Boehme 2011; Boum 2016; Calligaro 2017; Carriquiry 2012;
Chen 2017; Dorman 2018; Friedrich 2011; Hanrahan 2013;
Hanrahan 2014; Henostroza 2016; Huang 2015; Kurbaniyazova
2017; Kurbatova 2013; Kwak 2013; LaCourse 2016; Lawn 2011;
Luetkemeyer 2016; Meawed 2016; Metcalfe 2015; Mollel 2017;
Moure 2011; Mutingwende 2015; Ngabonziza 2016; Nliwasa
2016; O’Donnell 2015; Pimkina 2015; Reddy 2017; Rice 2017;
Scott 2011; Scott 2017; Shao 2017; Shenai 2016; Sohn 2014;
Ssengooba 2014; Theron 2011; Theron 2014a; Van Rie 2013;
Walusimbi 2013a; Yoon 2017). We considered 10 studies (12%)
to have high concern because participants were evaluated exclu-
sively as inpatients in tertiary care centres (Bates 2013a; Calligaro
2015; Chaisson 2014; Chew 2016; Cowan 2017; Davis 2014;
Kim CH 2015; Lippincott 2014; Meyer 2017; Mok 2016). We
considered 30 studies (35%) to have unclear concern because we
could not tell.
In the IndexTest domain, we considered all studies to have low risk
of bias.With respect to applicability, we consideredmost studies to
have lowconcern and eight studies to have unclear concernbecause
the ratio of sample reagent to specimen volume differed from that
recommended by the manufacturer or we could not tell (Balcells
2012; Friedrich 2011; Mok 2016; Moure 2011; Mutingwende
2015; Nosova 2013a; Reechaipichitkul 2017; Scott 2011).
In the Reference Standard domain, we considered 69 studies
(80%) to have low risk of bias because the results of the refer-
ence standard were interpreted without knowledge of the results
of the index test. We considered five studies (6%) to have high
risk of bias because the results of the reference standard were not
blinded (Chaisson 2014; Hanif 2011; Safianowska 2012; Zeka
2011; Zmak 2013) and the remaining 12 studies (14%) to have
unclear risk of bias because information about blinding was not
reported. With respect to applicability (Reference Standard do-
main), we considered most studies to have low concern; we con-
sidered one study to have high concern because this study did not
speciate mycobacteria isolated in culture (Mollel 2017) and two
studies (2%) to have unclear concern because we could not tell
(Adelman 2015; Barmankulova 2015).
In the Flow and Timing domain, we considered 72 studies (84%)
to have low risk of bias because all participants were included
in the analysis. We considered eight studies (9%) to have high
risk of bias: in seven studies, results for index or reference tests
were not available for many participants (Barmankulova 2015;
Barnard 2015; Boum 2016; Davis 2014; Mutingwende 2015;
Shao 2017; Van Rie 2013); in one study, participants who were
treated for tuberculosis on the basis of clinical and radiological
findings (smear-negative, culture-negative) were not included in
the analysis (Boehme 2011). We considered six studies (7%) to
have unclear risk of bias because we could not tell if all participants
were included in the analysis (Chaisson 2014; Dorman 2018;
Hanrahan 2014; Helb 2010; Rachow 2011; Tsuyuguchi 2017).
Studies evaluating Xpert MTB/RIF and Xpert Ultra
for detection of rifampicin resistance
Figure 7 and Figure 8 show risk of bias and applicability concerns
for 57 studies evaluating Xpert MTB/RIF and Xpert Ultra for
rifampicin resistance detection.
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Figure 7. Risk of bias and applicability concerns graph for rifampicin resistance detection: review authors’
judgements about each domain presented as percentages across included studies.
22Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Figure 8. Risk of bias and applicability concerns summary for rifampicin resistance detection: review
authors’ judgements about each domain for each included study.
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In the Patient Selection domain, we considered 36 studies (63%)
to have low risk of bias because the study enrolled a consecu-
tive or random sample of eligible participants and avoided inap-
propriate exclusions. We considered 10 studies (18% ) to have
high risk of bias because the study did not avoid inappropriate
exclusions and instead enrolled participants preselected on the
basis of their sputum specimens being either smear-positive or
smear-negative or the study exclusively enrolled retreatment par-
ticipants (Ali 2017; Friedrich 2011; Lee 2013; Le Palud 2014;
Makamure 2017; N’Guessan 2016; Tadesse 2016; Theron 2013;
Van Rie 2013; Williamson 2012). We considered 11 studies
(19%) to have unclear risk of bias because the manner of partic-
ipant selection was not reported (Barmankulova 2015; Barnard
2015; Bates 2013a; Huang 2015; Kim CH 2015; Luetkemeyer
2016; Meawed 2016; Moussa 2016; Nosova 2013a; Pimkina
2015; Singh 2016). With respect to applicability, we consid-
ered 26 studies (46%) to have low concern because participants
in these studies were evaluated in primary care facilities, lo-
cal hospitals, or both settings (Al-Darraji 2013; Balcells 2012;
Barmankulova 2015; Boehme 2010; Boehme 2011; Carriquiry
2012; Chikaonda 2017; Dorman 2018; Friedrich 2011; Huang
2015; Kurbaniyazova 2017; Kurbatova 2013; Kwak 2013; Lawn
2011; Lorent 2015; Luetkemeyer 2016; Meawed 2016; Metcalfe
2016; O’Donnell 2015; Pimkina 2015; Rice 2017; Scott 2011;
Sohn 2014; Ssengooba 2014; Theron 2011; Van Rie 2013). We
considered four studies to have high concern (7%) because par-
ticipants were evaluated exclusively as inpatients in tertiary care
centres (Bates 2013a; Calligaro 2015; Kim CH 2015; Lippincott
2014). We considered the remaining 27 studies (47%) to have
unclear concern because we could not tell.
In the Index Test domain, we considered all studies to have low
risk of bias. With respect to applicability, we considered 53 studies
(93%) to have low concern and four studies (7%) to have unclear
concern because the ratio of sample reagent to specimen volume
differed from that recommended by the manufacturer (Friedrich
2011; Nosova 2013a; Scott 2011; Singh 2016).
In the Reference Standard domain, we considered 47 studies
(82%) to have low risk of bias because the results of the reference
standard were interpreted without knowledge of the results of the
index test. We considered four studies (7%) to have high risk of
bias because the result of the reference standard was not blinded
(Lorent 2015; Safianowska 2012; Zeka 2011; Zmak 2013) and the
remaining six studies (11%) to have unclear risk of bias because
information was not reported. With respect to applicability in the
Reference Standard domain, we considered all studies to have low
concern because in these studies all specimens had already been
speciated and identified as Mycobacterium tuberculosis.
In the Flow and Timing domain, we considered 51 studies (90%)
to have low risk of bias because all participants were included in
the analysis. We considered three studies (5%) to have high risk
of bias because index and reference test results were not available
for many participants (Barmankulova 2015; Barnard 2015; Van
Rie 2013). We considered three studies (5%) to have unclear risk
of bias because we could not tell if all participants were included
in the analysis (Dorman 2018; Rachow 2011; Tsuyuguchi 2017).
Findings
I. Detection of PTB
A total of 86 studies involving 42,091 participants evaluated the
accuracy of Xpert MTB/RIF for PTB (Figure 9). For two multi-
centre studies (Boehme 2010; Boehme 2011) we provide two-by-
two data for the individual centres in Appendix 2. The median
number of participants in the studies was 256 (Interquartile range
(IQR) 145 to 494). Key characteristics for the included studies are
presented in Characteristics of included studies.
24Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Figure 9. Forest plots of Xpert sensitivity and specificity for detection of pulmonary tuberculosis. The
individual studies are ordered by decreasing sensitivity. The squares represent the sensitivity and specificity of
one study, the black line its confidence interval. FN: false-negative; FP: false-positive; TN: true-negative; TP:
true-positive.
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A. Primary analysis, Xpert MTB/RIF and Xpert Ultra for
detection of PTB
A.1. Xpert MTB/RIF
For the 86 studies, sensitivity estimates ranged from 43% to 100%
(Figure 9). Differences in enrolment criteria (different popula-
tions targeted), disease severity, and settings were notable in sev-
eral studies with low sensitivity: LaCourse 2016 (sensitivity 43%)
included HIV-positive pregnant women accessing prevention of
mother-to-child transmission services (no tuberculosis symptoms
reported) and sensitivity was based on a small number of tubercu-
losis cases (seven tuberculosis cases). Sohn 2014 (sensitivity 44%)
evaluated induced sputum specimens from participants with pre-
sumptive PTB, most of whom were asymptomatic. Atwebembeire
2016 (sensitivity 48%) only included adults unable to produce
sputumand frozen specimens. Adelman 2015 andAl-Darraji 2013
included few tuberculosis cases. Yoon 2017 enrolledHIV-positive
people initiating antiretroviral therapy. Lawn 2011 includedHIV-
positive participants irrespective of tuberculosis symptoms. Speci-
ficity varied less than sensitivity, with specificity estimates rang-
ing from 52% to 100%, although most specificity estimates were
greater than 90% (Figure 9). Nikam 2014 (specificity 52%) was
an outlier, and although we corresponded with the study author
we could not explain the low specificity in this study.
A.1.a. Xpert MTB/RIF accuracy, all studies meeting inclusion
criteria
In this meta-analysis, we included 85 studies involving 41,965
participants. We excluded one study that only reported sensitiv-
ity data (Friedrich 2011). Xpert pooled sensitivity and specificity
(95% credible interval (CrI)) were 85% (82% to 87%) and 98%
(97% to 98%), respectively (Table 1).
A.1.b. Xpert MTB/RIF accuracy, limited to studies with
unselected participants
We included 70 studies involving 37,237 unselected partici-
pants (Adelman 2015; Al-Darraji 2013; Atwebembeire 2016;
Balcells 2012; Balcha 2014; Barmankulova 2015; Bates 2013a;
Bjerrum 2016; Boehme 2010; Boehme 2011; Boum 2016;
Calligaro 2015; Calligaro 2017; Carriquiry 2012; Chaisson 2014;
Chen 2017; Chew 2016; Cowan 2017; Davis 2014; Dorman
2018; Geleta 2015; Hanif 2011; Hanrahan 2013; Hanrahan
2014; Helb 2010; Henostroza 2016; Huang 2015; Huh 2014;
Kawkitinarong 2017; Kim CH 2015; Ko 2016; Kurbaniyazova
2017; Kurbatova 2013; Kwak 2013; LaCourse 2016; Lawn 2011;
Lippincott 2014; Liu 2017; Luetkemeyer 2016; Mbelele 2017;
Mollel 2017; Moussa 2016; Mutingwende 2015; Ngabonziza
2016; Nikam 2014; Nliwasa 2016; Nosova 2013a; O’Donnell
2015; Park 2013; Pinyopornpanish 2015; Rachow 2011; Reddy
2017; Reechaipichitkul 2017; Rice 2017; Safianowska 2012; Sah
2017; Scott 2011; Scott 2017; Shao 2017; Sharma 2015; Shenai
2016; Sohn 2014; Ssengooba 2014; Tang 2017; Theron 2011;
Theron 2014a; Tsuyuguchi 2017; Yoon 2017; Zeka 2011; Zmak
2013). We excluded 16 studies, i.e. 13 studies that preselected
participants on the basis of a prior smear microscopy result
(participants whose sputum specimens were primarily or exclu-
sively smear-positive or smear-negative) (Barnard 2015; Friedrich
2011; Jo 2016; Lee 2013; Le Palud 2014; Meyer 2017; Mok
2016; Moure 2011; Tadesse 2016; Theron 2013; Van Rie 2013;
Walusimbi 2013a; Williamson 2012) and three studies that prese-
lected participants who had previously received tuberculosis treat-
ment (Meawed 2016; Metcalfe 2015; Pimkina 2015) (Figure 10).
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Figure 10. Forest plots of Xpert sensitivity and specificity for detection of pulmonary tuberculosis in studies
with unselected participants. The individual studies are ordered by decreasing sensitivity. The squares
represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false-negative;
FP: false-positive; TN: true-negative; TP: true-positive.
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XpertMTB/RIF pooled sensitivity and specificity (95% Crl) were
85% (82% to 88%) and 98% (97% to 98%), essentially the same
as the estimates obtained when including all studies regardless of
their selection criteria (Table 1).
Figure 11 presents the pooled and predicted sensitivity and speci-
ficity estimates together with the credible and prediction regions
for Xpert MTB/RIF for PTB. The summary point (pooled value)
appears close to the upper left-hand corner of the plot, suggesting
high accuracy of Xpert MTB/RIF for detection of PTB. The 95%
credible region around the summary point of sensitivity and speci-
ficity, the region that contains likely combinations of the pooled
sensitivity and specificity, is relatively narrow. The 95% prediction
region is wider, displaying more uncertainty as to where the likely
values of sensitivity and specificity might occur in a future study.
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Figure 11. Summary plots of Xpert MTB/RIF sensitivity and specificity for detection of pulmonary
tuberculosis. Each individual study is represented by an empty square. The size of the square is proportional to
the sample size of the study such that larger studies are represented by larger squares. The filled circle is the
median pooled estimate for sensitivity and specificity. The solid curves represent the 95% credible region
around the summary estimate; the dashed curves represent the 95% prediction region.
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A.2. Xpert Ultra
We identified one study that evaluated Xpert Ultra for PTB
(Dorman 2018). This multicentre study, which took place in Be-
larus, Brazil, China, Georgia, India, Kenya, South Africa, and
Uganda, compared Xpert Ultra and Xpert MTB/RIF on the same
participant specimens, (1439 participants). Based on a reference
standard of multiple cultures, Xpert Ultra yielded higher sensitiv-
ity at 88% (95% CI 85% to 91%), compared to Xpert MTB/RIF
sensitivity of 83% (79% to 86%), and lower specificity at 96%
(94% to 97%), compared to Xpert MTB/RIF specificity of 98%
(97% to 99%) (Figure 12).
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Figure 12. Summary ROC plots for sensitivity and specificity of Xpert MTB/RIF and Xpert Ultra for
detection of pulmonary tuberculosis.
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B. Investigations of heterogeneity
Unless otherwise noted, investigations of heterogeneity are limited
to those studies that enrolled unselected participants.
B.1. Xpert MTB/RIF for detection of PTB by smear status
B.1.a. Xpert MTB/RIF accuracy in participants with smear-
positive sputum specimens
Figure 13 displays the forest plots for studies reporting data for
participants with smear-positive specimens. Sensitivity estimates
ranged from 75% to 100% and specificity estimates from 0% to
100%. We thought some of the variability in specificity estimates
could be explained by small numbers of participants included in
the studies. In addition, in some studies, including the four largest,
the value for true negatives was zero (tuberculosis was not present
when measured against culture), and all participants were consid-
ered to be true positives (tuberculosis was present when measured
against culture).
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Figure 13. Forest plots of Xpert MTB/RIF sensitivity and specificity for detection of pulmonary tuberculosis,
participants with smear-positive (culture-positive) specimens. The individual studies are ordered by decreasing
sensitivity. The squares represent the sensitivity and specificity of one study, the black line its confidence
interval. FN: false-negative; FP: false-positive; TN: true-negative; TP: true-positive.
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For smear-positive, culture-positive PTB, using a univariate ran-
dom-effects model and including all studies for which sensitivity
data were available, XpertMTB/RIF pooled sensitivity (95% CrI)
was 98% (97% to 99%) (53 studies, 4574 participants). We did
not determine pooled specificity because inmany studies the value
for true negatives was zero.
B.1.b. Xpert MTB/RIF accuracy in participants with smear-
negative sputum specimens
Figure 14 displays the forest plots for studies reporting data for
participants with smear-negative specimens. Sensitivity estimates
ranged from 28% to 100%. The lowest sensitivity was described
by Sohn 2014; this study evaluated induced sputum specimens
from participants with presumptive PTB, most of whom were
asymptomatic. Specificity estimates ranged from 57% to 100%.
The lowest specificity was described by Nikam 2014, with the
remaining 55 studies ranging in specificity from 83% to 100%.
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Figure 14. Forest plots of Xpert MTB/RIF sensitivity and specificity for detection of pulmonary tuberculosis,
participants with smear-negative (culture-positive) specimens. The individual studies are ordered by
decreasing sensitivity. The squares represent the sensitivity and specificity of one study, the black line its
confidence interval. FN: false-negative; FP: false-positive; TN: true-negative; TP: true-positive.
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For smear-negative, culture-positive PTB, using a bivariate model
and including all studies for which sensitivity and specificity data
were available, Xpert MTB/RIF pooled sensitivity and specificity
(95% CrI) were 67% (63% to 72%) and 98% (97% to 99%), (56
studies, 22,581 participants).
B.1.c. Xpert MTB/RIF accuracy by smear status, studies that
provided data for both smear-positive and smear-negative
participants
We limited this analysis to 45 studies that reported results for
participants with smear-positive specimens and smear-negative
specimens within the same study (Balcells 2012; Balcha 2014;
Boehme 2010; Boehme 2011; Carriquiry 2012; Chaisson 2014;
Chen 2017; Chew 2016; Cowan 2017; Davis 2014; Dorman
2018; Geleta 2015; Hanif 2011; Hanrahan 2013; Hanrahan
2014; Helb 2010; Huang 2015; Huh 2014; Kawkitinarong 2017;
Ko 2016; Kurbatova 2013; Kwak 2013; Lawn 2011; Lippincott
2014; Luetkemeyer 2016;Moussa 2016Ngabonziza 2016;Nikam
2014; O’Donnell 2015; Park 2013; Rachow 2011; Reddy 2017;
Reechaipichitkul 2017; Rice 2017; Safianowska 2012; Sah 2017;
Scott 2011; Shao 2017; Sharma 2015; Shenai 2016; Sohn 2014;
Theron 2011; Tsuyuguchi 2017; Zeka 2011; Zmak 2013). For
smear-positive tuberculosis, Xpert MTB/RIF pooled sensitivity
was 98% (97% to 98%), considerably higher than the sensitivity
of 68% (63% to 73%) for smear-negative tuberculosis (Table 2).
B.1.d. Xpert MTB/RIF versus Xpert Ultra for detection of PTB by
smear status, direct comparison
One study compared Xpert Ultra and Xpert MTB/RIF for de-
tection of PTB by smear status against a reference standard of
multiple cultures (Dorman 2018). In smear-positive participants,
sensitivities (95% CI) of Xpert Ultra and Xpert MTB/RIF were
identical at 99% (97% to 100%) (323 participants). In smear-neg-
ative participants, Xpert Ultra yielded higher sensitivity at 63%
(95% CI 54% to 71%), compared to Xpert MTB/RIF sensitiv-
ity of 46% (37% to 55%), and lower specificity at 96% (94% to
97%), compared to Xpert MTB/RIF specificity of 98% (97% to
99%) (Figure 15).
Figure 15. Forest plots comparing Xpert MTB/RIF and Xpert Ultra sensitivity and specificity for detection
of pulmonary tuberculosis in smear-positive and smear-negative participants. The individual studies are
ordered by decreasing sensitivity. The squares represent the sensitivity and specificity of one study, the black
line its CI. TP = true positive; FP = false positive; FN = false negative; TN = true negative.
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B.2. Xpert MTB/RIF for detection of PTB by HIV status
B.2.a. Xpert MTB/RIF accuracy in HIV-negative people
In HIV-negative participants, Xpert MTB/RIF sensitivity esti-
mates ranged from 56% to 100% and specificity estimates from
95% to 100% (Figure 16). We included all studies that provided
data in this analysis. In HIV-negative participants, Xpert MTB/
RIF pooled sensitivity and specificity (95% CrI) were 89% (85%
to 92%) and 98% (97% to 99%), (18 studies, 5118 participants).
Figure 16. Forest plots of Xpert MTB/RIF sensitivity and specificity for detection of pulmonary tuberculosis
in HIV-negative participants. The individual studies are ordered by decreasing sensitivity. The squares
represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false-negative;
FP: false-positive; TN: true-negative; TP: true-positive.
B.2.b. Xpert MTB/RIF accuracy in HIV-positive people
In HIV-positive participants, Xpert MTB/RIF sensitivity esti-
mates ranged from 67% to 100% and specificity estimates from
92% to 100% (Figure 17). We included all studies that provided
data in this analysis. In HIV-positive participants, Xpert MTB/
RIF pooled sensitivity and specificity (95% CrI) were 77% (71%
to 82%) and 98% (98% to 99%), (30 studies, 9589 participants).
37Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Figure 17. Forest plots of Xpert MTB/RIF sensitivity and specificity for detection of pulmonary tuberculosis
in HIV-positive participants. The individual studies are ordered by decreasing sensitivity. The squares
represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false-negative;
FP: false-positive; TN: true-negative; TP: true-positive.
B.2.c. Xpert MTB/RIF accuracy by HIV status, studies that
provided data for both HIV-negative and HIV-positive
individuals
We limited this analysis to 14 studies that reported results forHIV-
negative and HIV-positive participants within the same study (
Bates 2013a; Boum 2016; Boehme2010; Boehme2011; Calligaro
2015; Calligaro 2017; Dorman 2018; Hanrahan 2013; Hanrahan
2014; Luetkemeyer 2016; Pinyopornpanish 2015; Rachow 2011;
Scott 2011; Theron 2011). In HIV-negative participants, Xpert
MTB/RIF pooled sensitivity was 88% (83% to 92%), higher than
the sensitivity of 81% (75% to 86%) inHIV-positive participants,
although the 95% CrIs overlapped. In HIV-negative participants,
Xpert MTB/RIF pooled specificity was 98% (97% to 99%), the
same as the pooled specificity of 98% (97% to 99%) in HIV-
positive participants (Table 2; Figure 18).
38Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Figure 18. Forest plots of Xpert MTB/RIF sensitivity and specificity for detection of pulmonary tuberculosis,
HIV-negative and HIV-positive participants compared within the same study. The squares represent the
sensitivity and specificity of one study, the black line its confidence interval. FN: false-negative; FP: false-
positive; TN: true-negative; TP: true-positive.
Figure 19 displays the summary ROC plot comparing Xpert
MTB/RIF accuracy in HIV-negative and HIV-positive people
in studies that involved both subgroups. The test demonstrated
higher accuracy in HIV-negative people.
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Figure 19. Summary plots of Xpert MTB/RIF sensitivity and specificity for detection of pulmonary
tuberculosis in HIV-negative people (red) and HIV-positive people (black). Each individual study is represented
by an empty square. The of the square is proportional to the sample size of the study such that larger studies
are represented by larger squares. The filled circle is the pooled median estimate for sensitivity and specificity.
The solid curve represents the 95% credible region around the summary estimate; the dashed curves
represent the 95% prediction region.
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B.2.d. Xpert MTB/RIF versus Xpert Ultra for detection of PTB by
HIV status, direct comparison
One study compared Xpert Ultra and Xpert MTB/RIF for detec-
tion of PTB by HIV status against a reference standard of multi-
ple cultures (Dorman 2018). In HIV-negative participants, Xpert
Ultra sensitivity (95% CI) was 91% (86% to 95%) compared to
Xpert MTB/RIF sensitivity of 90% (84% to 94%). In HIV-pos-
itive participants, Xpert Ultra yielded a higher sensitivity at 90%
(82% to 94%), compared to Xpert MTB/RIF sensitivity of 77%
(68% to 84%), and a lower specificity at 96% (93% to 98%)
compared to Xpert MTB/RIF specificity of 99% (98% to 100%)
(Figure 20).
Figure 20. Forest plots comparing Xpert MTB/RIF and Xpert Ultra sensitivity and specificity for detection
of pulmonary tuberculosis in HIV-negative and HIV-positive participants. The individual studies are ordered by
decreasing sensitivity. The squares represent the sensitivity and specificity of one study, the black line its CI.
TP = true positive; FP = false positive; FN = false negative; TN = true negative.
B.3. Xpert MTB/RIF accuracy for detection of PTB in
participants with a history of tuberculosis or previous
tuberculosis treatment
B.3.a. Xpert MTB/RIF accuracy in participants with a
history of tuberculosis
Eleven studies (4196 participants) reported a higher percentage
(> 25%) of participants with a history of tuberculosis (Adelman
2015; Al-Darraji 2013; Boehme 2010; Kawkitinarong 2017; Ko
2016; Lawn 2011; Mutingwende 2015; O’Donnell 2015; Reddy
2017; Reechaipichitkul 2017; Theron 2011) and 16 studies (8205
participants) reported a lower percentage (≤ 25%) of partici-
pants with a history of tuberculosis (Balcha 2014; Barmankulova
2015; Bates 2013a; Bjerrum 2016; Boehme 2010; Boum 2016;
41Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Carriquiry 2012; Dorman 2018; Hanrahan 2013; Helb 2010;
LaCourse 2016; Luetkemeyer 2016; Mbelele 2017; Scott 2017;
Sohn 2014; Yoon 2017). In studies with a higher percentage of
participants with previous tuberculosis, Xpert MTB/RIF pooled
sensitivity (95% CrI) was 86% (82% to 89%), similar to the
pooled sensitivity of 85% (81% to 89%) in studies with a lower
percentage of participants with previous tuberculosis. In studies
with a higher percentage of participants with previous tuberculo-
sis, Xpert MTB/RIF pooled specificity was 97% (95% to 98%),
lower than the specificity of 99% (98% to 99%) in studies with a
lower percentage of participants with previous tuberculosis (Table
2).
B.3.b. Xpert MTB/RIF accuracy in participants who had
received previous tuberculosis treatment
We identified three studies involving 999 participants that pref-
erentially enrolled participants who had received previous tuber-
culosis treatment (Meawed 2016; Metcalfe 2015; Pimkina 2015).
Sensitivity estimates ranged from 92% to 98% and specificity esti-
mates from 75% to 92%. Xpert MTB/RIF pooled sensitivity and
specificity (95% CrI) were 94% (87% to 97%) and 89% (75%
to 95%) respectively. Xpert MTB/RIF pooled specificity was con-
siderably lower than the pooled specificity of 98% (97% to 98%)
in the primary analysis (70 studies).
B.4. Xpert MTB/RIF accuracy by tuberculosis burden
There were 39 studies (21,965 participants) conducted in high
tuberculosis burden countries and 33 studies (5272 participants)
conducted in countries not considered to be high tuberculosis
burden. In countries with high tuberculosis burden, Xpert MTB/
RIF pooled sensitivity (95% CrI) was 86% (82% to 89%), similar
to the pooled sensitivity of 85% (81% to 89%) in countries not
considered to be high tuberculosis burden. In countries with high
tuberculosis burden, Xpert MTB/RIF pooled specificity was 97%
(95% to 98%), lower than the pooled specificity of 99% (98% to
99%) in countries not considered to be high tuberculosis burden
(Table 2).
B.5. Xpert MTB/RIF accuracy by TB/HIV burden
There were 42 studies (24,412 participants) conducted in high
TB/HIV burden countries and 30 studies (12,825 participants)
conducted in countries not considered to be high TB/HIV bur-
den. In countries with high TB/HIV burden, Xpert MTB/RIF
pooled sensitivity (95% CrI) was 83% (80% to 87%), lower than
the pooled sensitivity of 88% (84% to 90%) in countries not
considered to be high TB/HIV burden, although there was con-
siderable overlap in the Crls around these estimates. In countries
with high TB/HIV burden, Xpert MTB/RIF pooled specificity
was 97% (95% to 98%), lower than the pooled specificity of 99%
(98% to 99%) in countries not considered to be high TB/HIV
burden (Table 2).
B.6. Xpert MTB/RIF accuracy by setting that ran the test
There were 10 studies (5816 participants) that ran Xpert MTB/
RIF at point of care or in a peripheral setting (Al-Darraji
2013; Calligaro 2017; Chaisson 2014; Chew 2016; Geleta 2015;
Hanrahan 2013; Huang 2015; Kurbaniyazova 2017; Shao 2017;
Theron 2014a), and 60 studies (31,421 participants) that ran
Xpert MTB/RIF in an intermediate or central-level laboratory. In
studies running XpertMTB/RIF at point of care or in a peripheral
setting, the pooled sensitivity (95% CrI) was 83% (75% to 89%),
lower than the sensitivity of 85% (83% to 88%) in studies running
Xpert MTB/RIF in an intermediate or central-level laboratory. In
peripheral settings, the pooled specificity was 97% (94% to 99%),
lower than the pooled specificity of 98% (97% to 98%) in more
advanced laboratories. However, there was considerable overlap in
Crls around these accuracy estimates (Table 2).
B.7. Xpert MTB/RIF accuracy by tuberculosis prevalence
The prevalence of PTB cases confirmed by culture in the studies
ranged from 0.8% (Chen 2017) to 100% (Friedrich 2011). Based
on a median tuberculosis prevalence of 26%, in settings with tu-
berculosis prevalence above 26%, Xpert MTB/RIF pooled sensi-
tivity (95% CrI) was 89% (87% to 91%), higher than the pooled
sensitivity of 79% (75% to 83%) in settings with tuberculosis
prevalence at or below 26%. The corresponding pooled specifici-
ties were 96% (94% to 97%) and 99% (98% to 99%) (Table 2).
Uninterpretable results, detection of PTB
Among 47 studies involving 31,979 tests, the pooled proportion
of uninterpretable test results for Xpert MTB/RIF was very low,
at 1.1% (0.7% to 1.5%). In the study comparing Xpert Ultra
and Xpert MTB/RIF, of 2001 specimens initially tested, uninter-
pretable results were found for 79 specimens (4%) with Xpert Ul-
tra and 39 specimens (2%) with Xpert MTB/RIF. After exclusion
of errors related to instrumentation, uninterpretable results were
found for 64 specimens (3%) with Xpert Ultra and 28 specimens
(1%) with Xpert MTB/RIF (Dorman 2018).
II. Detection of rifampicin resistance
A. Xpert MTB/RIF for detection of rifampicin resistance
1.a. Primary analysis, Xpert MTB/RIF
The 57 studies involved 8287 specimens, of which 1775 were
rifampicin-resistant, median 88 specimens (range 1 to 250). Six
42Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
studies accounted for most (63%, 1127/1775) of the rifampicin-
resistant specimens (Boehme 2010; Boehme 2011;Dorman 2018;
Huang 2015; Kurbaniyazova 2017; Sharma 2015) (Figure 21).
Although there was heterogeneity in sensitivity estimates (ranging
from 75% to 100%), in general there was less variability among
studies with a higher number of rifampicin-resistant specimens.
Specificity showed less variability than sensitivity, ranging from
83% to 100%.
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Figure 21. Forest plots of Xpert MTB/RIF sensitivity and specificity for detection of rifampicin resistance.
The individual studies are ordered by decreasing sensitivity. The squares represent the sensitivity and
specificity of one study, the black line its CI. TP = true positive; FP = false positive; FN = false negative; TN =
true negative.
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XpertMTB/RIF pooled sensitivity and specificity (95% CrI) were
96% (94% to 97%) and 98% (98% to 99%) (48 studies, 8020
participants) (Table 1).
1.b. Primary analysis, Xpert Ultra
One study (Dorman 2018) evaluatedXpertUltra andXpertMTB/
RIF in the same participants for detection of rifampicin resistance.
The sensitivity and specificity estimates were similar. Xpert Ultra
sensitivity and specificity (95% CI) were 95% (90% to 98%) and
98% (97% to 99%) respectively (551 specimens, including 175
rifampicin-resistant specimens); while XpertMTB/RIF sensitivity
and specificity were 95% (91% to 98%) and 98% (96% to 99%)
respectively (552 specimens, including 175 rifampicin-resistant
specimens).
B. Investigations of heterogeneity, rifampicin resistance
B.1. Xpert MTB/RIF accuracy for detection of rifampicin
resistance by MDR-TB burden
In settings with high MDR-TB burden, Xpert MTB/RIF pooled
sensitivity (95% Crl) was 95% (93% to 97%), lower than the
pooled sensitivity of 97% (93% to 99%) for studies not in the
high MDR-TB category. The corresponding pooled specificities
(95% Crl) were 98% (96% to 99%) and 99% (95% CrI 98% to
99%) (Table 3). For both sensitivity and specificity, the 95% CrIs
in the two groups overlapped, suggesting that MDR-TB burden
did not have an effect on the accuracy estimates.
B.2. Xpert MTB/RIF accuracy for detection of rifampicin
resistance by previous tuberculosis treatment
Several studies designed to enrol participants suspected of MDR-
TB had high percentages of participants previously treated for
tuberculosis (Lorent 2015; Makamure 2017; Meawed 2016;
Metcalfe 2016; N’Guessan 2016; Pimkina 2015; Zetola 2014).
In these studies (7 studies, 1062 participants), Xpert MTB/RIF
pooled sensitivity at 98% (95%CrI 94% to 99%) was higher than
the pooled sensitivity of 95% (93% to 97%) in studies that did
not preferentially enrol previously treated participants (41 studies,
6958 participants); and conversely, pooled specificity was lower at
97% (93% to 99%) than the pooled specificity of 99% (95% CrI
98% to 99%) in studies that did not preferentially enrol previously
treated participants. However, for both sensitivity and specificity
estimates the CrIs overlapped, suggesting that previous tuberculo-
sis treatment did not have an effect on Xpert MTB/RIF accuracy
for detection of rifampicin resistance (Table 3).
B.3. Xpert MTB/RIF accuracy for detection of rifampicin
resistance by prevalence of rifampicin resistance
Based on a median prevalence of rifampicin resistance of 11%, in
studies with prevalence of rifampicin resistance above 11%, Xpert
MTB/RIF pooled sensitivity (95% CrI ) was 96% (94% to 97%),
higher than the pooled sensitivity of 94% (95% CrI 89% to 97%)
for studies with prevalence of rifampicin resistance at or below
11%, although the CrIs overlapped. The corresponding pooled
specificities were 97% (96% to 98%) and 99% (99% to 100%)
(Table 3).
Indeterminate results, rifampicin resistance
Among 21 studies involving 3591 tests, the pooled proportion of
Xpert MTB/RIF indeterminate test results was very low, at 0.9%
(0.4% to 1.5%). In the study comparing Xpert Ultra and Xpert
MTB/RIF, of 684 specimens tested, indeterminate results were
found for 16 specimens (2%) with Xpert Ultra and four specimens
(1%) with Xpert MTB/RIF (Dorman 2018).
Sensitivity analyses
For Xpert MTB/RIF for detection of PTB, we undertook sensi-
tivity analyses by limiting inclusion in the meta-analysis to:
• Studies that explicitly represented the use of the index test
for the diagnosis of individuals thought to have tuberculosis. We
excluded studies that involved HIV-positive participants
irrespective of tuberculosis symptoms;
• Studies where a single specimen yielded a single Xpert
MTB/RIF result for a given participant. We excluded studies
that included more specimens than participants;
• Studies that only included untreated participants;
• Studies that used liquid culture as the reference standard;
• Studies where a consecutive or random sample of
participants were enrolled;
• Studies where the reference standard was blinded;
• Studies that only used fresh specimens;
• Studies that accounted for all participants in the analysis.
We excluded studies where we answered ‘no’ or ‘unclear’ to the
QUADAS-2 Flow and Timing signalling question: Were all
patients included in the analysis?;
• Studies with exclusion of two large multicentre studies
(Boehme 2010; Boehme 2011).
These sensitivity analyses made little difference to any of the find-
ings (Table 4).
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Other analyses
NTM
Twenty-eight studies evaluating Xpert MTB/RIF and involving
8901 participants provided data on a variety of NTMs that
grew from the specimens tested, to look for evidence of cross-
reactivity: one NTM (Al-Darraji 2013); four NTMs (Balcells
2012); two NTMs (Barnard 2015); 50 NTMs (Bjerrum 2016);
one NTM (Chaisson 2014); 16 NTMs (Cowan 2017); three
NTMs (Davis 2014); 12 NTMs (Kim CH 2015); one NTM
(Kurbatova 2013); nine NTMs (Le Palud 2014); 16 NTMs (Lee
2013); 40 NTMs (Lippincott 2014); 14 NTMs (Lorent 2015);
95 NTMs (Luetkemeyer 2016); 20 NTMs (Moure 2011); four
NTMs (Nosova 2013a); 10 NTMs (Pinyopornpanish 2015); 45
NTMs (Rachow 2011); 122 NTMs (Rice 2017); seven NTMs
(Safianowska 2012); five NTMs (Scott 2011); three NTMs (Sohn
2014); 19 NTMs (Ssengooba 2014); two NTMs (Tang 2017);
eight NTMs (Theron 2011); three NTMs (Van Rie 2013); 22
NTMs (Williamson 2012); and twoNTMs (Zmak 2013). Among
these 28 studies comprising 536NTMs, XpertMTB/RIFwas pos-
itive in 16 specimens that grew NTMs, pooled proportion 2.0%
(0.4% to 4.4%). NTM data for Xpert Ultra were not reported.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Review question: What is the diagnost ic accuracy of Xpert MTB/ RIF and Xpert Ultra for detect ion of rif ampicin resistance?
Patients/population: Adults with conf irmed PTB
Role: An init ial test
Index tests: Xpert MTB/ RIF and Xpert Ultra
Threshold for index tests: An automated result is provided
Reference standards: Phenotypic culture-based DST and MTBDRplus
Studies: Cross-sect ional and cohort studies
Setting: Primary care facilit ies and local hospitals
Index test Effect (95% Crl) Number of partici-
pants (studies)
Test result Number of results per 1000 patients tested (95% CrI) Certainty of the evidence
(GRADE)
Prevalence 5% Prevalence 10% Prevalence 15%
Xpert MTB/ RIF Pooled sensit ivity
96% (94 to 97)
1775 (48 studies) True posit ives 48 (47 to 49) 96 (94 to 97) 144 (141 to 146) ⊕⊕⊕⊕
Higha
False nega-
t ives
2 (1 to 3) 4 (3 to 6) 6 (4 to 9)
Pooled specif icity
98% (98 to 99)
6245 (48 studies) True
negat ives
931 (931 to 941) 882 (882 to 891) 833 (833 to 842) ⊕⊕⊕⊕
Higha
False posi-
t ives
19 (9 to 19) 18 (9 to 18) 17 (8 to 17)
Xpert Ultra Sensit ivity 95% (90
to 98)
175 (1 study) True posit ives 48 (45 to 49) 95 (90 to 98) 143 (135 to 147) ⊕⊕⊕©
Moderateb,c
False nega-
t ives
2 (1 to 5) 5 (2 to 10) 7 (3 to 15)
Specif icity 98% (97
to 99)
376 (1 study) True
negat ives
931 (922 to 941) 882 (873 to 891) 833 (825 to 842) ⊕⊕⊕©
Moderateb,c
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False posi-
t ives
19 (9 to 28) 18 (9 to 27) 17 (8 to 25)
Abbreviat ions: CrI: credible interval; DST: drug suscept ibility test ing; PTB: pulmonary tuberculosis.
Prevalence est imates were suggested by the WHO Global TB Programme. The upper lim it for the prevalence of rif ampicin
resistance in new cases was est imated to be 5% (50/ 1000 cases); the lower lim it for the prevalence of rif ampicin resistance in
previously-treated cases was est imated to be 15% (150/ 1000 cases). For Xpert MTB/ RIF, the median prevalence of rif ampicin
resistance in the included studies was 11%. For Xpert Ultra, the prevalence of rif ampicin resistance in the study was 32%.
Credible lim its were est imated based on those around the point est imates for pooled sensit ivity and specif icity; 95%
conf idence intervals were est imated for the single study that evaluated Xpert Ultra.
a In the Patient Select ion domain, with respect to applicability, we had low concern in 46% of studies and high concern in only
7% of studies. In nearly half of the studies (47%) the clinical sett ing was not reported or there was insuf f icient information to
make a decision. We did not downgrade for indirectness.
bThe prevalence of rif ampicin resistance in the study was 32% (higher than the three prevalence levels considered in the
table). Although it is possible that the test will perform dif ferent ly at lower prevalences, we think that this is unlikely. The
magnitude of any ef fect (either direct ion) is probably small, given that in this study both Xpert MTB/ RIF and Xpert Ultra
sensit ivity and specif icity for rif ampicin resistance were nearly ident ical to the pooled sensit ivity and specif icity in the review.
We did not downgrade for indirectness.
cAlthough there was only one study on the accuracy of Xpert Ultra for rif ampicin resistance, this was a mult icentre study
conducted in eight countries (South Af rica, Uganda, Kenya, India, China, Georgia, Belarus, and Brazil). We downgraded by one
level for imprecision.
GRADE certainty of the evidence
High: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect,
but there is a possibility that it is substant ially dif f erent.
Low: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the
ef fect.
Very low: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the
est imate of ef fect.
The results presented in this table should not be interpreted in isolat ion f rom results of the individual included studies
contribut ing to each summary test accuracy measure.
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D I S C U S S I O N
This updated Cochrane Review on the diagnostic accuracy of
Xpert MTB/RIF (Xpert MTB/RIF) and Xpert MTB/RIF Ultra
(Xpert Ultra) for detection of tuberculosis and rifampicin resis-
tance in adults summarizes the current literature and integrates 77
new studies (81% of the total 95 included studies), identified since
the previous Cochrane Review (Steingart 2014). The findings in
this update are consistent with those reported previously.
Summary of main results
• For detection of PTB, Xpert MTB/RIF sensitivity and
specificity were 85% and 98%.
• Xpert MTB/RIF sensitivity was 98% for smear-positive,
culture-positive tuberculosis, and 67% for smear-negative,
culture-positive tuberculosis.
• Xpert MTB/RIF sensitivity for PTB was 88% in HIV-
negative people and 81% in HIV-positive people.
• For detection of PTB, the pooled proportion of Xpert
MTB/RIF uninterpretable test results was very low.
• For detection of rifampicin resistance, Xpert MTB/RIF
sensitivity and specificity were 96% and 98%.
• For detection of rifampicin resistance, the pooled
proportion of Xpert MTB/RIF indeterminate test results was
very low.
• In the one study that directly compared Xpert Ultra and
Xpert MTB/RIF, Xpert Ultra yielded a higher sensitivity (88%)
than Xpert MTB/RIF (83%), and a lower specificity (96%) than
Xpert MTB/RIF (98%).
• In the one study that directly compared Xpert Ultra and
Xpert MTB/RIF, for detection of smear-negative culture-positive
tuberculosis, Xpert Ultra yielded a higher sensitivity (63%) than
Xpert MTB/RIF (46%), and a lower specificity (96%) than
Xpert MTB/RIF (98%).
• In the one study that directly compared Xpert Ultra and
Xpert MTB/RIF, for detection of PTB in HIV-positive people,
Xpert Ultra yielded a higher sensitivity (90%) than Xpert MTB/
RIF (77%), and a lower specificity (96%) than Xpert MTB/RIF
(99%).
Xpert MTB/RIF for PTB
Results of these studies indicate that, in theory, for a population of
1000 people where 100 have tuberculosis on culture, 103 would
be XpertMTB/RIF-positive and 18 (17%) would not have tuber-
culosis (false-positives); 897 would be Xpert MTB/RIF-negative
and 15 (2%) would have tuberculosis (false-negatives) (Summary
of findings 1).
Xpert Ultra for PTB
Results of these studies indicate that, in theory, for a population of
1000 people where 100 have tuberculosis on culture, 124 would
be Xpert Ultra-positive; of these, 36 (29%) would not have tu-
berculosis (false-positives); and 876 would be Xpert Ultra-nega-
tive; of these, 12 (1%) would have tuberculosis (false-negatives)
(Summary of findings 1).
Xpert MTB/RIF for rifampicin resistance
Results of these studies indicate that, in theory, for a population of
1000 people where 100 have rifampicin-resistant tuberculosis, 114
would be positive for rifampicin-resistant tuberculosis; of these 18
(16%) would not have rifampicin resistance (false-positives); and
886 would be would be negative for rifampicin-resistant tubercu-
losis; of these, four (0.4%) would have rifampicin resistance (false-
negatives) (Summary of findings 2).
Xpert Ultra for rifampicin resistance
Results of these studies indicate that, in theory, for a population of
1000 people where 100 have rifampicin-resistant tuberculosis, 113
would be positive for rifampicin-resistant tuberculosis; of these,
18 (16%) would not have rifampicin resistance (false-positives);
and 887 would be negative for rifampicin-resistant tuberculosis; of
these, five (1%) would have rifampicin resistance (false-negatives)
(Summary of findings 2).
Xpert MTB/RIF performance in different subgroups and
settings
Xpert MTB/RIF detects DNA sequences of M tuberculosis after
amplification and has a lower limit of detection of 131 CFUs/
mL (Helb 2010). The cycle threshold value (CT ) is the number
of PCR cycles after which Xpert MTB/RIF probes successfully
detect M tuberculosis DNA in a given sample. Xpert MTB/RIF
CT values are strongly correlated with AFB smear status (Lange
2017). The lower sensitivity of Xpert MTB/RIF in individuals
with AFB smear-negative PTB is related to the lower bacillary
burden and higher associated CT value compared to individuals
with AFB smear-positive PTB. Individuals with PTB and HIV
co-infection are more likely to have smear-negative tuberculosis,
which implies a lower bacillary burden and highermean CT values
on Xpert testing (Beynon 2018; Lange 2017), and this is the likely
mechanism for the lower sensitivity of Xpert MTB/RIF for the
diagnosis of tuberculosis in people living with HIV.
In individuals with a history of treatment for tuberculosis, we
found that Xpert MTB/RIF pooled specificity (89%) was lower
than the pooled specificity in the primary analysis (98%). This
is consistent with findings from the literature that Xpert MTB/
RIF may be positive at the end of tuberculosis treatment despite
cure (Friedrich 2013; Theron 2016; Theron 2018), andmay rarely
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remain positive for up to five years after tuberculosis treatment
(Boyles 2014). Among individuals with a history of tuberculosis
treatment, the included Xpert Ultra paper found that specificity
improved as time since tuberculosis treatment increased, and ap-
proximated to that of participants without a history of tuberculo-
sis treatment when elapsed time was seven years (Dorman 2018).
Xpert MTB/RIF does not distinguish dead from living bacilli and
it is not surprising at the end of treatment to have Xpert MTB/
RIF-positive results (false-positives) and hence lower specificity.
CT values may help in differentiating between true-positive and
false-positive Xpert MTB/RIF results in people with a prior his-
tory of tuberculosis, with lower values in those with tuberculosis
recurrence compared to those with false-positive Xpert MTB/RIF
(Theron 2016; Theron 2018).
In countries with high TB/HIV burden, we found that Xpert
MTB/RIF pooled specificity (97%) was lower than the pooled
specificity (99%) in countries not considered to have a high TB/
HIV burden. This difference in specificity may be due to other
factors, such as the laboratory level of MTB/RIF testing rather
than the presence of HIV infection, as specificity in HIV-positive
and HIV-negative individuals was similar. Supporting the impor-
tance of laboratory setting, Xpert MTB/RIF specificity was lower
at point of care and in peripheral laboratories compared to inter-
mediate and central laboratories.
For prevalence of tuberculosis, in comparing settings with a higher
or lower prevalence of tuberculosis, for both XpertMTB/RIF sen-
sitivity and specificity, we found that the 95% credible intervals
(CrIs) in the two groups did not overlap, suggesting an association
of prevalence of tuberculosis with the accuracy estimates. In com-
paring settings with a higher or lower prevalence of rifampicin re-
sistance, we found that theCrls for specificity did not overlap, sug-
gesting an association of prevalence of rifampicin resistance with
the specificity estimates. Changes in disease prevalence have often
been found to be associated with other important changes, such
as changes in the disease spectrum, which may affect diagnostic
accuracy estimates (Leeflang 2013).
Sensitivity and specificity depend on the performance of a test in
a particular situation, defined by the population, the setting, and
prior testing. In a different population or setting or with a dif-
ferent testing strategy, the sensitivity and specificity are likely to
change (Bossuyt 2008). However, our sensitivity analyses of differ-
ent specimennumbers and conditions did not changeXpertMTB/
RIF performance. We did find that among specimens that were
culture-positive for NTM, false-positive Xpert MTB/RIF results
occurred in 2.0% (0.4% to 4.4%). Although there have been sug-
gestions that certain nontuberculous mycobacterial species (e.g.
Mmalmoense) may give false-positive Xpert MTB/RIF results due
to weak cross hybridization (Agizew 2017), the false-positive rate
in specimens culture-positive for NTM was similar to the overall
frequency of false positives.
Our systematic review included only one study that evaluated
Xpert Ultra (Dorman 2018). This multicentre study found that
Xpert Ultra yielded higher sensitivity at 88% (95% CI 85% to
91%) compared to Xpert MTB/RIF sensitivity of 83% (79% to
86%), but lower specificity of 96% (94% to 97%) compared
to Xpert MTB/RIF specificity of 98% (97% to 99%) (Dorman
2018). This study performed several post hoc analyses that evalu-
ated the impact of changing the classification of Xpert Ultra trace
calls, which in the primary analysis were considered positive for
the identification ofM tuberculosis. Reclassifying all trace calls as a
negative result increased Xpert Ultra specificity and decreased its
sensitivity. Reclassifying trace calls as negative in participants with
a history of tuberculosis or repeating trace calls with the second
result determining the ultimate classification, both resulted in sen-
sitivity estimates close to those observed in the primary analysis
with only slightly compromised specificity.
On 11 October 2018, we performed a literature search specifically
for studies that evaluated Xpert Ultra, but did not identify any
additional studies. Following this search and after the end date for
data analysis, we identified one additional study (Berhanu 2018).
Although not included in the main sections of this review, we
provide a brief summary of this study here. Berhanu 2018 com-
pared Xpert MTB/RIF and Xpert Ultra in 237 participants with
presumptive tuberculosis who were evaluated at three outpatient
clinics in South Africa. Similar to the results in Dorman 2018, this
multicentre study found that Xpert Ultra yielded higher sensitiv-
ity at 89% (78% to 96%), compared to Xpert MTB/RIF sensitiv-
ity of 82% (70% to 91%), but lower specificity at 96% (92% to
98%) compared to Xpert MTB/RIF specificity of 100% (98% to
100%). Importantly, in both studies, XpertUltra had superior sen-
sitivity for smear-negative tuberculosis: in Dorman 2018, Xpert
Ultra sensitivity was 63% (54% to 71%) versus Xpert MTB/RIF
46% (37% to 55%); and in Berhanu 2018, Xpert Ultra sensitiv-
ity was 65% (38% to 86%) versus Xpert MTB/RIF 41% (18%
to 67%). In both studies, Xpert Ultra’s increased sensitivity for
smear-negative tuberculosis was accompanied by decreased speci-
ficity, 96% in both studies, versus Xpert MTB/RIF specificity of
98% in Dorman 2018 and 100% in Berhanu 2018. In addition,
in Dorman 2018, in HIV-positive participants Xpert Ultra had
higher sensitivity (90%) than Xpert MTB/RIF (77%), again ac-
companied by a decrease in specificity (Xpert Ultra specificity of
96% versus Xpert MTB/RIF specificity of 99%). Xpert Ultra and
Xpert MTB/RIF had similar accuracy for rifampicin resistance.
As Xpert Ultra is rolled out globally, these differences in accu-
racy may have important ramifications depending on tuberculosis
prevalence (Kendall 2017).
Our prespecified subgroup analyses included an assessment of
whether Xpert MTB/RIF accuracy differs by the setting in which
the testwas performed. i.e. point of care or peripheral settings com-
pared with central and intermediate laboratories. Theron 2014a
found no difference in XpertMTB/RIF accuracy when it was per-
formedby trainednurses in a primary care setting compared toper-
formance by laboratory technicians at a centralised facility. When
we compared findings from studies by test setting, we found the
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pooled point estimates of Xpert MTB/RIF sensitivity and speci-
ficity to be lower in peripheral settings than in central and inter-
mediate laboratories. However, there was considerable overlap in
the credible intervals of these estimates and there is insufficient
evidence to suggest a difference in Xpert MTB/RIF accuracy by
setting. One of the confounding factors may be participant spec-
trum, the direction of which we cannot predict with certainty.
We acknowledge that patient health outcomes are clearly impor-
tant to patients, to decision-makers, and the wider tuberculosis
community. We could not, however, systematically address out-
comes in addition to diagnostic accuracy, as they would have re-
quired a differentmethodology.Nonetheless, we are aware of seven
trials that have examined the impact of Xpert MTB/RIF on mor-
tality in relation to smear microscopy or diagnostic algorithms re-
flective of usual practice (Calligaro 2015; Churchyard 2015; Cox
2014; Mupfumi 2014; Ngwira 2019; Theron 2014a; Trajman
2015). All of these trials were conducted in routine healthcare set-
tings. However, only two of these trials have shown a statistically
significant impact on mortality (Ngwira 2019; Trajman 2015).
Ngwira 2019 reported a significant impact on all-cause mortality
in people with clinically advanced HIV when Xpert MTB/RIF
testing at point of care was compared to LED microscopy among
newly-diagnosed HIV-positive adults with presumptive tubercu-
losis in primary health clinics in Malawi, with an incidence rate
ratio (RR) of 0.43% (95% CI 0.22% to 0.87%). Trajman 2015
reported a lower tuberculosis-attributed death rate in the Xpert
arm compared to the smear microscopy arm (2.3% versus 3.8%)
among adults with presumptive tuberculosis in primary health
clinics in Brazil. In particular, this trial showed an association be-
tween HIV positivity and increased risk of tuberculosis-attributed
death: adjusted odds ratio (aOR) 14.1 (95% CI 9.1% to 26.5%),
and a 35% reduction in tuberculosis-attributed death by Xpert
when adjusted for HIV status and age group; OR 0.65 (95% CI
0.44% to 0.97%) (Trajman 2015).
Reasons that have been proposed to explain the lack of evidence
for Xpert MTB/RIF’s impact on mortality include the following:
low statistical power; a limited focus on populations most likely
to benefit from Xpert MTB/RIF testing, such as people with ri-
fampicin resistance; high rates of empirical treatment; loss of pa-
tients to follow-up; and health system weaknesses (Auld 2016a;
Boyles 2017; Schumacher 2016; Theron 2014c). At the time of
this writing, Haraka and colleagues are carrying out a Cochrane
Review to assess the impact of Xpert MTB/RIF on health out-
comes (Haraka 2018).
Early detection of tuberculosis and rifampicin resistance may not
lead to improved patient outcomes if the test result is not linked
to appropriate treatment and other healthcare services. In a recent
editorial, Pai 2018 argues that introducing a new diagnostic tool
such as Xpert MTB/RIF into a fragmented healthcare system and
expecting to find improved impact on patient health is unrealistic.
Rather, changes in many or all steps in the healthcare cascade are
needed (Pai 2018). They propose a patient-centred approach to
assessing the impact of an innovation in patient health bymapping
the point in the healthcare cascade where the diagnostic tool is
introduced and identifying barriers to its effectiveness. In addition,
the use of well-designed implementation research should make it
possible to examine assumptions about how the new tool will work
and its impact on endpoints throughout the healthcare cascade
(Pai 2018).
Regarding resource requirements, the WHO convened a Guide-
lineDevelopmentGroupmeeting bywebinar specifically to review
economic analyses on the use of Xpert MTB/RIF as the initial di-
agnostic test for all persons with tuberculosis signs and symptoms
globally, and as an initial test in the 30 high tuberculosis burden
countries. A review identified 15 cost-effectiveness studies, most
of which took place in sub-Saharan Africa. Twelve studies found
the use of Xpert MTB/RIF to be cost-effective in their setting
and three studies (in India, Malawi, and South Africa) found the
use of the test to be cost or cost-effectiveness neutral. The Guide-
line Development Group judged the requirements to implement
Xpert MTB/RIF as being large (moderate-certainty evidence of
resource requirements), and judged cost effectiveness probably to
be in favour of the introduction of Xpert MTB/RIF. The group
decided that there was insufficient evidence to change the strength
of the recommendation for the use of Xpert MTB/RIF as the
initial diagnostic test for all persons with signs and symptoms of
tuberculosis from conditional to strong. With respect to the cer-
tainty of evidence, guideline members raised concerns about the
lack of internationally recognized thresholds for cost effectiveness
and affordability, limiting the interpretation of data about cost
effectiveness or affordability at the country level, as well as the dif-
ficulty of making recommendations globally when evidence varies
by setting (WHO 2016a).
Since theWHO recommended the use of Xpert MTB/RIF, coun-
try-level policy-makers have been making decisions about adop-
tion and scale-up. The uptake has been much faster than for any
other tuberculosis technology recommended by the WHO over
the last 10 years. A recent survey of market penetration of Xpert
MTB/RIF in high tuberculosis burden countries found greater use
of Xpert MTB/RIF compared to smear microscopy for tubercu-
losis diagnosis (Cazabon 2018).
This review represents the most comprehensive review of the di-
agnostic accuracy of Xpert MTB/RIF and Xpert Ultra, and pro-
vides evidence that may help countries to make decisions about
scaling up the tests for programmatic management of tuberculosis
and drug-resistant tuberculosis. Although the information in this
review will help to inform such decisions, other factors such as
resource requirements and feasibility (including stable electrical
power supply, temperature control, and maintenance of the car-
tridge modules) will also be important considerations.
Application of the meta-analysis to a hypothetical
cohort
Summary of findings 1 and Summary of findings 2 summarize
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the findings of the review by applying the results to a hypothetical
cohort of 1000 individuals with presumptive PTB or rifampicin
resistance. We present several different scenarios. For XpertMTB/
RIF and Xpert Ultra for detection of PTB, we used prevalences of
tuberculosis of 1%, 10%, and 30%. For detection of rifampicin re-
sistance, we used prevalences of rifampicin resistance of 5%, 10%,
and 15% (5% is estimated to be equivalent to the upper limit for
rifampicin resistance prevalence in new cases; 15% is estimated to
be the lower limit for rifampicin resistance prevalence among pre-
viously-treated cases). The consequences of false-positive results
are patient anxiety, morbidity from additional testing and unnec-
essary treatment, and possible delay in further diagnostic evalua-
tion. The consequences of false-negative results are increased risk
of patient morbidity and mortality, and continued risk of com-
munity transmission of tuberculosis.
Strengths and weaknesses of the review
Completeness of evidence
The findings in this review are based on comprehensive searching,
strict inclusion criteria, and standardized data extraction. This re-
view includes a total of 95 studies. For Xpert MTB/RIF for detec-
tion of PTB, we included 86 studies involving 42,091 participants.
For Xpert MTB/RIF for detection of rifampicin resistance, we in-
cluded 57 studies involving 8287 participants. For the diagnostic
accuracy of Xpert Ultra, we identified only one study. We had
repeated correspondence with study authors to obtain additional
data and information that was missing from the papers. The search
strategy included studies published in all languages. Although we
may have missed some studies despite the comprehensive search,
as this was a large review, it is unlikely that the findings would
have changed.
Accuracy of the reference standards used
Culture is regarded as the best available reference standard for ac-
tive tuberculosis disease and was the reference standard for tuber-
culosis in this review. We considered the type of culture used in the
included studies because liquid culture is more sensitive than solid
culture (American Thoracic Society 2000). Most studies did use
liquid culture or a combination of solid and liquid culture; only
13 of the 70 studies with unselected participants (19%) exclu-
sively used solid culture. Phenotypic culture-based DST methods
using WHO-recommended critical concentrations (WHO Policy
DST 2008) and MTBDRplus, a WHO-recommended test, were
the reference standards for rifampicin resistance. Concerning the
former, theWHO is currently reviewing the critical concentration
to recommend for rifampicin resistance testing. Concerning the
latter, only four of the 57 studies (7%) used MTBDRplus alone
as the reference standard.
Quality and quality of reporting of the included
studies
Most studies used consecutive selection of participants and inter-
preted the reference standard results without knowledge of index
test results. Xpert MTB/RIF and Xpert Ultra results are generated
automatically, without requiring subjective interpretation. In gen-
eral, studies were fairly well reported, although we corresponded
with many authors for additional data and missing information.
We encourage authors of future studies to follow the recommen-
dations in the STARD statement to improve the quality of report-
ing (Bossuyt 2015).
Interpretability of subgroup analyses
We investigated potential sources of heterogeneity in different sub-
groups and settings. For tuberculosis detection, the test had higher
sensitivity in smear-positive and HIV-negative participants. Gen-
erally, we found increased sensitivity in settings with higher tu-
berculosis prevalence (culture-confirmed tuberculosis cases in the
study) and similar or slightly lower specificity.
Comparison with other systematic reviews
We are aware of 10 systematic reviews previously published that
estimated diagnostic accuracy of Xpert MTB/RIF for PTB and ri-
fampicin resistance in adults (Table 5). In these reviews, summary
sensitivities ranged from 67% (limited to smear-negative speci-
mens) to 90% (in our review: 85%) and summary specificities
97% to 99% (in our review: 98%).
Compared with previous systematic reviews, our review extended
the date of the search for potential studies for inclusion. Our strict
inclusion criteria, for example, including only studies that used
culture as the reference standard and excluding case-control stud-
ies, meant that some of the studies included in other reviews were
excluded from our review.
Completeness and relevance of the review
This review included studies using all four generations of Xpert
(G1, G2, G3, G4 cartridges) and the newest version, Xpert Ul-
tra, although we identified only one study with Xpert Ultra. A
Cochrane Review on Xpert MTB/RIF for extrapulmonary tuber-
culosis (including one study with Xpert Ultra) was recently pub-
lished (Kohli 2018). This review found that in people with pre-
sumptive extrapulmonary tuberculosis, Xpert MTB/RIF may be
helpful in confirming the diagnosis. Xpert MTB/RIF sensitivity
varied across different extrapulmonary specimens, while for most
specimens specificity was high. In addition, Xpert MTB/RIF was
accurate for detection of rifampicin resistance (Kohli 2018). A
Cochrane Review on Xpert MTB/RIF and Xpert Ultra for active
tuberculosis in children is underway.
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Applicability of findings to the review question
For detection of PTB, most studies evaluated sputum specimens
submitted by participants with presumptive tuberculosis, and ran
the test in primary care facilities and local hospitals. Hence, for
most studies, the participant characteristics and settings matched
our review question. For detection of rifampicin resistance, we had
low concern in 46% of studies and high concern in only 7% of
studies. However, in nearly half of the studies (47%) the clinical
setting was not reported or there was insufficient information to
make a decision.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found Xpert MTB/RIF to be sensitive and specific for detec-
tion of PTB and rifampicin resistance, findings which are consis-
tent with those reported previously. Xpert MTB/RIF was more
sensitive for tuberculosis in smear-positive than smear-negative
participants, and HIV-negative than HIV-positive participants.
Compared with Xpert MTB/RIF, Xpert Ultra had higher sensi-
tivity and lower specificity for tuberculosis detection and similar
sensitivity and specificity for rifampicin resistance detection (one
study). Xpert MTB/RIF and Xpert Ultra provide accurate results
and can allow rapid initiation of treatment for multidrug-resistant
tuberculosis. The ongoing use of Xpert MTB/RIF or Xpert Ultra
in tuberculosis programmes in high tuberculosis burden settings,
as well as use in primary care clinics where the test provides the
opportunity to begin treatment promptly, will contribute evidence
on whether its use leads to improvements in patient health.
Implications for research
Future studies should assess the diagnostic accuracy of Xpert Ultra
compared with other rapid tests for tuberculosis and drug resis-
tance, especially in difficult-to-diagnose groups, i.e. children, peo-
ple living with HIV, and those with extrapulmonary tuberculosis.
Understanding the impact of Xpert Ultra in settings with differing
prevalences of tuberculosis, in previously-treated individuals, with
varying strategies for the classification of trace calls, and its impact
on patient health outcomes will be important.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Adelman 2015
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: people with at least one of the following: cough, fever, night sweats,
and weight loss
Age: 18 years and older
Sex, female: not reported
HIV infection: 100%
History of TB: 36%
Sample size: 212
Clinical setting: outpatient
Laboratory level: intermediate
Country: Ethiopia
World Bank Income Classification: low income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 2.8%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Adelman 2015 (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Unclear
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Al-Darraji 2013
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: not reported; HIV-positive prisoners were screened
Age: mean 37 years (standard deviation (SD) 6.6)
Sex, female: 10%
HIV infection: 100%
History of TB: 29%
Sample size: 125
Clinical setting: outpatient, point of care
Laboratory level: other, prison
Country: Malaysia
World Bank Income Classification: middle income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 12.0%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960, MTBDRplus for confirmation
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
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Al-Darraji 2013 (Continued)
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Ali 2017
Study characteristics
Patient sampling Cross-sectional design, unclear manner of enrolment, retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: people with pulmonary TB, recently found to have smear-positive
sputum
Age:
≤ 15 years 1 (0.8% )
16 to 30 81 (64.3%)
31 to 45 23 (18.2%)
46 to 60 15 (11.9%)
≥ 60 6 (4.8%)
Sex, female: 33%
HIV infection: not reported
History of TB: 57%
Sample size: 126
Clinical setting: laboratory-based
Laboratory level: central
Country: Sudan
World Bank Income Classification: middle income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: LJ
Flow and timing
Comparative
Notes Participants were recruited from random geographical clusters during a one-year period
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
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Ali 2017 (Continued)
High Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Unclear
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Atwebembeire 2016
Study characteristics
Patient sampling Cross-sectional design, unclear manner of enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: people whowere unable to produce sputumwith a clinical suspicion
of TB (presence of at least 1 of the following signs: cough of at least 2 weeks, chronic unexplained
weight loss, fever, or recent chest x-ray showing radiological features compatible with TB); specimens
were frozen
Age: adults, mean or median age not reported
Sex, female: 46%
HIV infection: 31%
History of TB: not reported
Sample size: 104
Clinical setting: laboratory-based
Laboratory level: central
Country: Uganda
World Bank Income Classification: low income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 31.7%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Flow and timing
Comparative
Notes Frozen sediments of sputum specimens previously evaluated using MGIT and LJ were used in this
study
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Atwebembeire 2016 (Continued)
Unclear Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Unclear
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Balcells 2012
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: people who fulfilled at least 1 of the following criteria: cough (> 10
days), bloody sputum, pneumonia unresponsive to previous antibiotics, fever (> 10 days), abnormal
CXR or weight loss
Age: mean 37.4 years, range 19 - 65 years
Sex, female: 20.6%
HIV infection: 100%
History of TB: 11.8%
Sample size: 160
Clinical setting: 5 hospitals and their respective HIV clinics
Laboratory level: central
Country: Chile
World Bank Income Classification: middle income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
TB incidence rate: 18 per 100,000
MDR-TB prevalence: percentage MDR-TB among new TB cases = 0.7% (Source: nationwide
survey 2001) and among retreatment cases = 3.2% (Source: nationwide surveillance 2011)
Prevalence of TB cases in the study: 7.5%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: proportion method on LJ media
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Balcells 2012 (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Balcha 2014
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: HIV-positive people screened for TB irrespective of symptoms
Age: 18 years and older, median 32 years (IQR 28 to 40)
Sex, female: 59%
HIV infection: 100%
History of TB: 6%
Sample size: 810
Clinical setting: outpatient
Laboratory level: intermediate
Country: Ethiopia
World Bank Income Classification: low income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 15.0%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Flow and timing
Comparative
Notes 2% of participants were on anti-TB treatment for up to 2 weeks
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
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Balcha 2014 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Barmankulova 2015
Study characteristics
Patient sampling Cross-sectional design, unknown manner of enrolment, direction of data collection unclear
Patient characteristics and set-
ting
Presenting signs and symptoms: at least 2 weeks of cough, accompanied with loss of weight, night
sweats and fever in labour migrants
Age: median 34 years (IQR 25 to 45)
Sex, female: 43%
HIV infection: not reported
History of TB: 25%
Sample size: 291
Clinical setting: outpatient
Laboratory level: intermediate and central
Country: Kyrgyzstan
World Bank Income Classification: middle income
High TB burden country: no
High MDR-TB burden country: yes
High TB/HIV burden country: no
Prevalence of TB cases in the study: 80.8%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance LJ and MGIT 960
Flow and timing 43 participants without microscopy results and 3415 participants without culture results were not
included
Comparative
Notes “Migrants in the TB REACH project are defined as labour migrants who registered in one region
but are working and living permanently in another region without registration and any access to
primary healthcare facilities.”
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
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Barmankulova 2015 (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
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Barnard 2015
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumed pulmonary TB defined as 2 of the following: HIV
infection, persistent cough lasting > 3 weeks, haemoptysis, weight loss > 4 kg, intermittent fever >
3 weeks or drenching night sweats > 2 weeks. In addition, at least 1 of the following radiological
criteria had to be present: cavitation, diffuse infiltrates, hilar or mediastinal adenopathy, primarily
smear-negative
Age: 44 years (SD 16)
Sex, female: 52%
HIV infection: not reported
History of TB: yes, % not reported
Sample size: 112
Clinical setting: not reported
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 34.8%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MTBDRplus
Flow and timing 72 participants were excluded due to incomplete data
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Barnard 2015 (Continued)
Did the study avoid inappropri-
ate exclusions?
No
High Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
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Bates 2013a
Study characteristics
Patient sampling Cross-sectional design, unknown manner of enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: people with cough and ability to produce a sputum sample who
presented to obstetrics or gynaecology wards
Age: median 28 years (IQR 24 to 32)
Sex, female: 100%
HIV infection: 66%
History of TB: 12%
Sample size: 94
Clinical setting: inpatient
Laboratory level: central
Country: Zambia
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 27.7%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear High
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Bates 2013a (Continued)
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Bjerrum 2016
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: HIV-infected adults screened for pulmonary TB irrespective of
symptoms
Age: 18 years and older, median 38 years (IQR 31 to 45)
Sex, female: 64%
HIV infection: 100%
History of TB: 6%
Sample size: 195
Clinical setting: both outpatient and inpatient
Laboratory level: central
Country: Ghana
World Bank Income Classification: middle income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 17.9%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Flow and timing
Comparative
Notes Screening study
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
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Bjerrum 2016 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Boehme 2010
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection, site in a multicentre
study
Patient characteristics and set-
ting
Presenting signs and symptoms: persistent productive cough for ≥ 2 weeks
Age: median 34 years, range 17 to 88 years
Sex, female: 37%
HIV infection: 40%
History of TB: 46%
Sample size: 1730
Clinical setting: special facility for prisoners (Azerbaijan); primary health care DOTS (directly
observed treatment, short-course) centres in shanty towns (Peru); clinic (South Africa, Cape Town)
; TB clinics (South Africa, Durban); tertiary hospital (India)
Laboratory level: central
Country: Azerbaijan, India, Peru, South Africa
World Bank Income Classification: middle income
High TB burden country: yes (India, South Africa)
High MDR-TB burden country: yes (Azerbaijan, India, Peru, South Africa)
High TB/HIV burden country: yes (India, South Africa)
Prevalence of TB cases in study: 50.9%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ culture. 7H11 culture, and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: proportion method on LJ media, MGIT, MTBDRplus
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Boehme 2010 (Continued)
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Boehme 2011
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection, site in a multicentre
study
Patient characteristics and set-
ting
Presenting signs and symptoms: cough lasting at least 2 weeks
Age: median 38 years (IQR 29 to 50)
Sex, female: 39%
HIV infection: 19%
History of TB: not reported
Sample size: 6648
Clinical setting: special facility for prisoners (Azerbaijan); 2 health centres and 1 district hospital
(Peru); 1 health centre and 1 provincial hospital (South Africa, Cape Town); emergency unit of
referral hospital (Uganda); health centre (India); MDR-TB evaluation facility (Philippines)
Laboratory level: central (Azerbaijan, Peru, Philippines, South Africa, Uganda); intermediate (India)
Country: Azerbaijan, India, Peru, Philippines, South Africa, Uganda
World Bank Income Classification: middle income (Azerbaijan, India, South Africa, Philippines);
low income (Uganda)
High TB burden country: yes (India, Philippines, South Africa)
High MDR-TB burden country: yes (Azerbaijan, India, Peru, Philippines, South Africa)
High TB/HIV burden country: yes (India, South Africa, Uganda)
Prevalence of TB cases in the study: 26.4%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ, Ogawa, MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: LJ proportion method; MGIT 960; MTBDRplus
Flow and timing Participants who were smear-negative and culture-negative but treated for TB on the basis of clinical
and radiological findings (clinical tuberculosis) were not included in determination of specificity
Comparative
Notes Follow-up reported for all sites combined: 24/153 participants with culture-negative, clinically-
diagnosed TB had positive results on MTB/RIF testing. 20/24 participants had follow-up, and all
20 improved on TB treatment
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Boehme 2011 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Boehme 2011 (Continued)
Were all patients included in the
analysis?
No
High
Boum 2016
Study characteristics
Patient sampling Cross-sectional design, unknown manner of enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumed pulmonary TB with cough for 2 weeks and at least 1
additional TB symptom (fever, weight loss, or night sweats)
Age: 18 years and older, median 35 years (IQR 29 to 43) for HIV-positive participants; median 46
years (IQR 30 to 60) for HIV-negative participants
Sex, female: 50%
HIV infection: 70%
History of TB: 12%
Sample size: 887
Clinical setting: both outpatient and inpatient
Laboratory level: biosafety level 3 laboratory of Epicentre/Médecins sans Frontières Mbarara Re-
search Centre
Country: Uganda
World Bank Income Classification: low income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 23.8%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Flow and timing Could not account for all patients
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Boum 2016 (Continued)
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Boum 2016 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Calligaro 2015
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumedpulmonaryTB (based on suggestive pulmonary infiltrates,
a history of constitutional symptoms preceding the ICU admission, or people known or suspected
to be infected with HIV, irrespective of the reason for admission to the ICU)
Age: 18 years and older, median 38 (IQR 28 to 51)
Sex, female: 40%
HIV infection: 27 %
History of TB: yes, % not reported
Sample size: 91
Clinical setting: inpatient
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 12.1%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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Calligaro 2015 (Continued)
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low High
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
103Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Calligaro 2015 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Calligaro 2017
Study characteristics
Patient sampling Randomized trial, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: HIV-positive patients with at least one TB symptom according
to predefined WHO criteria and HIV-positive patients irrespective of symptoms (in line with the
WHO recommendation to screen all HIV-positive individuals for TB)
Age: 18 years or older, median 38 (IQR 32 to 47)
Sex, female: 55%
HIV infection: 58%
History of TB: yes, per cent not reported
Sample size: 403
Clinical setting: outpatient
Laboratory level: in South Africa, diagnostic tests were done at the point-of-contact at the mobile
van, whereas in Zimbabwe, screened and eligible participants were transported to Mabvuku Clinic
and the investigations were done there
Country: Zimbabwe, South Africa
World Bank Income Classification: low and middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 10.4%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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Calligaro 2017 (Continued)
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Calligaro 2017 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Carriquiry 2012
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: cough for > 10 days with abnormal chest x-ray and at least 1 of the
following symptoms: fever, fatigue, night sweats, haemoptysis, chest pain, or weight loss
Age: 18 years or older, median 35 years (IQR 29 to 42)
Sex, female: 27.5%
HIV infection: 100%
History of TB: 25%
Sample size: 131
Clinical setting: both inpatient and outpatient
Laboratory level: central
Country: Peru
World Bank Income Classification: middle income
High TB burden country: no
High MDR-TB burden country: yes
High TB/HIV burden country: no
TB incidence rate: 101 per 100,000
MDR-TB prevalence: percentage MDR-TB among new TB cases = 5.3% (Source: nationwide
survey 2006) and among retreatment cases = 24% (Source: nationwide survey 2006)
Prevalence of TB cases in the study: 34.4%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ culture and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: proportion method on LJ media
Flow and timing
Comparative
Notes
Methodological quality
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Carriquiry 2012 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Carriquiry 2012 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Chaisson 2014
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumed pulmonary TB
Age: adults, median 54 years (IQR 43 to 60)
Sex, female: 23%
HIV infection: 30%
History of TB: not reported
Sample size: 142
Clinical setting: inpatient
Laboratory level: central
Country: USA
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 6.3%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: 7H11 and BacT/Alert MP
Flow and timing 59 participants (25% of eligible patients) were not tested, 46 owing to insufficient quantity and
13 for the following reasons: 6 samples rejected for culture because > 3 days had elapsed since
collection, 4 samples that were not tested for reasons that were not documented, 2 specimens that
arrived when the Xpert machine was not operating because it was undergoing routine maintenance,
and 1 specimen that was not 1 of the first 2 samples collected
Comparative
Notes
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Chaisson 2014 (Continued)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low High
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
No
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
High Low
DOMAIN 4: Flow and Timing
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Chaisson 2014 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Unclear
Chen 2017
Study characteristics
Patient sampling Cross-sectional design, unknown manner of enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: TB symptoms
Age: 15 years and older, median 64 years (IQR 58 to 71)
Sex, female: 42%
HIV infection: not reported
History of TB: not reported
Sample size: 733
Clinical setting: outpatient, health workers went door-to-door to identify individuals with TB
symptoms and send them to the clinic
Laboratory level: intermediate
Country: China
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 0.8%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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Chen 2017 (Continued)
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Chen 2017 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Chew 2016
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumed pulmonary TB
Age: adults
Sex, female: not reported
HIV infection: not reported
History of TB: not reported
Sample size: 238
Clinical setting: inpatient
Laboratory level: central
Country: Singapore
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 16.8%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Chew 2016 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low High
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Chew 2016 (Continued)
Were all patients included in the
analysis?
Yes
Low
Chikaonda 2017
Study characteristics
Patient sampling Cross-sectional design, random enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: people with microbiologically or clinically diagnosed TB for de-
tection of rifampicin resistance
Age: 18 years and older
Sex, female: not reported
HIV infection: 57%
History of TB: not reported
Sample size: 188
Clinical setting: outpatient
Laboratory level: central
Country: Malawi
World Bank Income Classification: low income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: yes
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MTBDRplus
Flow and timing
Comparative
Notes Xpert run especially in sputum smear-negative and HIV-positive people. Study used frozen speci-
mens
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Chikaonda 2017 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Unclear
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Chikaonda 2017 (Continued)
Were all patients included in the
analysis?
Yes
Low
Cowan 2017
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, both prospective and retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumed TB
Age: mean 50 years, range 18 - 88 years
Sex, female: 22%
HIV infection: 24%
History of TB: not reported
Sample size: 318
Clinical setting: inpatient
Laboratory level: central
Country: USA
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 6.3%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: 7H11 and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: 7H11 and MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Cowan 2017 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low High
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Cowan 2017 (Continued)
Were all patients included in the
analysis?
Yes
Low
Davis 2014
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumed pulmonary TB
Age: adults, median 52 years (IQR 39 to 60)
Sex, female: 35%
HIV infection: 8%
History of TB: yes, % not reported
Sample size: 156
Clinical setting: inpatient
Laboratory level: central
Country: USA
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 8.3%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ, 7H11, and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: LJ and 7H11 by proportion method and MGIT 960
Flow and timing Of 227 eligible patients, 71 (31%) were excluded because they were not tested
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Davis 2014 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low High
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Davis 2014 (Continued)
Were all patients included in the
analysis?
No
High
Dorman 2018
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection, multicentre study
Patient characteristics and set-
ting
Presenting signs and symptoms: presumed pulmonary TB
Age: adults, median 28 years (IQR 28 to 50)
Sex, female: 40%
HIV infection: 44%
History of TB: 21%
Sample size: 1439 for detection of MTB, 551 for rifampicin resistance
Clinical setting: both outpatient and inpatient
Laboratory level: central (reference)
Country: Belarus, Brazil, China, Georgia, India, Kenya, South Africa, Uganda
World Bank Income Classification: low and middle income
High TB burden country: yes (Brazil, China, India, Kenya, South Africa)
High MDR-TB burden country: yes (Belarus, China, India, Kenya, South Africa)
High TB/HIV burden country: yes (Brazil, China, India, Kenya, South Africa, Uganda)
Prevalence of TB cases in the study: 32.1%
Index tests Index: Xpert MTB/RIF and Xpert Ultra
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes 25 participants (3%) who were smear-positive but in whom all cultures were negative were excluded
from the analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Dorman 2018 (Continued)
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Dorman 2018 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Unclear
Friedrich 2011
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: people recently diagnosed with smear-positive first time TB, un-
treated
Age: 18 to 65 years
Sex, female: not reported
HIV infection: not reported
History of TB: not reported
Sample size: 126
Clinical setting: smear examination at TB clinic and referred to inpatient settings
Laboratory level: central
Country: South Africa, Cape Town
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
TB incidence rate: 993 per 100,000
MDR-TB prevalence: % MDR-TB among new TB cases = 0.9% (Source: survey in Western Cape
Province, 2002) and among retreatment cases = 4.0% (Source: survey in Western Cape Province,
2002)
Prevalence of TB cases in the study: 100.0%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes The aim of this study was to assess NAATs for selecting participants for clinical trials of anti-
TB medication. People with severe co-morbidities were excluded. This study was used only for
determination of sensitivity because all enrolled participants were predetermined to have TB disease
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Friedrich 2011 (Continued)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Friedrich 2011 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Geleta 2015
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, direction of data collection unclear
Patient characteristics and set-
ting
Presenting signs and symptoms: signs, symptoms, or chest x-ray suggestive of TB
Age: median 35 years, range 18 to 82 years
Sex, female: 37%
HIV infection: not reported
History of TB: not reported
Sample size: 220
Clinical setting: not reported
Laboratory level: central
Country: Ethiopia
World Bank Income Classification: low income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 26.4%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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Geleta 2015 (Continued)
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Geleta 2015 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Hanif 2011
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumedTB based on presence of cough and radiographic findings
Age: range 20 to 57 years
Sex, female: not reported
HIV infection: not reported
History of TB: not reported
Sample size: 206
Clinical setting: laboratory-based
Laboratory level: central
Country: Kuwait
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
TB incidence rate: 36 per 100,000
MDR-TB prevalence: %MDR-TB among new TB cases = 0% and among retreatment cases = 12%
(Source: nationwide surveillance, 2011)
Prevalence of TB cases in the study: 29.1%
Index tests Index: Xpert MTB/RIF assay
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ culture and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: BACTEC 460
Flow and timing
Comparative
Notes No participants were found to have rifampicin resistance
Methodological quality
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Hanif 2011 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
No
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
High Low
DOMAIN 4: Flow and Timing
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Hanif 2011 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
Low
Hanrahan 2013
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: prolonged (> 2 weeks) cough and/or other TB symptoms
Age: 18 years and older, median 35 years (IQR 29 to 44)
Sex, female: 65%
HIV infection: 69%
History of TB: 10%
Sample size: 553
Clinical setting: outpatient
Laboratory level: peripheral
Country: South Africa, Johannesburg
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
TB incidence rate: 993 per 100,000
MDR-TB prevalence: % MDR-TB among new TB cases = 1.4% (Source: survey in Gauteng
province, 2002) and among retreatment cases = 5.5% (Source: survey in Gauteng province, 2002)
Prevalence of TB cases in the study: 11.6%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
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Hanrahan 2013 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Hanrahan 2013 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Hanrahan 2014
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumed pulmonary TB
Age:15 years and older, median 37 years (IQR 29 to 46)
Sex, female: 62%
HIV infection: 58%
History of TB: not reported
Sample size: 2082
Clinical setting: outpatient
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 19.5%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: Pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Flow and timing
Comparative
Notes This study focused on drug-susceptible TB and therefore excluded 10 people found to have ri-
fampicin resistance on Xpert
Methodological quality
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Hanrahan 2014 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Low Low
DOMAIN 4: Flow and Timing
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Hanrahan 2014 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
Helb 2010
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: cough lasting at least 2 weeks
Age: median 34 years, range 18 to 76 years
Sex, female: 30.8%
HIV infection: 0.9%
History of TB: 1.9%
Sample size: 107
Clinical setting: TB hospital, unclear whether inpatient or outpatient or both
Laboratory level: central
Country: Vietnam
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: no
TB incidence rate: 199 per 100,000
MDR-TB prevalence: Percent MDR-TB among new TB cases = 2.7% (Source: nationwide survey,
2006) and among retreatment cases = 19% (Source: nationwide survey, 2006)
Proportion of TB cases in the study: 76.6%
Index tests Index: Xpert MTB/RIF assay
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard: LJ culture and MGIT 960
Flow and timing
Comparative
Notes Rifampicin resistance data were not reported
Methodological quality
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Helb 2010 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Helb 2010 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
Henostroza 2016
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: ART-naïve people presenting for initiation of HIV care
Age: 16 years and older, median 34 years (IQR 29 to 40)
Sex, female: 49%
HIV infection: 100%
History of TB: not reported
Sample size: 332
Clinical setting: outpatient
Laboratory level: central
Country: Zambia
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 18.6%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Flow and timing
Comparative
Notes The paper states that outpatients in this cohort were likely to have been less ill than hospitalized
patients
Methodological quality
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Henostroza 2016 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Low Low
DOMAIN 4: Flow and Timing
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Henostroza 2016 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Huang 2015
Study characteristics
Patient sampling Cross-sectional design, manner of enrolment unclear, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: not reported
Age: mean 42 years, range 15 to 55 years
Sex, female: 44%
HIV infection: not reported
History of TB: not reported
Sample size: 378
Clinical setting: laboratory-based
Laboratory level: peripheral
Country: China
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 49.7%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Target condition: Rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
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Huang 2015 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Huang 2015 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Huh 2014
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumptive pulmonary TB as defined by the presence of the clinical
symptoms (cough, fever, night sweats, or weight loss) and radiologic findings compatible with TB,
in either a chest x-ray or a computed tomography scan
Age: median 58 years, range 18 to 93 years
Sex, female: 34%
HIV infection: 0.3%
History of TB: not reported
Sample size: 271
Clinical setting: tertiary care hospital, unclear if outpatient, inpatient, or both
Laboratory level: central
Country: Republic of Korea
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 38.4%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960, Ogawa culture
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960, LJ-DST
Flow and timing
Comparative
Notes
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Huh 2014 (Continued)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Huh 2014 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Jo 2016
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: not reported, included patients from bronchoscopy registry, pri-
marily smear-negative
Age: adults, mean 63 years (SD 17)
Sex, female: 34%
HIV infection: 0.3%
History of TB: 15%
Sample size: 320
Clinical setting: not reported
Laboratory level: central
Country: Republic of Korea
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 20.0%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: Ogawa and MGIT 960
Flow and timing
Comparative
Notes Only 10 bronchoscopically obtained specimens (7.69%) were smear-positive
Methodological quality
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Jo 2016 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Low Low
DOMAIN 4: Flow and Timing
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Jo 2016 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Kawkitinarong 2017
Study characteristics
Patient sampling Cross-sectional design, random enrolment for 2 sites, consecutive enrolment for 1 site, prospective
data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumed pulmonary TB
Age: adults, median 41 years (IQR 30.8 to 54.3)
Sex, female: 42.5%
HIV infection: 25.9%
History of TB: not reported
Sample size: 389
Clinical setting: not reported
Laboratory level: central
Country: Thailand
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 64.3%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: Pulmonary TB
Reference standard for pulmonary TB: Ogawa and MGIT 960
Target condition: Rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
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Kawkitinarong 2017 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Kawkitinarong 2017 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Kim CH 2015
Study characteristics
Patient sampling Cross-sectional design, manner of participant selection unknown, retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumed TB
Age: mean 56 years (SD 18)
Sex, female: 43%
HIV infection: 0.1%
History of TB: not reported
Sample size: 405
Clinical setting: inpatient
Laboratory level: central
Country: Republic of Korea
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 12.8%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: Ogawa and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: LJ, concentration method
Flow and timing
Comparative
Notes
Methodological quality
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Kim CH 2015 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear High
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Unclear
Low Low
DOMAIN 4: Flow and Timing
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Kim CH 2015 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Ko 2016
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumed pulmonary TB
Age: adults (range 17 - 87 years), median 58 years (IQR 43 to 71)
Sex, female: 42%
HIV infection: 0.4%
History of TB: not reported
Sample size: 249
Clinical setting: not reported
Laboratory level: central
Country: Republic of Korea
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 42.2%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: Pulmonary TB
Reference standard for pulmonary TB: Ogawa and MGIT
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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Ko 2016 (Continued)
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Unclear
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Ko 2016 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Kurbaniyazova 2017
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: people with cough of 2 weeks, fever, night sweats and weight
loss; TB patients with positive smear results or a sputum smear-negative result but radiographic
abnormalities suggestive of TB; retreatment cases; contacts of TB or MDR-TB patients; patients
with severe clinical condition; andHIV-positive patients or those with unknown HIV status in high-
risk settings such as migrants or prisoners; according to the diagnostic algorithm of Kyrgyzstan’s
National Tuberculosis Programme’s clinical protocol
Age: adults > 18
Sex, female: not reported
HIV infection: not reported
History of TB: not reported
Sample size: 2734
Clinical setting: outpatient
Laboratory level: central
Country: Kyrgyzstan
World Bank Income Classification: middle income
High TB burden country: no
High MDR-TB burden country: yes
High TB/HIV burden country: no
Prevalence of TB cases in the study: 62.2%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT
Target condition: Rifampicin resistance
Reference standard for rifampicin resistance: LJ and MGIT
Flow and timing
Comparative
Notes
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Kurbaniyazova 2017 (Continued)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Kurbaniyazova 2017 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Kurbatova 2013
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumptive or recently diagnosed TB
Age: 18 years and older
Sex, female: not reported
HIV infection: estimated < 5 %
History of TB: not reported
Sample size: 228
Clinical setting: outpatient and inpatient
Laboratory level: central
Country: Russia
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: no
High TB/HIV burden country: yes
TB incidence rate: 97 per 100,000
MDR-TB prevalence: Percent MDR-TB among new TB cases = 20% (Source: Surveillance in 20
Oblasts 2010) and among retreatment cases = 46% (Source: Surveillance in 20 Oblasts 2008)
Prevalence of TB cases in the study: 46.9%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes Fresh, unconcentrated sputum was initially homogenized using a vortex with glass beads
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Kurbatova 2013 (Continued)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Kurbatova 2013 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Kwak 2013
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: people presumed to have pulmonary TB
Age: adults > 15 years, median 61 years (IQR 47.5 to 73)
Sex, female: 37%
HIV infection: 0.7%
History of TB: not reported
Sample size: 681
Clinical setting: both outpatient and inpatient
Laboratory level: central
Country: Republic of Korea
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 22.9%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: Ogawa and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: LJ by method of absolute concentration
Flow and timing
Comparative
Notes
Methodological quality
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Kwak 2013 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Kwak 2013 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
LaCourse 2016
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: none reported. HIV-infected women accessing prevention of
mother-to-child transmission services as part of antenatal care were eligible
Age: 16 years and older, median 25 years (IQR 22 to 30)
Sex, female: 100%
HIV infection: 100%
History of TB: 9%
Sample size: 288
Clinical setting: outpatient
Laboratory level: central
Country: Kenya
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 2.4%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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LaCourse 2016 (Continued)
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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LaCourse 2016 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Lawn 2011
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: HIV-infected people with advanced immunodeficiency; most had
1 or more of the following TB symptoms: current cough, fever, night sweats, or weight loss
Age: median 34 years (IQR 28 to 41)
Sex, female: 65.4%
HIV infection: 100%
History of TB: 26.5%
Sample size: 394
Clinical setting: HIV anti-retroviral clinic; all participants were screened for TB
Laboratory level: central
Country: South Africa, Cape Town
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
TB incidence rate: 993 per 100,000
MDR-TB prevalence: % MDR-TB among new TB cases = 0.9% (Source: survey in Western Cape
Province, 2002) and among retreatment cases = 4.0% (Source: survey in Western Cape Province,
2002)
Prevalence of TB cases in the study: 18.3%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes This study evaluated the use of Xpert to screen HIV-infected people with advanced immunode-
ficiency enrolling in antiretroviral therapy services regardless of symptoms, although most partici-
pants in the study had TB symptoms. Of 3 participants with apparent false-positive Xpert MTB/
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Lawn 2011 (Continued)
RIF results, on follow-up 2 had overt pulmonary and systemic symptoms suggestive of TB and
improved on anti-TB treatment. The 3rd participant was lost to follow-up
Median CD4 cell count, 171 cells/ml; IQR 102 to 236
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
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Lawn 2011 (Continued)
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Le Palud 2014
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumptive pulmonary TB based on clinical features (e.g. cough,
haemoptysis, fever, asthenia, loss of weight, and night sweats) or radiological features (e.g. nodule,
pneumonia, cavitation, and pleurisy), smear-negative
Age: median 54 years (IQR 34 to 74)
Sex, female: 37%
HIV infection: 4%
History of TB: not reported
Sample size: 162
Clinical setting: not reported
Laboratory level: central
Country: France
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 12.3%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: Colestos slant and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
158Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Le Palud 2014 (Continued)
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
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Le Palud 2014 (Continued)
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Lee 2013
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumed pulmonary TB, smear-negative
Age: median: 54 years, range 18 to 90 years
Sex, female: 41%
HIV infection: 1%
History of TB: 21%
Sample size: 132
Clinical setting: not reported
Laboratory level: central
Country: Republic of Korea
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 28.8%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: Ogawa medium and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: Ogawa medium, proportion method
Flow and timing
Comparative
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Lee 2013 (Continued)
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Unclear
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Unclear
Unclear Low
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Lee 2013 (Continued)
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Lippincott 2014
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumptive pulmonary TB
Age: median: 51 years (IQR 39 to 63)
Sex, female: 36%
HIV infection: 24%
History of TB: not reported
Sample size: 499
Clinical setting: inpatient
Laboratory level: central
Country: USA
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 3.0%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes
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Lippincott 2014 (Continued)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low High
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Lippincott 2014 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Liu 2017
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: people presumed to have pulmonary TB, who had cough, expec-
toration or haemoptysis for more than 2 weeks were enrolled
Age: 15 years and older
Sex, female: not reported
HIV infection: not reported
History of TB: not reported
Sample size: 3096
Clinical setting: not reported
Laboratory level: intermediate
Country: China
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 14.1%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: LJ
Flow and timing
Comparative
Notes
Methodological quality
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Liu 2017 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Liu 2017 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Lorent 2015
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumptive drug-resistant TB, including previously treated people
(failure, relapse, return after default); symptomatic close contacts of known MDR-TB cases; new
TB patients with delayed smear conversion at month 2 or 3 of first-line treatment; and all HIV-
infected people, regardless of smear results
Age: median: 43 years (IQR 34 to 52)
Sex, female: 47%
HIV infection: 65%
History of TB: 46%
Sample size: 274
Clinical setting: outpatient
Laboratory level: central
Country: Cambodia
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: no
High TB/HIV burden country: no
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: LJ proportion method
Flow and timing
Comparative
Notes
Methodological quality
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Lorent 2015 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
No
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
No
High Low
DOMAIN 4: Flow and Timing
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Lorent 2015 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Luetkemeyer 2016
Study characteristics
Patient sampling Cross-sectional design, unknown manner of enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: cough, fever, night sweats, or weight loss
Age: 18 years and older, median 46 years (IQR 35 to 54)
Sex, female: 38%
HIV infection: 45%
History of TB: 13%
Sample size: 992
Clinical setting: inpatient and outpatient
Laboratory level: central
Country: Brazil, South Africa and USA
World Bank Income Classification: high and middle income
High TB burden country: yes (South Africa), no (USA)
High MDR-TB burden country: yes (South Africa), no (USA)
High TB/HIV burden country: yes (South Africa), no (USA)
Prevalence of TB cases in the study: 22.4
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: solid media and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: Middlebrook agar
Flow and timing
Comparative
Notes
Methodological quality
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Luetkemeyer 2016 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Luetkemeyer 2016 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Makamure 2017
Study characteristics
Patient sampling Cross-sectional design, enrolment by convenience, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: MDR-TB high-risk patients (TB symptoms with at least 1 of
the following: previously confirmed MDR-TB, failure to convert after at least 2 months therapy,
treatment failure, return after default, relapse after completion of treatment or contacts of known
MDR-TB cases)
Age: 15 years and older, median: 38 years (IQR 30 to 47)
Sex, female: 42%
HIV infection: 63%
History of TB: 78%
Sample size: 210
Clinical setting: not reported
Laboratory level: central
Country: Zimbabwe
World Bank Income Classification: low income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: LJ
Flow and timing
Comparative
Notes
Methodological quality
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Makamure 2017 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
High Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Makamure 2017 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Mbelele 2017
Study characteristics
Patient sampling Cross-sectional design, unknown manner of enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumed pulmonary TB
Age: 18 years and older, mean 43 years (SD 15)
Sex, female: 66%
HIV infection: 15%
History of TB: 14%
Sample size: 262
Clinical setting: not reported
Laboratory level: central
Country: Tanzania
World Bank Income Classification: low income
High TB burden country: yes
High MDR-TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 32.4%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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Mbelele 2017 (Continued)
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Mbelele 2017 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Meawed 2016
Study characteristics
Patient sampling Cross-sectional design, unknown manner of enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: recurrence of general or local chest symptoms, suspected retreatment
TB
Age: mean 33 years (SD 19), age range 21 - 67 years
Sex, female: 33%
HIV infection: not reported
History of TB: 100%
Sample size: 58
Clinical setting: outpatient
Laboratory level: central
Country: Egypt
World Bank Income Classification: middle income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 93.1%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Meawed 2016 (Continued)
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Unclear
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Meawed 2016 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Metcalfe 2015
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: recurrent TB (TB following cure or completion of treatment of a
previous TB episode), or prevalent retreatment TB (treatment failure, i.e. sputum smear-positivity
at month 5 or later)
Age: 15 years and older
Sex, female: not reported
HIV infection: 75%
History of TB: 100%
Sample size: 149
Clinical setting: outpatient
Laboratory level: central
Country: Zimbabwe
World Bank Income Classification: low income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 59.7
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ, MGIT 960 and MODS
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
176Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Metcalfe 2015 (Continued)
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Metcalfe 2015 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Metcalfe 2016
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: cough (any duration), fever, night sweats, or weight loss, with a
history of prior TB
Age: 15 years and older
Sex, female: not reported
HIV infection: 68%
History of TB: 100%
Sample size: 352
Clinical setting: outpatient
Laboratory level: central
Country: Zimbabwe
World Bank Income Classification: low income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: LJ and MODS
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Metcalfe 2016 (Continued)
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Metcalfe 2016 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Meyer 2017
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumptive TB with cough ≥ 2 weeks but < 6 months, smear-
negative
Age: 18 years and older, median 34 years (IQR 28 to 44)
Sex, female: 49%
HIV infection: 66%
History of TB: 12%
Sample size: 1782
Clinical setting: inpatient
Laboratory level: central
Country: Uganda
World Bank Income Classification: low income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 22%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Meyer 2017 (Continued)
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Meyer 2017 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Mok 2016
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumptive pulmonary TB, sputum scarce or sputum smear-
negative
Age: 21 years and older, median 59 years (IQR 43 to 66)
Sex, female: 29%
HIV infection: not reported
History of TB: not reported
Sample size: 158
Clinical setting: inpatient
Laboratory level: central
Country: Singapore
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 28%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Mok 2016 (Continued)
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Mok 2016 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Mokaddas 2015
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumptive TB
Age: 14 years and older
Sex, female: not reported
HIV infection: not reported
History of TB: not reported
Sample size: 287
Clinical setting: laboratory-based
Laboratory level: central
Country: Kuwait
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 21.9%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Mokaddas 2015 (Continued)
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Mokaddas 2015 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Mollel 2017
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: not reported
Age: 16 years and older, mean 42 years
Sex, female: 55%
HIV infection: 100%
History of TB: not reported
Sample size: 69
Clinical setting: outpatient
Laboratory level: intermediate
Country: Tanzania
World Bank Income Classification: low income
High TB burden country: yes
High MDR-TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 13.0%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Mollel 2017 (Continued)
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Unclear
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Unclear High
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Mollel 2017 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Moure 2011
Study characteristics
Patient sampling Cross-sectional design, enrolment by convenience, retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: not reported; participants found tobe smear-negative onmicroscopy
Age: older than 15 years; mean: 42 years
Sex, female: not reported
HIV infection: not reported
History of TB: not reported
Sample size: 107
Clinical setting: laboratory-based
Laboratory level: central
Country: Spain
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
TB incidence rate: 15 per 100,000
MDR-TB prevalence: percentageMDR-TB among new TB cases = 0.2% (Source: Survey in Galicia
region, 2005) and among retreatment cases = 1.5% (Source: Survey in Galicia region, 2005)
Prevalence of TB cases in the study: 72.9%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ culture and MGIT 960
Flow and timing
Comparative
Notes Sample set included 1 pulmonary biopsy specimen
Of 85 pulmonary and extrapulmonary specimens tested, 6 were positive by Xpert MTB/RIF for
rifampicin resistance, and 7 specimens were positive by the reference standard
Methodological quality
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Moure 2011 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
High Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Moure 2011 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Moussa 2016
Study characteristics
Patient sampling Cross-sectional design, unknown manner of enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: clinical signs of pulmonary TB
Age: 18 to 60 years
Sex, female: not reported
HIV infection: 0%
History of TB: not reported
Sample size: 218
Clinical setting: laboratory-based
Laboratory level: central
Country: Egypt
World Bank Income Classification: middle income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 32.1%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: Middlebrook 7H11 agar
Flow and timing
Comparative
Notes
Methodological quality
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Moussa 2016 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Moussa 2016 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Mutingwende 2015
Study characteristics
Patient sampling Cross-sectional design, unknown manner of enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumptive TB in miners
Age: median 46 years (IQR 39 to 51)
Sex, female: 4%
HIV infection: 74%
History of TB: 57%
Sample size: 306
Clinical setting: outpatient
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 75.7%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Flow and timing 242 test results were missing for Xpert, microscopy and MGIT
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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Mutingwende 2015 (Continued)
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Mutingwende 2015 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
N’Guessan 2016
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumed pulmonary TB, smear-positive (failure, relapse, default)
Age: mean 33 years (SD 11), range 15 to 73 years
Sex, female: 32%
HIV infection: 18%
History of TB: 100%
Sample size: 63
Clinical setting: not reported
Laboratory level: central
Country: Cote d’Ivoire
World Bank Income Classification: middle income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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N’Guessan 2016 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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N’Guessan 2016 (Continued)
Were all patients included in the
analysis?
Yes
Low
Ngabonziza 2016
Study characteristics
Patient sampling Cross-sectional design with consecutive enrolment of participants, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: people with presumptive TB
Age: 15 years and older, median 37 years (IQR 28 to 50)
Sex, female: 38%
HIV infection: 27%
History of TB: not reported
Sample size: 600
Clinical setting: outpatient
Laboratory level: central
Country: Rwanda
World Bank Income Classification: low income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 16.0%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Ngabonziza 2016 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Unclear
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Ngabonziza 2016 (Continued)
Were all patients included in the
analysis?
Yes
Low
Nikam 2014
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: symptoms of pulmonary TB
Age: 15 years and older
Sex, female: not reported
HIV infection: not reported
History of TB: not reported
Sample size: 274
Clinical setting: laboratory-based
Laboratory level: central
Country: India
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 55.1%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Flow and timing
Comparative
Notes The authors thought that the study may have included participants on anti-TB treatment
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Nikam 2014 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Nikam 2014 (Continued)
Were all patients included in the
analysis?
Yes
Low
Nliwasa 2016
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: cough for > 2 weeks
Age: 15 years and older, median: 32 years (IQR 25 to 41)
Sex, female: 44%
HIV infection: 44%
History of TB: not reported
Sample size: 273
Clinical setting: outpatient
Laboratory level: central
Country: Malawi
World Bank Income Classification: low income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 17.4%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Nliwasa 2016 (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Nosova 2013a
Study characteristics
Patient sampling Cross-sectional design, unknown manner of enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumed pulmonary TB
Age: adults
Sex, female: not reported
HIV infection: not reported
History of TB: not reported
Sample size: 278
Clinical setting: laboratory-based
Laboratory level: central
Country: Russia
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: no
Prevalence of TB cases in the study: 37.2%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Reference standard for rifampicin resistance detection: MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
202Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Nosova 2013a (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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O’Donnell 2015
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumed pulmonary TB
Age: median 33 years, range 18 to 63 years
Sex, female: 47%
HIV infection: 51%
History of TB: 28%
Sample size: 173
Clinical setting: outpatient and inpatient
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 76.8%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: 7H10 agar plates and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: 7H10
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
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O’Donnell 2015 (Continued)
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Park 2013
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumed pulmonary TB
Age: 15 years and older
Sex, female: not reported
HIV infection: not reported
History of TB: not reported
Sample size: 320
Clinical setting: not reported
Laboratory level: central
Country: Republic of Korea
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 7.2%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: LJ and MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
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Park 2013 (Continued)
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Pimkina 2015
Study characteristics
Patient sampling Cross-sectional design, unknown manner of enrolment, retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: people with known risk factors for MDR-TB and all retreatment
patients including those with extensive lung damage, e.g. cavities
Age: 18 years and older; median 50 years
Sex, female: 29%
HIV infection: not reported
History of TB: 100%
Sample size: 792
Clinical setting: laboratory-based, specimens submitted from local general practitioners andhospitals
Laboratory level: central
Country: Lithuania
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 48.2%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 950
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: LJ and MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
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Pimkina 2015 (Continued)
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Unclear
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Pinyopornpanish 2015
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: 2 or more of the following symptoms: fever, chronic cough, weight
loss, pleuritic chest pain, haemoptysis, and with or without abnormal chest radiograph compatible
with pulmonary tuberculosis (e.g. cavitary lesion, infiltration, and miliary pattern)
Age: 15 years and older, mean 56 years (SD 20)
Sex, female: 40%
HIV infection: 26%
History of TB: not reported
Sample size: 109
Clinical setting: not reported
Laboratory level: central
Country: Thailand
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 39.4%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
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Pinyopornpanish 2015 (Continued)
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Rachow 2011
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumptive pulmonary TB based on clinical and radiographic
findings
Age: mean 39 years (SD 13.8)
Sex, female: 51.7%
HIV infection: 58.9%
History of TB: not reported
Sample size: 249
Clinical setting: referral hospital
Laboratory level: central
Country: Tanzania
World Bank Income Classification: low income
High TB burden country: yes
High MDR-TB burden country: no
High TB/HIV burden country: yes
TB incidence rate: 169 per 100,000
MDR-TB prevalence: percentage MDR-TB among new TB cases = 1.1% (Source: nationwide
survey, 2007) and among retreatment cases = 0% (Source: Nationwide survey, 2007)
Prevalence of TB cases in the study: 27.7%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ culture and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes Participants were followed for a period of 56 days. Among 77 participants classified as smear-
negative, culture-negative ’clinical TB’, Xpert MTB/RIF was positive in 7 (9.1%) participants
No participants were found to have rifampicin resistance
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Rachow 2011 (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
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Reddy 2017
Study characteristics
Patient sampling Cross-sectional design, random enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: TB symptoms
Age: 18 to 60 years
Sex, female: 47%
HIV infection: not reported
History of TB: 33%
Sample size: 705
Clinical setting: outpatient
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 23.8%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
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Reddy 2017 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Reechaipichitkul 2017
Study characteristics
Patient sampling Cross-sectional design, unknown manner of enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: clinical signs and symptoms of pulmonary TB, including cough
and prolonged fever of > 2 weeks
Age: 15 years and older, mean 55 years (SD 18)
Sex, female: 34%
HIV infection: 5%
History of TB: 38%
Sample size: 125
Clinical setting: not reported
Laboratory level: intermediate
Country: Thailand
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 50.4%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
216Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Reechaipichitkul 2017 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Unclear
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
217Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Rice 2017
Study characteristics
Patient sampling Cross-sectional design consecutive enrolment, retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: signs and symptoms of pulmonary TB
Age: median 50 years (IQR 35 to 60)
Sex, female: not reported
HIV infection: not reported
History of TB: not reported
Sample size: 751
Clinical setting: outpatient
Laboratory level: central
Country: USA
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 18.2%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: Middlebrook solid, MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes Participants were also tested with Xpert if the test result would alter case management or TB control
activities
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
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Rice 2017 (Continued)
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Unclear
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Safianowska 2012
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumptive TB
Age: mean 61 years, range 20 to 97 years
Sex, female: 36.6%
HIV infection: 0%
History of TB: not reported
Sample size: 145
Clinical setting: laboratory-based
Laboratory level: intermediate
Country: Poland
World Bank Income Classification: high income
TB incidence rate: 23 per 100,000
MDR-TB prevalence: percentage MDR-TB among new TB cases = 0.5% (Source: nationwide
surveillance, 2011) and among retreatment cases = 3.5% (Source: nationwide surveillance, 2011)
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 11.8%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ culture
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: LJ media, method not specified
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Safianowska 2012 (Continued)
Low Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
No
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
No
High Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Sah 2017
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumptive TB
Age: 20 to 83 years
Sex, female: not reported
HIV infection: not reported
History of TB: not reported
Sample size: 105
Clinical setting: not reported
Laboratory level: central
Country: Nepal
World Bank Income Classification: low income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 37.1%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: LJ
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
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Sah 2017 (Continued)
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Scott 2011
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumptive TB presenting with cough, fever, night sweats, and/
or weight loss
Age: mean 32 years, range 19 to 75 years
Sex, female: 41.1%
HIV infection: 69.0%
History of TB: not reported
Sample size: 177
Clinical setting: primary care clinic
Laboratory level: central
Country: South Africa, Johannesburg
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
TB incidence rate: 993 per 100,000
MDR-TBprevalence: percentageMDR-TBamongnewTBcases = 1.4%(Source: survey inGauteng
province, 2002) and among retreatment cases = 5.5% (Source: survey in Gauteng province, 2002)
Prevalence of TB cases in the study: 37.9%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes 1 follow-up visit was performed approximately 60 days after enrolment
Xpert MTB/RIF was performed on frozen specimens while MGIT culture and smear microscopy
were performed on fresh specimens
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Scott 2011 (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Scott 2017
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumptive TB, including presence of a cough for 2 weeks, weight
loss, night sweats, fever, chest pain
Age: mean 34 years, range 18 to 60 years
Sex, female: 38%
HIV infection: 73%
History of TB: 15%
Sample size: 206
Clinical setting: outpatient
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 32.1%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
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Scott 2017 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Shao 2017
Study characteristics
Patient sampling Cross-sectional design, unknown manner of enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumptive TB
Age: mean 53 years (SD 19)
Sex, female: 31%
HIV infection: not reported
History of TB: not reported
Sample size: 225
Clinical setting: outpatient
Laboratory level: peripheral
Country: China
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 38.1%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ
Flow and timing 129 presumed TB patients were excluded
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Low
DOMAIN 2: Index Test Xpert MTB/RIF
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Shao 2017 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
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Sharma 2015
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: clinical suspicion of TB
Age: adults, mean 37 years (SD 18)
Sex, female: 35%
HIV infection: not reported
History of TB: not reported
Sample size: 1437
Clinical setting: laboratory-based
Laboratory level: central
Country: India
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 31.2%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: LJ
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
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Sharma 2015 (Continued)
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Shenai 2016
Study characteristics
Patient sampling Cross-sectional design, unknown manner of enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: cough for 2 weeks and 1 or more of the following: fever, night
sweats, or weight loss
Age: 18 years or older; median 40 years (IQR 30 to 50)
Sex, female: 40%
HIV infection: 18%
History of TB: not reported
Sample size: 336
Clinical setting: outpatient
Laboratory level: central
Country: Brazil, South Africa, Uganda
World Bank Income Classification: low and middle income
High TB burden country: yes (Brazil), yes (South Africa), no (Uganda)
High MDR-TB burden country: no (Brazil), yes (South Africa), no (Uganda)
High TB/HIV burden country: yes (Brazil), yes (South Africa), yes (Uganda)
Prevalence of TB cases in the study: 28.9%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Low
DOMAIN 2: Index Test Xpert MTB/RIF
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Shenai 2016 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Singh 2016
Study characteristics
Patient sampling Cross-sectional design, unknown manner of enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumptive pulmonary TB
Age: range 15 to 60 years
Sex, female: not reported
HIV infection: 0%
History of TB: not reported
Sample size: 72
Clinical setting: not reported
Laboratory level: central
Country: India
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
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Singh 2016 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Sohn 2014
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumptive active pulmonary TB, only 18% of participants were
symptomatic
Age: median 44 years (IQR 31 to 61), range 18 to > 50 years
Sex, female: 44%
HIV infection: 2%
History of TB: 22%
Sample size: 501
Clinical setting: outpatient
Laboratory level: central
Country: Canada
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 5.0%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes Only 18% of the included participants had symptoms suggestive of active TB (e.g. fever, cough,
night sweats, weight loss)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Sohn 2014 (Continued)
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Ssengooba 2014
Study characteristics
Patient sampling Cross-sectional design, random enrolment, prospective study design
Patient characteristics and set-
ting
Presenting signs and symptoms: clinical TB symptoms
Age: 18 years and older, median 33 years (IQR 29 to 37)
Sex, female: 63%
HIV infection: 100%
History of TB: not reported
Sample size: 424
Clinical setting: inpatient and outpatient
Laboratory level: central
Country: Uganda
World Bank Income Classification: low income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 29.0%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes Substudy of Nakiyingi 2014
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
238Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Ssengooba 2014 (Continued)
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Tadesse 2016
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment of participants, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: clinical suspicion of TB, smear-negative
Age: 18 years and older, median 38 years (IQR 23 to 55)
Sex, female: 38%
HIV infection: 0%
History of TB: not reported
Sample size: 185
Clinical setting: not reported
Laboratory level: central
Country: Ethiopia
World Bank Income Classification: low income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 10.3%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: LJ and MGIT 960
Flow and timing
Comparative
Notes “One hundred twenty-four patients were excluded from the study (56 wereHIV-positive/unknown,
30 were smear positive, 19 provided a sample with inadequate volume, 13 did not provide three
sputa, and six had missing acid-fast bacilli-smear results).”
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
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Tadesse 2016 (Continued)
High Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Tang 2017
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: clinical suspicion of TB
Age: median 36 years, range 16 to 78 years
Sex, female: 47%
HIV infection: not reported
History of TB: not reported
Sample size: 240
Clinical setting: not reported
Laboratory level: central
Country: China
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 36.0%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes Study authors considered the quality of specimens, collection, transport, and testing times as possible
explanations for low Xpert specificity in this study
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
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Tang 2017 (Continued)
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Theron 2011
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumptive TB based on compatible signs and symptoms
Age: median 36 years, range 18 to 83 years
Sex, female: 32.3%
HIV infection: 31.3%
History of TB: 34.3%
Sample size: 480
Clinical setting: 2 primary care clinics in a high HIV prevalence area
Laboratory level: central
Country: South Africa, Cape Town
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
TB incidence rate: 993 per 100,000
MDR-TBprevalence: percentageMDR-TB among newTB cases = 0.9% (Source: survey inWestern
Cape Province, 2002) and among retreatment cases = 4.0% (Source: survey in Western Cape
Province, 2002)
Prevalence of TB cases in the study: 29.4%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes Short-term follow-up cultures were obtained; 16 of 19 Xpert MTB/RIF-positive culture-negative
participants were considered likely to be TB cases based on follow-up cultures, gene sequencing,
and the presence of characteristic radiographic features using a standardized scoring system
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Theron 2011 (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Theron 2013
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumptive pulmonary TB, sputum scarce or smear-negative
Age: 18 years and older, median 46 years (IQR 33 to 56)
Sex, female: 46%
HIV infection: 30%
History of TB: 34%
Sample size: 154
Clinical setting: not reported
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 17.8%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Unclear
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Theron 2013 (Continued)
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Theron 2014a
Study characteristics
Patient sampling Randomized, parallel-group, multicentre trial, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: 1 or more symptoms of pulmonary TB according to predefined
WHO criteria
Age: 18 years or older, median 37 years (IQR 30 to 46)
Sex, female: 43%
HIV infection: 69%
History of TB: not reported
Sample size: 729
Clinical setting: outpatient
Laboratory level: peripheral
Country: South Africa, Zimbabwe, Zambia, and Tanzania
World Bank Income Classification: low and middle income
High TB burden country: yes (South Africa), yes (Zimbabwe), yes (Zambia), yes (Tanzania)
High MDR-TB burden country: yes (South Africa), yes (Zimbabwe), no (Zambia), no (Tanzania)
High TB/HIV burden country: yes (South Africa), yes (Zimbabwe), yes (Zambia), yes (Tanzania)
Prevalence of TB cases in the study: 25.4%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
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Theron 2014a (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Tsuyuguchi 2017
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumed TB
Age: mean 65 years (SD 17), range 23 to 94 years
Sex, female: 38%
HIV infection: not reported
History of TB: not reported
Sample size: 417
Clinical setting: not reported
Laboratory level: central
Country: Japan
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 55.0%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: Ogawa and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing A total of 515 sputum specimens were collected; however, 35 were ineligible due to over-testing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
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Tsuyuguchi 2017 (Continued)
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
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Van Rie 2013
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: prolonged (> 2 weeks) cough or other TB symptoms, or both, and
had 2 prior-negative smear by fluorescence microscopy
Age: median 36 years (IQR 30 to 34)
Sex, female: 56.8%
HIV infection: 72.4%
History of TB: 17.6%
Sample size: 161
Clinical setting: primary care clinic
Laboratory level: peripheral
Country: South Africa, Johannesburg
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
TB incidence rate: 993 per 100,000
MDR-TBprevalence: percentageMDR-TBamongnewTBcases = 1.4%(Source: survey inGauteng
province, 2002) and among retreatment cases = 5.5% (Source: survey in Gauteng province, 2002)
Prevalence of TB cases in the study: 9.3%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing Only those participants presumed tohaveTBwho returned for results of the initial smearmicroscopy
examinations were enrolled
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Van Rie 2013 (Continued)
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
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Walusimbi 2013a
Study characteristics
Patient sampling Cross-sectional design, unknown manner of enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: cough for > 2 weeks, with or without fever, night sweats, loss of
weight, or blood-stained sputum, smear-negative
Age: adults, median 34 years (IQR 29 to 40)
Sex, female: 56%
HIV infection: 100%
History of TB: not reported
Sample size: 601
Clinical setting: inpatient and outpatient
Laboratory level: central
Country: Uganda
World Bank Income Classification: low income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 11.7%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test Xpert MTB/RIF
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Walusimbi 2013a (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Williamson 2012
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: not reported: smear-positive specimens
Age: 15 years and older
Sex, female: not reported
HIV infection: estimated < 1%
History of TB: not reported
Sample size: 89
Clinical setting: laboratory-based
Laboratory level: central
Country: New Zealand
World Bank Income Classification: high income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
TB incidence rate: 7.6 per 100,000
MDR-TB prevalence: percentage MDR-TB among new TB cases = 2.5% (Source: nationwide
surveillance 2009) and among retreatment cases = 13% (Source: nationwide surveillance 2009)
Prevalence of TB cases in the study: 75.3%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
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Williamson 2012 (Continued)
High Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Yoon 2017
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: HIV-positive people initiating antiretroviral therapy
Age: 18 years and older, median 33 years (IQR 27 to 40)
Sex, female: 53%
HIV infection: 100%
History of TB: 4%
Sample size: 1177
Clinical setting: outpatient HIV/AIDS clinics
Laboratory level: central
Country: Uganda
World Bank Income Classification: middle income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 13.8%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Xpert MTB/RIF
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Yoon 2017 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Yes
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Zeka 2011
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: clinical findings of possible TB
Age: median 48 years, range 25 to 70 years
Sex, female: 42.4%
HIV infection: not reported
History of TB: not reported
Sample size: 103
Clinical setting: laboratory-based
Laboratory level: central
Country: Turkey
World Bank Income Classification: middle income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
TB incidence rate: 24 per 100,000
MDR-TB prevalence: percentageMDR-TB among new TB cases = 0.9% (Source: survey in Ankara
City 2011) and among retreatment cases = 38% (Source: survey in Ankara City 2011)
Prevalence of TB cases in the study: 34.0%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ culture and MB/MBacT liquid medium
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: proportion method on 7H10 media
Flow and timing
Comparative
Notes Only one rifampicin resistant isolate was identified. Data for sputum specimens were provided by
the study author
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Zeka 2011 (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
No
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
No
High Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Zetola 2014
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, retrospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: (i) people with presumed pulmonary TB at high risk forMDR-TB,
(ii) people who had been treated with anti-TB drugs and in whom TB had again been diagnosed,
i.e. all retreatment categories (failure, default, and relapse), (iii) HIV-positive people with signs or
symptoms of TB, (iv) people who were seriously ill and suspected of having TB regardless of HIV
status, and (v) people with unknown HIV status presenting with clinical evidence of HIV infection
and signs or symptoms of PTB
Age: 18 years or older, median 37 years (IQR 31 to 44)
Sex, female: 40%
HIV infection: 75%
History of TB: 62%
Sample size: 370
Clinical setting: not reported
Laboratory level: central
Country: Botswana
World Bank Income Classification: middle income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: yes
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: LJ
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Zetola 2014 (Continued)
Low Unclear
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Zmak 2013
Study characteristics
Patient sampling Cross-sectional design, consecutive enrolment, prospective data collection
Patient characteristics and set-
ting
Presenting signs and symptoms: presumed pulmonary TB
Age: adults
Sex, female: not reported
HIV infection: not reported
History of TB: not reported
Sample size: 120
Clinical setting: laboratory-based
Laboratory level: central
Country: Croatia
World Bank Income Classification: middle income
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 6.0%
Index tests Index: Xpert MTB/RIF
Target condition and reference
standard(s)
Target condition: pulmonary TB
Reference standard for pulmonary TB: LJ and MGIT 960
Target condition: rifampicin resistance
Reference standard for rifampicin resistance: LJ
Flow and timing
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
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Zmak 2013 (Continued)
DOMAIN 2: Index Test Xpert MTB/RIF
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults for TB detection inter-
preted without knowledge of
the results of the index test?
No
Were the reference standard re-
sults for rifampicin resistance
detection interpreted without
knowledge of the results of the
index test?
No
High Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Abbreviations: HIV: human immunodeficiency virus; ICU: intensive care unit; IQR: interquartile range; LJ: Löwenstein-Jensen; MDR-
TB: multidrug-resistant TB; MGIT: mycobacterial growth indicator tube; MODS: microscopic observation drug susceptibility; SD:
standard deviation; TB: tuberculosis
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Acuna-Villaorduna 2017 Duplicate data with additional analyses; Boum 2016 includes same data set
Ade 2016 Includes both adults and children or no information about age of enrolment
Adelman 2014 Abstract
Agizew 2017 Data insufficient for 2 x 2 table
Agrawal 2016 Includes both adults and children or no information about age of enrolment
Al-Ateah 2012 Includes both adults and children or no information about age of enrolment
Al-Darraji 2016 Data insufficient for 2 x 2 table
Alame-Emane 2017 Data insufficient for 2 x 2 table
Albay 2016 Includes both adults and children or no information about age of enrolment
Ali 2016 Abstract
Alland 2015 Abstract
Alnimr 2014 Data insufficient for 2 x 2 table
Alvarez 2015 Includes both adults and children or no information about age
Alvarez-Uria 2012 Reference standard not satisfied
Alvis-Zakzuk 2017 Systematic review
Andriani 2016 Abstract
Antonenka 2013 Case-control study
Armand 2011 This was a case-control study that compared Xpert MTB/RIF with an in-house IS6110-based real-time
PCR using TaqMan probes (IS6110-TaqMan assay) for TB detection
Asencio 2013 Cost-effectiveness study
Aston 2016 Abstract
Atashi 2017 Data insufficient for 2 x 2 table
Atehortua 2015 Includes both adults and children or no information about age of enrolment
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Atuhumuza 2016 Abstract
Atwine 2015 Data insufficient for 2 x 2 table
Auld 2016b Includes both adults and children
Aurin 2014 Includes both adults and children or no information about age of enrolment
Avashia 2016 Reference standard not satisfied
Ayala 2016 Data insufficient for 2 x 2 table
Bablishvili 2015 Includes both adults and children or no information about age of enrolment
Badal-Faesen 2017 Duplicate data with additional analyses; Luetkemeyer 2016 includes same data set
Bajrami 2016 Includes data for pulmonary and extrapulmonary TB combined
Balcha 2014a Xpert was not the index test
Banu 2014 Data insufficient for 2 x 2 table
Barkham 2016 Abstract
Barnard 2012 Includes both adults and children or no information about age of enrolment
Bates 2013b This study evaluated Xpert MTB/RIF for the diagnosis of TB in children
Biadglegne 2014 Includes both adults and children or no information about age of enrolment
Bilgin 2016 Includes both adults and children or no information about age of enrolment
Bisognin 2018 Not a diagnostic accuracy study
Bjerrum 2015 Xpert was not the index test
Boakye-Appiah 2016 Data insufficient for 2 x 2 table
Bojang 2016 Xpert was not the index test
Bonnet 2017 Data insufficient for 2 x 2 table
Bowles 2011 Includes both adults and children or no information about age of enrolment
Bunsow 2014a Includes respiratory specimens and gastric aspirates
Capocci 2016 Abstract
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(Continued)
Causse 2011 This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TB
Cavanaugh 2016 Data insufficient for 2 x 2 table
Cayci 2017 Includes both adults and children or no information about age of enrolment
Celik 2015 Includes both adults and children or no information about age of enrolment
Chakravorty 2017 Includes both adults and children or no information about age of enrolment
Chishty 2016 Abstract
Ciftçi 2011 Includes both adults and children or no information about age of enrolment
Clouse 2012 Study on patient impact
Cross 2014 Reference standard not satisfied
Cross 2015 Includes both adults and children or no information about age of enrolment
Dagnra 2015 Data insufficient for 2 x 2 table
Daum 2015 Xpert not the index test
Deggim 2013 Includes both adults and children or no information about age of enrolment
Dierberg 2016 Data insufficient for 2 x 2 table
Dorjee 2012 Case report
Dorman 2012 Prevalence survey
Dowdy 2011 Cost-effectiveness study
Feasey 2013 Data insufficient for 2 x 2 table
Fernandez 2017 Abstract
FIND 2011 This study compared Xpert MTB/RIF G3 and G4. We excluded it because of concern about duplicate
data. In addition, the criteria for the reference standard for rifampicin resistance detection were not
satisfied
Fong 2017 Abstract
Friedrich 2011a This study evaluated Xpert MTB/RIF for the diagnosis of pleural TB
Gama de Andrade 2017 Abstract
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(Continued)
Gelalcha 2017 Includes both adults and children or no information about age of enrolment
Gounder 2014 Includes both adults and children or no information about age of enrolment
Griesel 2016 Abstract
Griesel 2017 Includes data for pulmonary and extrapulmonary TB combined
Guenaoui 2016 Includes both adults and children or no information about age of enrolment
Gupta 2014 Abstract
Gurbanova 2016 Abstract
Gurbanova 2017 Includes data for pulmonary and extrapulmonary TB combined
Gursoy 2016 Includes both adults and children or no information about age of enrolment
Habeenzu 2017 Includes both adults and children or no information about age of enrolment
Hanifa 2016 Reference standard not satisfied
Heidebrecht 2016 Data insufficient for 2 x 2 table
Hillemann 2011 This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TB
Hiza 2017 Not a diagnostic accuracy study
Ho 2016 Community-based screening
Horo 2017 Includes both adults and children or no information about age of enrolment
Hu 2014 Includes both adults and children or no information about age of enrolment
Huang 2018 Includes both adults and children or no information about age of enrolment
Huerga 2017 Xpert was not the index test
Ioannidis 2010 We could not obtain this article
Ioannidis 2011 Includes both adults and children or no information about age of enrolment
Iram 2015 Includes both adults and children or no information about age of enrolment
Jafari 2013 Data insufficient for 2 x 2 table
Jing 2017 Includes both adults and children or no information about age of enrolment
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Jipa 2016 Abstract
Jones-Lopez 2014 Xpert was not the index test
Kang 2016 Abstract
Kaur 2016 Systematic review
Kayigire 2013 Not a diagnostic accuracy study
Kelly-Cirino 2017 Xpert was not the index test
Kerkhoff 2013 Data insufficient for 2 x 2 table
Kerkhoff 2014 Data insufficient for 2 x 2 table
Khalil 2015 includes both adults and children or no information about age of enrolment
Khan 2016 Data insufficient for 2 x 2 table
Kim 2012 Case-control study
Kim CH 2014 Duplicate data; Kim CH 2015 includes the same data with more participants
Kim MJ 2015 Data insufficient for 2 x 2 table
Kim YW 2015 Includes both adults and children or no information about age of enrolment
Lange 2017 Systematic review
Laskar 2017 Could not obtain full text
Lawn 2012a Study on patient impact
Lawn 2012b Data insufficient for 2 x 2 table
Lawn 2012c Primarily a lipoarabinomannan detection study
Lawn 2013 Data insufficient for 2 x 2 table
Lawn 2015 Reference standard not satisfied
Lawn 2017 Reference standard not satisfied
Lebina 2016 Community-based screening
Lessells 2017 Impact study
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Li 2016 Includes both adults and children or no information about age of enrolment
Li 2017 Systematic review
Ligthelm 2011 This study evaluated Xpert MTB/RIF for the diagnosis of TB lymphadenitis
Lombardi 2017 Includes both adults and children or no information about age of enrolment
Mafort 2017 Abstract
Malbruny 2011 Includes both adults and children or no information about age of enrolment
Marlowe 2011 Includes both adults and children or no information about age of enrolment
Matabane 2015 Includes both adults and children or no information about age of enrolment
Mave 2017 Screening
Maynard-Smith 2014 Systematic review
Miller 2011 Includes both adults and children or no information about age of enrolment
Miotto 2012 Treatment monitoring
Mntonintshi 2017 Data insufficient for 2 x 2 table
Modi 2016 Xpert was not the index test
Mokaddas 2016 Abstract
More 2017 Data insufficient for 2 x 2 table
Morozova 2016 Abstract
Moure 2012 This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TB
Mukherjee 2017 Reference standard not satisfied
Mulder 2017 Xpert was not the index test
Muñoz 2013 Study on patient impact
Myneedu 2014 Includes both adults and children or no information about age of enrolment
Naidoo 2016 Data insufficient for 2 x 2 table
Narasimooloo 2012 Study on patient impact
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(Continued)
Ng 2018 Case-control study
Nguyen 2018 Includes both adults and children or no information about age of enrolment
Ngwira 2017 Abstract
Nhu 2013 This study evaluated Xpert MTB/RIF for the diagnosis of TB in children
Nicol 2011 This study evaluated Xpert for the diagnosis of TB in children
Ninan 2016 Xpert was not the index test
Nosova 2013b Duplicate data; same study as Nosova 2013a. Nosova 2013b is written in Russian
Ntinginya 2012 Active case finding, not a diagnostic test accuracy study
O’Grady 2012 This study evaluated Xpert MTB/RIF in patients able to produce sputum, irrespective of admission
diagnosis, not presumed TB patients
Omrani 2014 Not a diagnostic accuracy study
Opota 2016 Includes both adults and children or no information about age of enrolment
Osman 2014 Case-control study
Ou 2015 Includes both adults and children or no information about age of enrolment
Ozkutuk 2014 Includes both adults and children or no information about age of enrolment
Pandey P 2017 Includes both adults and children or no information about age of enrolment
Pandey S 2017 Includes both adults and children or no information about age of enrolment
Parcell 2017 Includes both adults and children or no information about age of enrolment
Patil 2014 Case report
Patil 2017 Reference standard not satisfied
Peter 2012 This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TB
Peter 2013 Data insufficient for 2 x 2 table
Peter 2015 Duplicate data; study was nested in Theron 2014a
Rachow 2012 This study evaluated Xpert for the diagnosis of TB in children
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Rahman 2016 Not a diagnostic accuracy study
Raizada 2015 Not a diagnostic accuracy study
Ramamurthy 2016 Data insufficient for 2 x 2 table
Ramirez 2014 Not a diagnostic accuracy study
Reechaipichitkul 2016 Duplicate data; more participants were included in Reechaipichitkul 2017
Reed 2016 Xpert was not the index test
Rees 2018 Impact study
Rossato 2018 Study design unclear, possibly case-control
Rufai 2014 Data insufficient for 2 x 2 table
Ruiz 2017 Xpert was not the index test
Sachdeva 2015 Not a diagnostic accuracy study
Saeed 2017 Data insufficient for 2 x 2 table
Sanchez-Padilla 2015 Not a diagnostic accuracy study
Sauzullo 2016 Includes both adults and children or no information about age of enrolment
Shah 2014 Case-control study
Shenai 2013 Data insufficient for 2 x 2 table
Shilpa 2017 Reference standard not satisfied
Smith 2014 Not a diagnostic accuracy study
Somashekar 2014 Reference standard not satisfied
Somily 2016 Includes both pulmonary and extrapulmonary specimens combined
Strydom 2015 Case-control study
Sureshbabu 2016 Reference standard not satisfied
Tadesse 2016b Abstract
Tahseen 2016 Drug resistance survey
273Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(Continued)
Tan 2017 Xpert was not the index test
Taylor 2012 This study evaluated Xpert for the diagnosis of extrapulmonary TB
Teo 2011 Includes both adults and children or no information about age of enrolment
Theron 2012 Treatment monitoring
Theron 2014b Duplicate data set for Theron 2014a with a different aim
Theron 2016 Duplicate data. Author reported that this study overlaps with the Theron 2014a and can be excluded
Theron 2018 Screening study
Thibbadee 2016 Abstract
Thit 2017 Xpert was not the index test
To 2017 Abstract
Tortoli 2012 This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TB
Ullah 2016 Includes both adults and children or no information about age of enrolment
Ullah 2017 Includes both adults and children or no information about age of enrolment
Vadwai 2011 This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TB
Van Kampen 2015 Includes both adults and children or no information about age of enrolment
Van Rie 2011 Case report
Walters 2012 This study evaluated Xpert MTB/RIF for the diagnosis of TB in children
Walusimbi 2013b Systematic review
Wang 2015 Systematic review
Wang 2016 Includes both adults and children or no information about age of enrolment
Williamson 2012a Case-control study
Wood 2012 This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TB
Xie 2017 Xpert was not the index test
Yadav 2017 Includes both adults and children or no information about age of enrolment
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Yan 2016 Systematic review
Zar 2012 This study evaluated Xpert MTB/RIF for the diagnosis of TB in children
Zemlyansky 2016 Includes both adults and children or no information about age of enrolment
Characteristics of ongoing studies [ordered by study ID]
Koenig 2018
Trial name or title A trial of same-day testing and treatment to improve outcomes among symptomatic
patients newly diagnosed with HIV
Target condition and reference standard(s) Tuberculosis, HIV/AIDS
Index and comparator tests Spot and early-morning Xpert Ultra results and chest x-ray, as single and as combined
tests, with liquid culture as reference standard
Starting date 16 May 2017
Contact information Serena P Koenig, MD, skoenig@bwh.harvard.edu
Notes ClinicalTrials.gov Identifier: NCT03154320
Reid 2018
Trial name or title Achieving tuberculosis control In Zambia
Target condition and reference standard(s) Tuberculosis
Index and comparator tests Comparison of two diagnostic tools (chest-xray with computer-assisted diagnosis ver-
sus C-reactive protein) and Xpert Ultra for active community-based tuberculosis case
detection
Starting date 13 April 2018
Contact information Stewart Reid, MD, MPH, stewart.reid@cidrz.org
Notes ClinicalTrials.gov Identifier: NCT03497195
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Theron 2018a
Trial name or title Improving tuberculosis diagnosis and treatment through Basic, Applied and health
systems Research (BAR)
Target condition and reference standard(s) Tuberculosis
Index and comparator tests Xpert Ultra point-of-care testing compared to the standard of care tuberculosis testing
at a centralised facility
Starting date 29 November 2017
Contact information Grant Theron, PhD. gtheron@sun.ac.za
Notes ClinicalTrials.gov Identifier: NCT03356925
Theron 2018b
Trial name or title Xpert Ultra and Xpert HIV-VL in people living with HIV (UltraHIV)
Target condition and reference standard(s) Tuberculosis, HIV/AIDS
Index and comparator tests Impact study
Starting date 15 June 2017
Contact information Grant Theron, PhD. gtheron@sun.ac.za
Notes ClinicalTrials.gov Identifier: NCT03187964
Zhang 2018
Trial name or title Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous bronchoalveolar lavage
fluid in HIV-infected adults: a prospective cohort study
Target condition and reference standard(s) Tuberculosis and HIV/AIDS, MGIT
Index and comparator tests Xpert Ultra
Starting date 12 February 2018
Contact information Peize Zhang, 516472422@qq.com
Notes WHO International Clinical Trials: Chi CTR1800014792
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Xpert MTB/RIF for detection of
pulmonary tuberculosis (PTB)
86 42091
2 Xpert Ultra for detection of PTB 1 1439
3 Smear-positive, Xpert MTB/RIF 53 4943
4 Smear-positive, Xpert MTB/RIF,
direct comparison Xpert
MTB/RIF vs Xpert Ultra
1 323
5 Smear-positive, Xpert Ultra,
direct comparison Xpert
MTB/RIF vs Xpert Ultra
1 323
6 Smear-negative, XpertMTB/RIF 56 22581
7 Smear-negative, Xpert
MTB/RIF, direct comparison
Xpert MTB/RIF vs Xpert Ultra
1 1111
8 Smear-negative, Xpert Ultra,
direct comparison Xpert
MTB/RIF vs Xpert Ultra
1 1111
9 HIV-negative, Xpert MTB/RIF 18 5118
10 HIV-positive, Xpert MTB/RIF 30 9593
11 HIV-negative, within study
comparisons
14 4681
12 HIV-positive, within study
comparisons
14 4663
13 HIV-negative, Xpert
MTB/RIF, direct comparison
Xpert MTB/RIF vs Xpert Ultra
1 483
14 HIV-negative, Xpert Ultra,
direct comparison Xpert
MTB/RIF vs Xpert Ultra
1 483
15 HIV-positive, Xpert MTB/RIF,
direct comparison Xpert
MTB/RIF vs Xpert Ultra
1 432
16 HIV-positive, Xpert Ultra,
direct comparison Xpert
MTB/RIF vs Xpert Ultra
1 432
17 Xpert MTB/RIF for detection
of rifampicin resistance
57 8287
18 Xpert Ultra for detection of
rifampicin resistance
1 551
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Test 1. Xpert MTB/RIF for detection of pulmonary tuberculosis (PTB).
Review: Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
Test: 1 Xpert MTB/RIF for detection of pulmonary tuberculosis (PTB)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Adelman 2015 3 2 3 204 0.50 [ 0.12, 0.88 ] 0.99 [ 0.97, 1.00 ]
Al-Darraji 2013 8 0 7 110 0.53 [ 0.27, 0.79 ] 1.00 [ 0.97, 1.00 ]
Atwebembeire 2016 16 1 17 70 0.48 [ 0.31, 0.66 ] 0.99 [ 0.92, 1.00 ]
Balcells 2012 11 1 1 147 0.92 [ 0.62, 1.00 ] 0.99 [ 0.96, 1.00 ]
Balcha 2014 81 13 41 677 0.66 [ 0.57, 0.75 ] 0.98 [ 0.97, 0.99 ]
Barmankulova 2015 191 1 44 55 0.81 [ 0.76, 0.86 ] 0.98 [ 0.90, 1.00 ]
Barnard 2015 36 9 3 64 0.92 [ 0.79, 0.98 ] 0.88 [ 0.78, 0.94 ]
Bates 2013a 21 2 5 66 0.81 [ 0.61, 0.93 ] 0.97 [ 0.90, 1.00 ]
Bjerrum 2016 27 5 8 155 0.77 [ 0.60, 0.90 ] 0.97 [ 0.93, 0.99 ]
Boehme 2010 675 26 57 681 0.92 [ 0.90, 0.94 ] 0.96 [ 0.95, 0.98 ]
Boehme 2011 933 30 100 2846 0.90 [ 0.88, 0.92 ] 0.99 [ 0.99, 0.99 ]
Boum 2016 194 22 17 654 0.92 [ 0.87, 0.95 ] 0.97 [ 0.95, 0.98 ]
Calligaro 2015 11 5 0 75 1.00 [ 0.72, 1.00 ] 0.94 [ 0.86, 0.98 ]
Calligaro 2017 35 13 7 348 0.83 [ 0.69, 0.93 ] 0.96 [ 0.94, 0.98 ]
Carriquiry 2012 44 2 1 84 0.98 [ 0.88, 1.00 ] 0.98 [ 0.92, 1.00 ]
Chaisson 2014 8 0 1 133 0.89 [ 0.52, 1.00 ] 1.00 [ 0.97, 1.00 ]
Chen 2017 5 3 1 724 0.83 [ 0.36, 1.00 ] 1.00 [ 0.99, 1.00 ]
Chew 2016 34 1 6 197 0.85 [ 0.70, 0.94 ] 0.99 [ 0.97, 1.00 ]
Cowan 2017 17 0 3 298 0.85 [ 0.62, 0.97 ] 1.00 [ 0.99, 1.00 ]
Davis 2014 12 3 1 140 0.92 [ 0.64, 1.00 ] 0.98 [ 0.94, 1.00 ]
Dorman 2018 383 17 79 960 0.83 [ 0.79, 0.86 ] 0.98 [ 0.97, 0.99 ]
Friedrich 2011 117 0 9 0 0.93 [ 0.87, 0.97 ] 0.0 [ 0.0, 0.0 ]
Geleta 2015 38 6 20 156 0.66 [ 0.52, 0.78 ] 0.96 [ 0.92, 0.99 ]
Hanif 2011 54 0 6 146 0.90 [ 0.79, 0.96 ] 1.00 [ 0.98, 1.00 ]
Hanrahan 2013 42 2 22 487 0.66 [ 0.53, 0.77 ] 1.00 [ 0.99, 1.00 ]
Hanrahan 2014 299 38 107 1638 0.74 [ 0.69, 0.78 ] 0.98 [ 0.97, 0.98 ]
Helb 2010 67 0 15 25 0.82 [ 0.72, 0.89 ] 1.00 [ 0.86, 1.00 ]
Henostroza 2016 39 5 23 266 0.63 [ 0.50, 0.75 ] 0.98 [ 0.96, 0.99 ]
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Huang 2015 166 31 22 159 0.88 [ 0.83, 0.93 ] 0.84 [ 0.78, 0.89 ]
Huh 2014 95 10 9 157 0.91 [ 0.84, 0.96 ] 0.94 [ 0.89, 0.97 ]
Jo 2016 59 47 5 209 0.92 [ 0.83, 0.97 ] 0.82 [ 0.76, 0.86 ]
Kawkitinarong 2017 227 6 23 133 0.91 [ 0.87, 0.94 ] 0.96 [ 0.91, 0.98 ]
Kim CH 2015 46 5 6 348 0.88 [ 0.77, 0.96 ] 0.99 [ 0.97, 1.00 ]
Ko 2016 97 12 8 132 0.92 [ 0.86, 0.97 ] 0.92 [ 0.86, 0.96 ]
Kurbaniyazova 2017 1577 99 124 934 0.93 [ 0.91, 0.94 ] 0.90 [ 0.88, 0.92 ]
Kurbatova 2013 102 17 5 104 0.95 [ 0.89, 0.98 ] 0.86 [ 0.78, 0.92 ]
Kwak 2013 124 20 32 505 0.79 [ 0.72, 0.86 ] 0.96 [ 0.94, 0.98 ]
LaCourse 2016 3 1 4 280 0.43 [ 0.10, 0.82 ] 1.00 [ 0.98, 1.00 ]
Lawn 2011 42 2 30 320 0.58 [ 0.46, 0.70 ] 0.99 [ 0.98, 1.00 ]
Le Palud 2014 16 2 4 140 0.80 [ 0.56, 0.94 ] 0.99 [ 0.95, 1.00 ]
Lee 2013 31 0 7 94 0.82 [ 0.66, 0.92 ] 1.00 [ 0.96, 1.00 ]
Lippincott 2014 13 1 1 484 0.93 [ 0.66, 1.00 ] 1.00 [ 0.99, 1.00 ]
Liu 2017 405 231 32 2428 0.93 [ 0.90, 0.95 ] 0.91 [ 0.90, 0.92 ]
Luetkemeyer 2016 175 10 40 735 0.81 [ 0.76, 0.86 ] 0.99 [ 0.98, 0.99 ]
Mbelele 2017 73 25 12 152 0.86 [ 0.77, 0.92 ] 0.86 [ 0.80, 0.91 ]
Meawed 2016 53 1 1 3 0.98 [ 0.90, 1.00 ] 0.75 [ 0.19, 0.99 ]
Metcalfe 2015 82 8 7 52 0.92 [ 0.84, 0.97 ] 0.87 [ 0.75, 0.94 ]
Meyer 2017 207 68 183 1324 0.53 [ 0.48, 0.58 ] 0.95 [ 0.94, 0.96 ]
Mok 2016 30 2 14 112 0.68 [ 0.52, 0.81 ] 0.98 [ 0.94, 1.00 ]
Mollel 2017 9 0 0 60 1.00 [ 0.66, 1.00 ] 1.00 [ 0.94, 1.00 ]
Moure 2011 61 0 17 29 0.78 [ 0.67, 0.87 ] 1.00 [ 0.88, 1.00 ]
Moussa 2016 67 3 3 145 0.96 [ 0.88, 0.99 ] 0.98 [ 0.94, 1.00 ]
Mutingwende 2015 191 12 33 60 0.85 [ 0.80, 0.90 ] 0.83 [ 0.73, 0.91 ]
Ngabonziza 2016 77 5 19 499 0.80 [ 0.71, 0.88 ] 0.99 [ 0.98, 1.00 ]
Nikam 2014 135 59 16 64 0.89 [ 0.83, 0.94 ] 0.52 [ 0.43, 0.61 ]
Nliwasa 2016 31 9 9 181 0.78 [ 0.62, 0.89 ] 0.95 [ 0.91, 0.98 ]
Nosova 2013a 47 0 4 86 0.92 [ 0.81, 0.98 ] 1.00 [ 0.96, 1.00 ]
O’Donnell 2015 112 1 7 35 0.94 [ 0.88, 0.98 ] 0.97 [ 0.85, 1.00 ]
Park 2013 19 6 4 291 0.83 [ 0.61, 0.95 ] 0.98 [ 0.96, 0.99 ]
Pimkina 2015 358 34 24 376 0.94 [ 0.91, 0.96 ] 0.92 [ 0.89, 0.94 ]
Pinyopornpanish 2015 41 9 2 57 0.95 [ 0.84, 0.99 ] 0.86 [ 0.76, 0.94 ]
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rachow 2011 61 8 8 172 0.88 [ 0.78, 0.95 ] 0.96 [ 0.91, 0.98 ]
Reddy 2017 117 35 37 458 0.76 [ 0.68, 0.82 ] 0.93 [ 0.90, 0.95 ]
Reechaipichitkul 2017 53 5 10 57 0.84 [ 0.73, 0.92 ] 0.92 [ 0.82, 0.97 ]
Rice 2017 120 2 14 600 0.90 [ 0.83, 0.94 ] 1.00 [ 0.99, 1.00 ]
Safianowska 2012 15 1 2 127 0.88 [ 0.64, 0.99 ] 0.99 [ 0.96, 1.00 ]
Sah 2017 32 5 7 61 0.82 [ 0.66, 0.92 ] 0.92 [ 0.83, 0.97 ]
Scott 2011 58 3 9 107 0.87 [ 0.76, 0.94 ] 0.97 [ 0.92, 0.99 ]
Scott 2017 57 3 5 128 0.92 [ 0.82, 0.97 ] 0.98 [ 0.93, 1.00 ]
Shao 2017 106 31 6 151 0.95 [ 0.89, 0.98 ] 0.83 [ 0.77, 0.88 ]
Sharma 2015 430 6 19 984 0.96 [ 0.93, 0.97 ] 0.99 [ 0.99, 1.00 ]
Shenai 2016 89 5 8 234 0.92 [ 0.84, 0.96 ] 0.98 [ 0.95, 0.99 ]
Sohn 2014 11 1 14 475 0.44 [ 0.24, 0.65 ] 1.00 [ 0.99, 1.00 ]
Ssengooba 2014 94 10 29 291 0.76 [ 0.68, 0.84 ] 0.97 [ 0.94, 0.98 ]
Tadesse 2016 12 2 7 164 0.63 [ 0.38, 0.84 ] 0.99 [ 0.96, 1.00 ]
Tang 2017 68 15 13 129 0.84 [ 0.74, 0.91 ] 0.90 [ 0.83, 0.94 ]
Theron 2011 111 19 30 320 0.79 [ 0.71, 0.85 ] 0.94 [ 0.91, 0.97 ]
Theron 2013 25 5 2 120 0.93 [ 0.76, 0.99 ] 0.96 [ 0.91, 0.99 ]
Theron 2014a 154 27 31 517 0.83 [ 0.77, 0.88 ] 0.95 [ 0.93, 0.97 ]
Tsuyuguchi 2017 197 6 30 180 0.87 [ 0.82, 0.91 ] 0.97 [ 0.93, 0.99 ]
Van Rie 2013 10 1 5 145 0.67 [ 0.38, 0.88 ] 0.99 [ 0.96, 1.00 ]
Walusimbi 2013a 21 16 22 310 0.49 [ 0.33, 0.65 ] 0.95 [ 0.92, 0.97 ]
Williamson 2012 67 0 0 22 1.00 [ 0.95, 1.00 ] 1.00 [ 0.85, 1.00 ]
Yoon 2017 84 8 79 1006 0.52 [ 0.44, 0.59 ] 0.99 [ 0.98, 1.00 ]
Zeka 2011 31 0 4 68 0.89 [ 0.73, 0.97 ] 1.00 [ 0.95, 1.00 ]
Zmak 2013 6 0 1 110 0.86 [ 0.42, 1.00 ] 1.00 [ 0.97, 1.00 ]
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Test 2. Xpert Ultra for detection of PTB.
Review: Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
Test: 2 Xpert Ultra for detection of PTB
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dorman 2018 408 43 54 934 0.88 [ 0.85, 0.91 ] 0.96 [ 0.94, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 3. Smear-positive, Xpert MTB/RIF.
Review: Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
Test: 3 Smear-positive, Xpert MTB/RIF
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Balcells 2012 8 0 0 2 1.00 [ 0.63, 1.00 ] 1.00 [ 0.16, 1.00 ]
Balcha 2014 27 3 1 0 0.96 [ 0.82, 1.00 ] 0.0 [ 0.0, 0.71 ]
Boehme 2010 551 0 10 0 0.98 [ 0.97, 0.99 ] 0.0 [ 0.0, 0.0 ]
Boehme 2011 637 0 11 0 0.98 [ 0.97, 0.99 ] 0.0 [ 0.0, 0.0 ]
Carriquiry 2012 31 1 0 2 1.00 [ 0.89, 1.00 ] 0.67 [ 0.09, 0.99 ]
Chaisson 2014 8 0 0 1 1.00 [ 0.63, 1.00 ] 1.00 [ 0.03, 1.00 ]
Chen 2017 3 0 0 2 1.00 [ 0.29, 1.00 ] 1.00 [ 0.16, 1.00 ]
Chew 2016 16 0 0 0 1.00 [ 0.79, 1.00 ] 0.0 [ 0.0, 0.0 ]
Cowan 2017 15 0 1 7 0.94 [ 0.70, 1.00 ] 1.00 [ 0.59, 1.00 ]
Davis 2014 11 3 0 8 1.00 [ 0.72, 1.00 ] 0.73 [ 0.39, 0.94 ]
Dorman 2018 319 0 4 0 0.99 [ 0.97, 1.00 ] 0.0 [ 0.0, 0.0 ]
Geleta 2015 20 0 1 1 0.95 [ 0.76, 1.00 ] 1.00 [ 0.03, 1.00 ]
Hanif 2011 45 0 1 0 0.98 [ 0.88, 1.00 ] 0.0 [ 0.0, 0.0 ]
Hanrahan 2013 15 0 0 1 1.00 [ 0.78, 1.00 ] 1.00 [ 0.03, 1.00 ]
Hanrahan 2014 178 3 8 7 0.96 [ 0.92, 0.98 ] 0.70 [ 0.35, 0.93 ]
Helb 2010 29 0 0 0 1.00 [ 0.88, 1.00 ] 0.0 [ 0.0, 0.0 ]
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Huang 2015 88 0 3 5 0.97 [ 0.91, 0.99 ] 1.00 [ 0.48, 1.00 ]
Huh 2014 76 3 3 18 0.96 [ 0.89, 0.99 ] 0.86 [ 0.64, 0.97 ]
Kawkitinarong 2017 128 3 0 3 1.00 [ 0.97, 1.00 ] 0.50 [ 0.12, 0.88 ]
Ko 2016 33 0 0 0 1.00 [ 0.89, 1.00 ] 0.0 [ 0.0, 0.0 ]
Kurbatova 2013 91 0 0 0 1.00 [ 0.96, 1.00 ] 0.0 [ 0.0, 0.0 ]
Kwak 2013 56 0 7 16 0.89 [ 0.78, 0.95 ] 1.00 [ 0.79, 1.00 ]
Lawn 2011 19 0 0 0 1.00 [ 0.82, 1.00 ] 0.0 [ 0.0, 0.0 ]
Le Palud 2014 5 0 0 6 1.00 [ 0.48, 1.00 ] 1.00 [ 0.54, 1.00 ]
Lippincott 2014 12 0 0 5 1.00 [ 0.74, 1.00 ] 1.00 [ 0.48, 1.00 ]
Luetkemeyer 2016 129 1 2 17 0.98 [ 0.95, 1.00 ] 0.94 [ 0.73, 1.00 ]
Meawed 2016 49 0 0 0 1.00 [ 0.93, 1.00 ] 0.0 [ 0.0, 0.0 ]
Metcalfe 2015 79 0 2 0 0.98 [ 0.91, 1.00 ] 0.0 [ 0.0, 0.0 ]
Mok 2016 9 0 0 0 1.00 [ 0.66, 1.00 ] 0.0 [ 0.0, 0.0 ]
Moussa 2016 61 0 0 0 1.00 [ 0.94, 1.00 ] 0.0 [ 0.0, 0.0 ]
Ngabonziza 2016 46 0 3 1 0.94 [ 0.83, 0.99 ] 1.00 [ 0.03, 1.00 ]
Nikam 2014 92 13 1 2 0.99 [ 0.94, 1.00 ] 0.13 [ 0.02, 0.40 ]
O’Donnell 2015 91 1 0 0 1.00 [ 0.96, 1.00 ] 0.0 [ 0.0, 0.97 ]
Park 2013 15 0 3 20 0.83 [ 0.59, 0.96 ] 1.00 [ 0.83, 1.00 ]
Pimkina 2015 273 1 6 2 0.98 [ 0.95, 0.99 ] 0.67 [ 0.09, 0.99 ]
Rachow 2011 50 0 1 0 0.98 [ 0.90, 1.00 ] 0.0 [ 0.0, 0.0 ]
Reddy 2017 41 0 1 2 0.98 [ 0.87, 1.00 ] 1.00 [ 0.16, 1.00 ]
Reechaipichitkul 2017 27 1 3 3 0.90 [ 0.73, 0.98 ] 0.75 [ 0.19, 0.99 ]
Rice 2017 85 0 2 124 0.98 [ 0.92, 1.00 ] 1.00 [ 0.97, 1.00 ]
Safianowska 2012 12 1 0 7 1.00 [ 0.74, 1.00 ] 0.88 [ 0.47, 1.00 ]
Sah 2017 22 2 6 1 0.79 [ 0.59, 0.92 ] 0.33 [ 0.01, 0.91 ]
Scott 2011 47 0 2 0 0.96 [ 0.86, 1.00 ] 0.0 [ 0.0, 0.0 ]
Shao 2017 82 1 5 4 0.94 [ 0.87, 0.98 ] 0.80 [ 0.28, 0.99 ]
Sharma 2015 374 0 3 0 0.99 [ 0.98, 1.00 ] 0.0 [ 0.0, 0.0 ]
Shenai 2016 74 0 1 0 0.99 [ 0.93, 1.00 ] 0.0 [ 0.0, 0.0 ]
Sohn 2014 6 0 1 4 0.86 [ 0.42, 1.00 ] 1.00 [ 0.40, 1.00 ]
Theron 2011 89 0 5 0 0.95 [ 0.88, 0.98 ] 0.0 [ 0.0, 0.0 ]
Theron 2013 16 1 0 0 1.00 [ 0.79, 1.00 ] 0.0 [ 0.0, 0.97 ]
Tsuyuguchi 2017 180 4 9 32 0.95 [ 0.91, 0.98 ] 0.89 [ 0.74, 0.97 ]
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Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Van Rie 2013 3 0 1 2 0.75 [ 0.19, 0.99 ] 1.00 [ 0.16, 1.00 ]
Williamson 2012 67 0 0 22 1.00 [ 0.95, 1.00 ] 1.00 [ 0.85, 1.00 ]
Zeka 2011 24 0 0 0 1.00 [ 0.86, 1.00 ] 0.0 [ 0.0, 0.0 ]
Zmak 2013 3 0 0 0 1.00 [ 0.29, 1.00 ] 0.0 [ 0.0, 0.0 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 4. Smear-positive, Xpert MTB/RIF, direct comparison Xpert MTB/RIF vs Xpert Ultra.
Review: Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
Test: 4 Smear-positive, Xpert MTB/RIF, direct comparison Xpert MTB/RIF vs Xpert Ultra
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dorman 2018 319 0 4 0 0.99 [ 0.97, 1.00 ] 0.0 [ 0.0, 0.0 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 5. Smear-positive, Xpert Ultra, direct comparison Xpert MTB/RIF vs Xpert Ultra.
Review: Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
Test: 5 Smear-positive, Xpert Ultra, direct comparison Xpert MTB/RIF vs Xpert Ultra
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dorman 2018 322 0 1 0 1.00 [ 0.98, 1.00 ] 0.0 [ 0.0, 0.0 ]
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Test 6. Smear-negative, Xpert MTB/RIF.
Review: Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
Test: 6 Smear-negative, Xpert MTB/RIF
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Balcells 2012 3 1 1 145 0.75 [ 0.19, 0.99 ] 0.99 [ 0.96, 1.00 ]
Balcha 2014 54 10 40 675 0.57 [ 0.47, 0.68 ] 0.99 [ 0.97, 0.99 ]
Boehme 2010 124 5 47 604 0.73 [ 0.65, 0.79 ] 0.99 [ 0.98, 1.00 ]
Boehme 2011 296 30 89 2846 0.77 [ 0.72, 0.81 ] 0.99 [ 0.99, 0.99 ]
Carriquiry 2012 13 1 1 82 0.93 [ 0.66, 1.00 ] 0.99 [ 0.93, 1.00 ]
Chaisson 2014 0 0 1 132 0.0 [ 0.0, 0.97 ] 1.00 [ 0.97, 1.00 ]
Chen 2017 2 3 1 722 0.67 [ 0.09, 0.99 ] 1.00 [ 0.99, 1.00 ]
Chew 2016 18 1 6 197 0.75 [ 0.53, 0.90 ] 0.99 [ 0.97, 1.00 ]
Cowan 2017 2 0 2 291 0.50 [ 0.07, 0.93 ] 1.00 [ 0.99, 1.00 ]
Davis 2014 1 0 1 132 0.50 [ 0.01, 0.99 ] 1.00 [ 0.97, 1.00 ]
Dorman 2018 63 17 74 957 0.46 [ 0.37, 0.55 ] 0.98 [ 0.97, 0.99 ]
Geleta 2015 18 6 19 155 0.49 [ 0.32, 0.66 ] 0.96 [ 0.92, 0.99 ]
Hanif 2011 9 0 5 146 0.64 [ 0.35, 0.87 ] 1.00 [ 0.98, 1.00 ]
Hanrahan 2013 26 2 22 478 0.54 [ 0.39, 0.69 ] 1.00 [ 0.99, 1.00 ]
Hanrahan 2014 97 32 91 1440 0.52 [ 0.44, 0.59 ] 0.98 [ 0.97, 0.99 ]
Helb 2010 38 0 15 25 0.72 [ 0.58, 0.83 ] 1.00 [ 0.86, 1.00 ]
Huang 2015 78 31 19 154 0.80 [ 0.71, 0.88 ] 0.83 [ 0.77, 0.88 ]
Huh 2014 19 7 6 139 0.76 [ 0.55, 0.91 ] 0.95 [ 0.90, 0.98 ]
Kawkitinarong 2017 103 3 19 130 0.84 [ 0.77, 0.90 ] 0.98 [ 0.94, 1.00 ]
Ko 2016 64 12 8 132 0.89 [ 0.79, 0.95 ] 0.92 [ 0.86, 0.96 ]
Kurbatova 2013 11 17 5 104 0.69 [ 0.41, 0.89 ] 0.86 [ 0.78, 0.92 ]
Kwak 2013 68 20 25 489 0.73 [ 0.63, 0.82 ] 0.96 [ 0.94, 0.98 ]
Lawn 2011 23 2 30 320 0.43 [ 0.30, 0.58 ] 0.99 [ 0.98, 1.00 ]
Le Palud 2014 11 2 4 134 0.73 [ 0.45, 0.92 ] 0.99 [ 0.95, 1.00 ]
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Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lippincott 2014 1 1 1 479 0.50 [ 0.01, 0.99 ] 1.00 [ 0.99, 1.00 ]
Luetkemeyer 2016 46 9 38 718 0.55 [ 0.44, 0.66 ] 0.99 [ 0.98, 0.99 ]
Meawed 2016 5 1 0 3 1.00 [ 0.48, 1.00 ] 0.75 [ 0.19, 0.99 ]
Metcalfe 2015 3 8 5 52 0.38 [ 0.09, 0.76 ] 0.87 [ 0.75, 0.94 ]
Meyer 2017 207 68 183 1324 0.53 [ 0.48, 0.58 ] 0.95 [ 0.94, 0.96 ]
Mok 2016 21 2 14 112 0.60 [ 0.42, 0.76 ] 0.98 [ 0.94, 1.00 ]
Moure 2011 61 0 17 29 0.78 [ 0.67, 0.87 ] 1.00 [ 0.88, 1.00 ]
Moussa 2016 6 3 3 145 0.67 [ 0.30, 0.93 ] 0.98 [ 0.94, 1.00 ]
Ngabonziza 2016 31 5 16 498 0.66 [ 0.51, 0.79 ] 0.99 [ 0.98, 1.00 ]
Nikam 2014 43 46 15 62 0.74 [ 0.61, 0.85 ] 0.57 [ 0.48, 0.67 ]
O’Donnell 2015 21 1 7 34 0.75 [ 0.55, 0.89 ] 0.97 [ 0.85, 1.00 ]
Park 2013 4 6 1 271 0.80 [ 0.28, 0.99 ] 0.98 [ 0.95, 0.99 ]
Pimkina 2015 85 32 18 375 0.83 [ 0.74, 0.89 ] 0.92 [ 0.89, 0.95 ]
Rachow 2011 11 1 7 102 0.61 [ 0.36, 0.83 ] 0.99 [ 0.95, 1.00 ]
Reddy 2017 37 12 19 250 0.66 [ 0.52, 0.78 ] 0.95 [ 0.92, 0.98 ]
Reechaipichitkul 2017 26 4 7 54 0.79 [ 0.61, 0.91 ] 0.93 [ 0.83, 0.98 ]
Rice 2017 35 2 12 476 0.74 [ 0.60, 0.86 ] 1.00 [ 0.98, 1.00 ]
Safianowska 2012 3 0 2 120 0.60 [ 0.15, 0.95 ] 1.00 [ 0.97, 1.00 ]
Sah 2017 10 3 1 60 0.91 [ 0.59, 1.00 ] 0.95 [ 0.87, 0.99 ]
Scott 2011 11 3 7 107 0.61 [ 0.36, 0.83 ] 0.97 [ 0.92, 0.99 ]
Shao 2017 24 30 1 147 0.96 [ 0.80, 1.00 ] 0.83 [ 0.77, 0.88 ]
Sharma 2015 56 6 16 984 0.78 [ 0.66, 0.87 ] 0.99 [ 0.99, 1.00 ]
Shenai 2016 15 5 7 234 0.68 [ 0.45, 0.86 ] 0.98 [ 0.95, 0.99 ]
Sohn 2014 5 1 13 406 0.28 [ 0.10, 0.53 ] 1.00 [ 0.99, 1.00 ]
Tadesse 2016 12 2 7 164 0.63 [ 0.38, 0.84 ] 0.99 [ 0.96, 1.00 ]
Theron 2011 22 19 25 320 0.47 [ 0.32, 0.62 ] 0.94 [ 0.91, 0.97 ]
Theron 2013 9 4 2 120 0.82 [ 0.48, 0.98 ] 0.97 [ 0.92, 0.99 ]
Tsuyuguchi 2017 17 2 21 148 0.45 [ 0.29, 0.62 ] 0.99 [ 0.95, 1.00 ]
Van Rie 2013 7 1 4 142 0.64 [ 0.31, 0.89 ] 0.99 [ 0.96, 1.00 ]
Walusimbi 2013a 21 16 22 310 0.49 [ 0.33, 0.65 ] 0.95 [ 0.92, 0.97 ]
Zeka 2011 7 0 4 68 0.64 [ 0.31, 0.89 ] 1.00 [ 0.95, 1.00 ]
Zmak 2013 3 0 1 110 0.75 [ 0.19, 0.99 ] 1.00 [ 0.97, 1.00 ]
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Test 7. Smear-negative, Xpert MTB/RIF, direct comparison Xpert MTB/RIF vs Xpert Ultra.
Review: Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
Test: 7 Smear-negative, Xpert MTB/RIF, direct comparison Xpert MTB/RIF vs Xpert Ultra
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dorman 2018 63 17 74 957 0.46 [ 0.37, 0.55 ] 0.98 [ 0.97, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 8. Smear-negative, Xpert Ultra, direct comparison Xpert MTB/RIF vs Xpert Ultra.
Review: Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
Test: 8 Smear-negative, Xpert Ultra, direct comparison Xpert MTB/RIF vs Xpert Ultra
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dorman 2018 86 43 51 931 0.63 [ 0.54, 0.71 ] 0.96 [ 0.94, 0.97 ]
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Test 9. HIV-negative, Xpert MTB/RIF.
Review: Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
Test: 9 HIV-negative, Xpert MTB/RIF
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bates 2013a 3 0 0 19 1.00 [ 0.29, 1.00 ] 1.00 [ 0.82, 1.00 ]
Boehme 2010 335 1 26 173 0.93 [ 0.90, 0.95 ] 0.99 [ 0.97, 1.00 ]
Boehme 2011 304 5 31 748 0.91 [ 0.87, 0.94 ] 0.99 [ 0.98, 1.00 ]
Boum 2016 72 7 5 190 0.94 [ 0.85, 0.98 ] 0.96 [ 0.93, 0.99 ]
Calligaro 2015 5 4 0 39 1.00 [ 0.48, 1.00 ] 0.91 [ 0.78, 0.97 ]
Calligaro 2017 10 2 3 138 0.77 [ 0.46, 0.95 ] 0.99 [ 0.95, 1.00 ]
Dorman 2018 143 9 16 315 0.90 [ 0.84, 0.94 ] 0.97 [ 0.95, 0.99 ]
Hanrahan 2013 5 0 4 182 0.56 [ 0.21, 0.86 ] 1.00 [ 0.98, 1.00 ]
Hanrahan 2014 120 13 29 689 0.81 [ 0.73, 0.87 ] 0.98 [ 0.97, 0.99 ]
Luetkemeyer 2016 111 4 17 396 0.87 [ 0.80, 0.92 ] 0.99 [ 0.97, 1.00 ]
Moussa 2016 67 3 3 145 0.96 [ 0.88, 0.99 ] 0.98 [ 0.94, 1.00 ]
Pinyopornpanish 2015 28 2 2 41 0.93 [ 0.78, 0.99 ] 0.95 [ 0.84, 0.99 ]
Rachow 2011 17 0 2 53 0.89 [ 0.67, 0.99 ] 1.00 [ 0.93, 1.00 ]
Safianowska 2012 15 1 2 127 0.88 [ 0.64, 0.99 ] 0.99 [ 0.96, 1.00 ]
Scott 2011 12 0 2 17 0.86 [ 0.57, 0.98 ] 1.00 [ 0.80, 1.00 ]
Theron 2011 68 9 14 195 0.83 [ 0.73, 0.90 ] 0.96 [ 0.92, 0.98 ]
Theron 2013 12 3 0 69 1.00 [ 0.74, 1.00 ] 0.96 [ 0.88, 0.99 ]
Van Rie 2013 2 0 1 33 0.67 [ 0.09, 0.99 ] 1.00 [ 0.89, 1.00 ]
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Test 10. HIV-positive, Xpert MTB/RIF.
Review: Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
Test: 10 HIV-positive, Xpert MTB/RIF
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Adelman 2015 3 2 3 204 0.50 [ 0.12, 0.88 ] 0.99 [ 0.97, 1.00 ]
Al-Darraji 2013 8 0 7 110 0.53 [ 0.27, 0.79 ] 1.00 [ 0.97, 1.00 ]
Balcells 2012 11 1 1 147 0.92 [ 0.62, 1.00 ] 0.99 [ 0.96, 1.00 ]
Balcha 2014 81 13 41 677 0.66 [ 0.57, 0.75 ] 0.98 [ 0.97, 0.99 ]
Bates 2013a 17 2 4 39 0.81 [ 0.58, 0.95 ] 0.95 [ 0.83, 0.99 ]
Bjerrum 2016 27 5 8 155 0.77 [ 0.60, 0.90 ] 0.97 [ 0.93, 0.99 ]
Boehme 2010 97 2 14 225 0.87 [ 0.80, 0.93 ] 0.99 [ 0.97, 1.00 ]
Boehme 2011 173 3 37 382 0.82 [ 0.77, 0.87 ] 0.99 [ 0.98, 1.00 ]
Boum 2016 122 15 12 464 0.91 [ 0.85, 0.95 ] 0.97 [ 0.95, 0.98 ]
Calligaro 2015 3 0 0 22 1.00 [ 0.29, 1.00 ] 1.00 [ 0.85, 1.00 ]
Calligaro 2017 25 11 4 204 0.86 [ 0.68, 0.96 ] 0.95 [ 0.91, 0.97 ]
Carriquiry 2012 44 2 1 84 0.98 [ 0.88, 1.00 ] 0.98 [ 0.92, 1.00 ]
Dorman 2018 88 2 27 315 0.77 [ 0.68, 0.84 ] 0.99 [ 0.98, 1.00 ]
Hanrahan 2013 36 2 16 325 0.69 [ 0.55, 0.81 ] 0.99 [ 0.98, 1.00 ]
Hanrahan 2014 169 23 74 887 0.70 [ 0.63, 0.75 ] 0.97 [ 0.96, 0.98 ]
Henostroza 2016 39 5 23 266 0.63 [ 0.50, 0.75 ] 0.98 [ 0.96, 0.99 ]
LaCourse 2016 3 1 4 280 0.43 [ 0.10, 0.82 ] 1.00 [ 0.98, 1.00 ]
Lawn 2011 42 2 30 320 0.58 [ 0.46, 0.70 ] 0.99 [ 0.98, 1.00 ]
Luetkemeyer 2016 64 6 23 339 0.74 [ 0.63, 0.82 ] 0.98 [ 0.96, 0.99 ]
Mollel 2017 9 0 0 60 1.00 [ 0.66, 1.00 ] 1.00 [ 0.94, 1.00 ]
O’Donnell 2015 49 1 4 26 0.92 [ 0.82, 0.98 ] 0.96 [ 0.81, 1.00 ]
Pinyopornpanish 2015 10 0 0 16 1.00 [ 0.69, 1.00 ] 1.00 [ 0.79, 1.00 ]
Rachow 2011 41 1 9 49 0.82 [ 0.69, 0.91 ] 0.98 [ 0.89, 1.00 ]
Scott 2011 45 3 7 84 0.87 [ 0.74, 0.94 ] 0.97 [ 0.90, 0.99 ]
Ssengooba 2014 94 10 29 291 0.76 [ 0.68, 0.84 ] 0.97 [ 0.94, 0.98 ]
Theron 2011 32 7 14 77 0.70 [ 0.54, 0.82 ] 0.92 [ 0.84, 0.97 ]
Theron 2013 6 2 2 34 0.75 [ 0.35, 0.97 ] 0.94 [ 0.81, 0.99 ]
Van Rie 2013 8 1 4 99 0.67 [ 0.35, 0.90 ] 0.99 [ 0.95, 1.00 ]
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Walusimbi 2013a 21 16 22 310 0.49 [ 0.33, 0.65 ] 0.95 [ 0.92, 0.97 ]
Yoon 2017 84 8 79 1006 0.52 [ 0.44, 0.59 ] 0.99 [ 0.98, 1.00 ]
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Test 11. HIV-negative, within study comparisons.
Review: Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
Test: 11 HIV-negative, within study comparisons
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bates 2013a 3 0 0 19 1.00 [ 0.29, 1.00 ] 1.00 [ 0.82, 1.00 ]
Boehme 2010 335 1 26 173 0.93 [ 0.90, 0.95 ] 0.99 [ 0.97, 1.00 ]
Boehme 2011 304 5 31 748 0.91 [ 0.87, 0.94 ] 0.99 [ 0.98, 1.00 ]
Boum 2016 72 7 5 190 0.94 [ 0.85, 0.98 ] 0.96 [ 0.93, 0.99 ]
Calligaro 2015 5 4 0 39 1.00 [ 0.48, 1.00 ] 0.91 [ 0.78, 0.97 ]
Calligaro 2017 10 2 3 138 0.77 [ 0.46, 0.95 ] 0.99 [ 0.95, 1.00 ]
Dorman 2018 143 9 16 315 0.90 [ 0.84, 0.94 ] 0.97 [ 0.95, 0.99 ]
Hanrahan 2013 5 0 4 182 0.56 [ 0.21, 0.86 ] 1.00 [ 0.98, 1.00 ]
Hanrahan 2014 120 13 29 689 0.81 [ 0.73, 0.87 ] 0.98 [ 0.97, 0.99 ]
Luetkemeyer 2016 111 4 17 396 0.87 [ 0.80, 0.92 ] 0.99 [ 0.97, 1.00 ]
Pinyopornpanish 2015 67 3 3 145 0.96 [ 0.88, 0.99 ] 0.98 [ 0.94, 1.00 ]
Rachow 2011 28 2 2 41 0.93 [ 0.78, 0.99 ] 0.95 [ 0.84, 0.99 ]
Scott 2011 17 0 2 53 0.89 [ 0.67, 0.99 ] 1.00 [ 0.93, 1.00 ]
Theron 2011 15 1 2 127 0.88 [ 0.64, 0.99 ] 0.99 [ 0.96, 1.00 ]
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Test 12. HIV-positive, within study comparisons.
Review: Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
Test: 12 HIV-positive, within study comparisons
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bates 2013a 17 2 4 39 0.81 [ 0.58, 0.95 ] 0.95 [ 0.83, 0.99 ]
Boehme 2010 92 2 14 225 0.87 [ 0.79, 0.93 ] 0.99 [ 0.97, 1.00 ]
Boehme 2011 173 3 37 382 0.82 [ 0.77, 0.87 ] 0.99 [ 0.98, 1.00 ]
Boum 2016 122 15 12 464 0.91 [ 0.85, 0.95 ] 0.97 [ 0.95, 0.98 ]
Calligaro 2015 3 0 0 22 1.00 [ 0.29, 1.00 ] 1.00 [ 0.85, 1.00 ]
Calligaro 2017 25 11 4 204 0.86 [ 0.68, 0.96 ] 0.95 [ 0.91, 0.97 ]
Dorman 2018 88 2 27 315 0.77 [ 0.68, 0.84 ] 0.99 [ 0.98, 1.00 ]
Hanrahan 2013 36 2 16 325 0.69 [ 0.55, 0.81 ] 0.99 [ 0.98, 1.00 ]
Hanrahan 2014 169 23 74 887 0.70 [ 0.63, 0.75 ] 0.97 [ 0.96, 0.98 ]
Luetkemeyer 2016 64 6 23 339 0.74 [ 0.63, 0.82 ] 0.98 [ 0.96, 0.99 ]
Pinyopornpanish 2015 10 0 0 16 1.00 [ 0.69, 1.00 ] 1.00 [ 0.79, 1.00 ]
Rachow 2011 41 1 9 49 0.82 [ 0.69, 0.91 ] 0.98 [ 0.89, 1.00 ]
Scott 2011 45 3 7 84 0.87 [ 0.74, 0.94 ] 0.97 [ 0.90, 0.99 ]
Theron 2011 32 7 14 77 0.70 [ 0.54, 0.82 ] 0.92 [ 0.84, 0.97 ]
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Test 13. HIV-negative, Xpert MTB/RIF, direct comparison Xpert MTB/RIF vs Xpert Ultra.
Review: Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
Test: 13 HIV-negative, Xpert MTB/RIF, direct comparison Xpert MTB/RIF vs Xpert Ultra
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dorman 2018 143 9 16 315 0.90 [ 0.84, 0.94 ] 0.97 [ 0.95, 0.99 ]
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Test 14. HIV-negative, Xpert Ultra, direct comparison Xpert MTB/RIF vs Xpert Ultra.
Review: Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
Test: 14 HIV-negative, Xpert Ultra, direct comparison Xpert MTB/RIF vs Xpert Ultra
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dorman 2018 145 17 14 307 0.91 [ 0.86, 0.95 ] 0.95 [ 0.92, 0.97 ]
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Test 15. HIV-positive, Xpert MTB/RIF, direct comparison Xpert MTB/RIF vs Xpert Ultra.
Review: Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
Test: 15 HIV-positive, Xpert MTB/RIF, direct comparison Xpert MTB/RIF vs Xpert Ultra
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dorman 2018 88 2 27 315 0.77 [ 0.68, 0.84 ] 0.99 [ 0.98, 1.00 ]
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Test 16. HIV-positive, Xpert Ultra, direct comparison Xpert MTB/RIF vs Xpert Ultra.
Review: Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
Test: 16 HIV-positive, Xpert Ultra, direct comparison Xpert MTB/RIF vs Xpert Ultra
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dorman 2018 103 14 12 303 0.90 [ 0.82, 0.94 ] 0.96 [ 0.93, 0.98 ]
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Test 17. Xpert MTB/RIF for detection of rifampicin resistance.
Review: Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
Test: 17 Xpert MTB/RIF for detection of rifampicin resistance
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Al-Darraji 2013 0 0 0 8 0.0 [ 0.0, 0.0 ] 1.00 [ 0.63, 1.00 ]
Ali 2017 46 0 0 80 1.00 [ 0.92, 1.00 ] 1.00 [ 0.95, 1.00 ]
Balcells 2012 2 0 0 10 1.00 [ 0.16, 1.00 ] 1.00 [ 0.69, 1.00 ]
Barmankulova 2015 91 8 3 89 0.97 [ 0.91, 0.99 ] 0.92 [ 0.84, 0.96 ]
Barnard 2015 0 0 0 36 0.0 [ 0.0, 0.0 ] 1.00 [ 0.90, 1.00 ]
Bates 2013a 0 0 1 20 0.0 [ 0.0, 0.97 ] 1.00 [ 0.83, 1.00 ]
Boehme 2010 200 10 5 505 0.98 [ 0.94, 0.99 ] 0.98 [ 0.96, 0.99 ]
Boehme 2011 236 14 14 796 0.94 [ 0.91, 0.97 ] 0.98 [ 0.97, 0.99 ]
Calligaro 2015 1 0 0 10 1.00 [ 0.03, 1.00 ] 1.00 [ 0.69, 1.00 ]
Carriquiry 2012 6 3 0 30 1.00 [ 0.54, 1.00 ] 0.91 [ 0.76, 0.98 ]
Chikaonda 2017 2 1 0 185 1.00 [ 0.16, 1.00 ] 0.99 [ 0.97, 1.00 ]
Dorman 2018 167 7 8 369 0.95 [ 0.91, 0.98 ] 0.98 [ 0.96, 0.99 ]
Friedrich 2011 3 0 0 90 1.00 [ 0.29, 1.00 ] 1.00 [ 0.96, 1.00 ]
Hanif 2011 0 0 0 54 0.0 [ 0.0, 0.0 ] 1.00 [ 0.93, 1.00 ]
Huang 2015 128 1 6 20 0.96 [ 0.91, 0.98 ] 0.95 [ 0.76, 1.00 ]
Huh 2014 6 1 1 90 0.86 [ 0.42, 1.00 ] 0.99 [ 0.94, 1.00 ]
Kawkitinarong 2017 12 2 4 210 0.75 [ 0.48, 0.93 ] 0.99 [ 0.97, 1.00 ]
Kim CH 2015 4 1 0 31 1.00 [ 0.40, 1.00 ] 0.97 [ 0.84, 1.00 ]
Kurbaniyazova 2017 228 49 25 476 0.90 [ 0.86, 0.94 ] 0.91 [ 0.88, 0.93 ]
Kurbatova 2013 55 2 1 42 0.98 [ 0.90, 1.00 ] 0.95 [ 0.85, 0.99 ]
Kwak 2013 8 0 1 90 0.89 [ 0.52, 1.00 ] 1.00 [ 0.96, 1.00 ]
Lawn 2011 4 3 0 48 1.00 [ 0.40, 1.00 ] 0.94 [ 0.84, 0.99 ]
Le Palud 2014 1 0 0 15 1.00 [ 0.03, 1.00 ] 1.00 [ 0.78, 1.00 ]
Lee 2013 2 0 0 29 1.00 [ 0.16, 1.00 ] 1.00 [ 0.88, 1.00 ]
Lippincott 2014 1 0 0 5 1.00 [ 0.03, 1.00 ] 1.00 [ 0.48, 1.00 ]
Liu 2017 15 0 1 383 0.94 [ 0.70, 1.00 ] 1.00 [ 0.99, 1.00 ]
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Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lorent 2015 24 6 3 69 0.89 [ 0.71, 0.98 ] 0.92 [ 0.83, 0.97 ]
Luetkemeyer 2016 5 1 0 154 1.00 [ 0.48, 1.00 ] 0.99 [ 0.96, 1.00 ]
Makamure 2017 25 5 0 34 1.00 [ 0.86, 1.00 ] 0.87 [ 0.73, 0.96 ]
Meawed 2016 37 0 0 16 1.00 [ 0.91, 1.00 ] 1.00 [ 0.79, 1.00 ]
Metcalfe 2016 54 2 0 90 1.00 [ 0.93, 1.00 ] 0.98 [ 0.92, 1.00 ]
Mokaddas 2015 7 1 0 279 1.00 [ 0.59, 1.00 ] 1.00 [ 0.98, 1.00 ]
Moussa 2016 0 0 0 67 0.0 [ 0.0, 0.0 ] 1.00 [ 0.95, 1.00 ]
N’Guessan 2016 23 1 0 39 1.00 [ 0.85, 1.00 ] 0.98 [ 0.87, 1.00 ]
Nosova 2013a 13 0 0 33 1.00 [ 0.75, 1.00 ] 1.00 [ 0.89, 1.00 ]
O’Donnell 2015 20 4 4 84 0.83 [ 0.63, 0.95 ] 0.95 [ 0.89, 0.99 ]
Park 2013 2 1 0 16 1.00 [ 0.16, 1.00 ] 0.94 [ 0.71, 1.00 ]
Pimkina 2015 39 4 0 221 1.00 [ 0.91, 1.00 ] 0.98 [ 0.96, 1.00 ]
Rachow 2011 0 0 0 59 0.0 [ 0.0, 0.0 ] 1.00 [ 0.94, 1.00 ]
Rice 2017 2 2 0 116 1.00 [ 0.16, 1.00 ] 0.98 [ 0.94, 1.00 ]
Safianowska 2012 0 0 0 15 0.0 [ 0.0, 0.0 ] 1.00 [ 0.78, 1.00 ]
Sah 2017 3 0 0 29 1.00 [ 0.29, 1.00 ] 1.00 [ 0.88, 1.00 ]
Scott 2011 4 2 1 10 0.80 [ 0.28, 0.99 ] 0.83 [ 0.52, 0.98 ]
Sharma 2015 104 7 6 305 0.95 [ 0.89, 0.98 ] 0.98 [ 0.95, 0.99 ]
Singh 2016 14 0 2 56 0.88 [ 0.62, 0.98 ] 1.00 [ 0.94, 1.00 ]
Sohn 2014 1 1 0 9 1.00 [ 0.03, 1.00 ] 0.90 [ 0.55, 1.00 ]
Ssengooba 2014 4 0 0 90 1.00 [ 0.40, 1.00 ] 1.00 [ 0.96, 1.00 ]
Tadesse 2016 0 0 0 12 0.0 [ 0.0, 0.0 ] 1.00 [ 0.74, 1.00 ]
Tang 2017 4 1 0 63 1.00 [ 0.40, 1.00 ] 0.98 [ 0.92, 1.00 ]
Theron 2011 5 1 0 151 1.00 [ 0.48, 1.00 ] 0.99 [ 0.96, 1.00 ]
Theron 2013 1 0 0 24 1.00 [ 0.03, 1.00 ] 1.00 [ 0.86, 1.00 ]
Tsuyuguchi 2017 22 3 0 176 1.00 [ 0.85, 1.00 ] 0.98 [ 0.95, 1.00 ]
Van Rie 2013 0 1 0 9 0.0 [ 0.0, 0.0 ] 0.90 [ 0.55, 1.00 ]
Williamson 2012 2 1 0 64 1.00 [ 0.16, 1.00 ] 0.98 [ 0.92, 1.00 ]
Zeka 2011 1 0 0 34 1.00 [ 0.03, 1.00 ] 1.00 [ 0.90, 1.00 ]
Zetola 2014 51 1 4 314 0.93 [ 0.82, 0.98 ] 1.00 [ 0.98, 1.00 ]
Zmak 2013 0 0 0 6 0.0 [ 0.0, 0.0 ] 1.00 [ 0.54, 1.00 ]
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Test 18. Xpert Ultra for detection of rifampicin resistance.
Review: Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
Test: 18 Xpert Ultra for detection of rifampicin resistance
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dorman 2018 166 6 9 370 0.95 [ 0.90, 0.98 ] 0.98 [ 0.97, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Xpert MTB/RIF for detection of pulmonary tuberculosis and rifampicin resistance
Type of analysis (num-
ber of studies; partici-
pants)
Median
pooledsensitivity
(95% CrI)
Median
pooledspecificity
(95% CrI)
Median predicted sen-
sitivity
(95% CrI)
Median predicted
specificity
(95% CrI)
Xpert MTB/RIF sensi-
tivity and specificity for
detection of PTB, all
studiesa (85; 41,965)
85% (82 to 87) 98% (97 to 98) 85% (52 to 97) 98% (76 to 100)
Xpert MTB/RIF sensi-
tivity and specificity for
detection of PTB, stud-
ies with unselected par-
ticipants (70; 37,237)
85% (82 to 88) 98% (97 to 98) 85% (56 to 96) 98% (78 to 100)
Xpert MTB/RIF sensi-
tivity and specificity for
detection of rifampicin
resistance (48; 8020)
96% (94 to 97) 98% (98 to 99) 96% (86 to 99) 98% (89 to 100)
Abbreviations: CrI: credible interval; PTB: pulmonary tuberculosis.
aThis analysis included all studies, including those studies that preselected participants based on microcopy results and mainly involved
participants who had received previous tuberculosis treatment.
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Table 2. Xpert MTB/RIF for detection of pulmonary tuberculosis, investigations of heterogeneity
Type of analysis (num-
ber of studies; partici-
pants)
Median pooled sensi-
tivity
(95% CrI)
Median pooled speci-
ficity
(95% CrI)
Median predicted sen-
sitivity
(95% CrI)
Median predicted
specificity
(95% CrI)
Xpert MTB/RIF accuracy for tuberculosis detection in clinical subgroups
Smear positive (45;
4064)a
98% (97 to 98) Could not determine 98% (89 to 100) Could not determine
Smear negative (45; 18,
962)a
67% (62 to 72) 98% (98 to 99) 67% (37 to 88) 98% (80 to 100)
HIV negative (14; 3866)
a
88% (83 to 92) 98% (97 to 99) 88% (71 to 96) 98% (92 to 100)
HIV positive (14; 4664)
a
81% (75 to 86) 98% (97 to 99) 81% (59 to 93) 98% (92 to 100)
XpertMTB/RIF accuracy for tuberculosis detection based on percentage of participants with a history of previous tuberculosis
Previous tuberculosis >
25% (11; 4196)
82% (74 to 88) 96% (93 to 98) 82% (48 to 96) 96% (78 to 99)
Previous tuberculosis ≤
25% (16; 8205)
81% (72 to 87) 98% (97 to 99) 81% (39 to 97) 98% (90 to 100)
Xpert MTB/RIF accuracy for tuberculosis detection by tuberculosis burdena
High tuberculosis bur-
den = Yes (39; 21,965)b
86% (82 to 89) 97% (95 to 98) 86% (57 to 96) 97% (71 to 100)
High tuberculosis bur-
den = No (33; 15,272)b
85% (81 to 89) 99% (98 to 99) 85% (55 to 96) 99% (89 to 100)
Xpert MTB/RIF accuracy for tuberculosis detection by TB/HIV burdena
High TB/HIV burden =
Yes (42; 24,412)b
83% (80 to 87) 97% (95 to 98) 84% (51 to 96) 97% (74 to 100)
High TB/HIV burden =
No (30; 12,825)b
88% (84 to 90) 99% (98 to 99) 88% (67 to 96) 99% (86 to 100)
Xpert MTB/RIF accuracy for tuberculosis detection by setting that ran the test
Xpert run at point of care
or in a peripheral setting
(10; 5816)
83% (75 to 89) 97% (93 to 99) 83% (52 to 96) 97% (66 to 100)
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Table 2. Xpert MTB/RIF for detection of pulmonary tuberculosis, investigations of heterogeneity (Continued)
Central or intermediate
laboratory (60; 31,421)
85% (83 to 88) 98% (97 to 98) 85% (57 to 96) 98% (80 to 100)
Xpert MTB/RIF accuracy for tuberculosis detection by median tuberculosis prevalence
Prevalence > 26% (35;
17,983)
89% (87 to 91) 96% (94 to 97) 89% (69 to 97) 96% (72 to 100)
Prevalence ≤ 26% (35;
19,254)
79% (75 to 83) 99% (98 to 99) 79% (51 to 93) 99% (89 to 100)
Abbreviations: CrI: credible interval; HIV: human immunodeficiency virus; TB: tuberculosis.
aAccuracy estimates were determined in studies providing data for both subgroups.
bSubstudies from Boehme 2010 and Boehme 2011 contributed to both tuberculosis burden categories.
Table 3. Xpert MTB/RIF for detection of rifampicin resistance, investigations of heterogeneity
Type of analysis (Num-
ber of studies; partici-
pants)
Median pooled sensi-
tivity
(95% CrI)
Median pooled speci-
ficity
(95% CrI)
Median predicted sen-
sitivity
(95% CrI)
Median predicted
specificity
(95% CrI)
Xpert MTB/RIF accuracy for rifampicin resistance detection by MDR-TB burden
High MDR-TB burden
= Yes (24; 5553)
95% (93 to 97) 98% (96 to 99) 95% (85 to 99) 98% (85 to 100)
High MDR-TB burden
= No (25; 2467)
97% (93 to 99) 99% (98 to 99) 97% (76 to 100) 99% (95 to 100)
Xpert MTB/RIF accuracy for rifampicin resistance detection by history of previous tuberculosis treatment
Previously-treated tuber-
culosisa = Yes (7; 1062)
98% (94 to 99) 97% (93 to 99) 98% (87 to 100) 97% (81 to 100)
Previously-treated tuber-
culosis = No (41, 6958)
95% (93 to 97) 99% (98 to 99) 95% (86 to 99) 98% (91 to 100)
Xpert MTB/RIF accuracy for detection of rifampicin resistance by median tuberculosis prevalence
Prevalence > 11% (24;
5505)
96% (94 to 97) 97% (96 to 98) 96% (87 to 99) 97% (88 to 99)
Prevalence ≤ 11% (24;
2515)
94% (89 to 97) 99% (99 to 100) 94% (80 to 99) 99% (96 to 100)
Abbreviations: CrI: credible interval; MDR-TB: multidrug-resistant tuberculosis.
aStudies with high percentages of participants previously treated for tuberculosis.
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Table 4. Sensitivity analyses, Xpert MTB/RIF
Type of analysis (Num-
ber of studies; partici-
pants)
Median pooled sensi-
tivity (95% Crl)
Median pooled speci-
ficity (95% Crl)
Median predicted sen-
sitivity (95% Crl)
Median predicted
specificity (95% Crl)
Xpert MTB/RIF sensi-
tivity and specificity for
tuberculosis detection in
studies with unselected
patients (70; 37,237)
85% (82 to 88) 98% (97 to 98) 85% (56 to 96) 98% (78 to 100)
Studies that explicitly
represented the use of the
index test for the diag-
nosis of individuals with
signs and symptoms of
tuberculosis (presump-
tive tuberculosis) (62;
33,844)
86% (84 to 89) 98% (97 to 98) 86% (54 to 97) 98% (78 to 100)
Studies where a single
specimen yielded a sin-
gle Xpert MTB/RIF re-
sult for a given partici-
pant (53; 27,306)
85% (81 to 87) 98% (97 to 98) 85% (50 to 97) 97% (80 to 100)
Studies that included
only untreated partici-
pants (36; 15,502)
82% (79 to 86) 98% (98 to 99) 83% (52 to 96) 98% (90 to 100)
Studies that used liquid
culture as the reference
standard (24; 12,548)
83% (78 to 88) 97% (95 to 98) 83% (48 to 97) 97% (65 to 100)
Studies where consecu-
tive or random partici-
pants were selected (52;
28,633)
84% (80 to 87) 98% (97 to 98) 84% (50 to 96) 98% (78 to 100)
Studies where the refer-
ence standard was
blinded (56; 31,228)
84% (81 to 87) 97% (96 to 98) 85% (50 to 97) 97% (77 to 100)
Studies using fresh spec-
imens (56; 29,090)
86% (83 to 88) 98% (97 to 98) 86% (50 to 97) 98% (75 to 100)
Studies that accounted
for all participants in the
analysis (59; 27,128)
85% (82 to 88) 98% (97 to 98) 85% (49 to 97) 98% (76 to 100)
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Table 4. Sensitivity analyses, Xpert MTB/RIF (Continued)
Excluding Boehme 2010
and Boehme 2011 (68;
31889)
85% (82 to 87) 98% (97 to 98) 85% (55 to 96) 98% (77 to 100)
Abbreviations: Crl: credible interval.
Table 5. Systematic reviews on the diagnostic accuracy of XpertMTB/RIF for pulmonary tuberculosis and rifampicin resistance
Author, year Date
searched up
to
No.
studies (par-
ticipants)
PTB, summary estimates
(95% CI)
No. studies Rifampicin resistance, sum-
mary estimates (95% CrI)
Sensitivity Specificity Sensitivity Specificity
Chang 2012 October
2011
15 (8117) 90% (89 to
91)
98% (98 to
99)
7 see note see note
Walusimbi
2013b
(smear-
negative)
May
2012
15 (2046) 67% (62 to
71)
98% (97 to
99)
NA NA NA
Steingart
2014
December
2013
27 (6026) 89% (85 to
92)
99% (98 to
99)
sensitivity: 17
specificity: 24
95% (90 to
97)
98% (97 to
99)
Yan 2016 not reported 12 (8122) 89% (87 to
90)
98% (98 to
99)
NA NA NA
Li 2017 June
2015
24 (2486) 87% (83 to
90)
97% (96 to
98)
NA NA NA
Alvis-Zakzuk
2017
December
2015
NA NA NA 8 see note see note
Horne 2019 January
2018
85 (41,965) 85% (82 to
87)
98% (97 to
98)
48 (8020) 96% (94 to
97)
98% (98 to
99)
Abbreviations: CI: confidence interval; Crl: credible interval; NA: not applicable; PTB: pulmonary tuberculosis.
Chang 2012 included adults and children; Xpert for detection of rifampicin resistance, sensitivity range 17% to 100%, specificity range
72% to 100%.
Walusimbi 2013b only included smear-negative participants.
Steingart 2014 is the previous Cochrane Review.
Yan 2016 only included studies that provided data by smear and HIV status.
Li 2017 106 studies (52,410 specimens) for both PTB and extrapulmonary tuberculosis.
Alvis-Zakzuk 2017 2017 summarized accuracy of Xpert for detection of rifampicin resistance, sensitivity range 33% to 100%; specificity
range 91% to 100%.
Horne 2019 is this updated Cochrane Review.
Systematic reviews not included in this table:
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Kaur 2016 did not provide summary sensitivity and specificity estimates.
Lange 2017 provided sensitivity and specificity with respect to Xpert cycle threshold (Ct) values.
Maynard-Smith 2014 provided accuracy estimates for PTB on gastric aspirates and stool.
Wang 2015 only included children.
A P P E N D I C E S
Appendix 1. Search strategy
MEDLINE (OVID) and Embase (OVID)
1. (tuberculosis or TB).tw
limit 1 to yr=“2007 -Current”
2. Mycobacterium tuberculosis/
limit 2 to yr=“2007 -Current”
3. Tuberculosis, Multidrug-Resistant/ or Tuberculosis/ or Tuberculosis, Pulmonary/
limit 3 to yr=“2007 -Current”
4. 1 or 2 or 3
5. (Xpert or GeneXpert or cepheid or( near* patient)). tw.
limit 4 to yr=“2007 -Current”
4 and 5
Web of Knowledge (SCI-expanded, SSCI, Conference Proceedings science, BIOSIS previews)
(tuberculosis OR TB OR mycobacterium) (topic) AND (Xpert OR Genexpert OR cepheid) (topic)
LILACS
(tuberculosis OR TB OR mycobacterium) (Words) AND (xpert OR Genexpert OR Cepheid) (Words)
SCOPUS
(tuberculosisORTBORmycobacterium) (title, abstract, keywords) AND(xpertORGenexpertORCepheid) (title, abstract, keywords)
Appendix 2. Boehme 2010 and Boehme 2011, multicentre studies
A. Boehme 2010 and Boehme 2011, multicentre studies, Xpert MTB/RIF for detection of pulmonary tuberculosis
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Study Site True positive False positive False negative True negative
Boehme 2010a Azerbaijan 123 8 24 91
Boehme 2010b Peru 201 1 8 105
Boehme 2010c South Africa, Cape
Town
136 9 10 188
Boehme 2010d South Africa, Dur-
ban
36 7 7 257
Boehme 2010e India 179 1 8 40
Boehme 2011a Azerbaijan 203 4 26 303
Boehme 2011a,b Peru 171 3 6 825
Boehme 2011c South Africa 201 2 32 669
Boehme 2011d Uganda 121 0 24 144
Boehme 2011e India 101 16 0 671
Boehme 2011f The Philippines 136 5 12 234
B. Boehme 2010 and Boehme 2011, multicentre studies, Xpert MTB/RIF for detection of rifampicin resistance
Study Site True positive False positive False negative True negative
Boehme 2010a Azerbaijan 47 4 2 90
Boehme 2010b Peru 16 3 0 190
Boehme 2010c South Africa, Cape
Town
15 0 1 126
Boehme 2010d South Africa, Dur-
ban
3 0 0 38
Boehme 2010e India 119 3 2 61
Boehme 2011a Azerbaijan 47 1 3 160
Boehme 2011b Peru 22 1 1 161
Boehme 2011c South Africa 9 3 1 175
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(Continued)
Boehme 2011d Uganda 1 1 2 112
Boehme 2011e India 8 2 2 91
Boehme 2011f The Philippines 149 6 5 97
Footnotes: In the 2014 Cochrane Review, for multicentre studies, the study-naming scheme uniquely identified multiple study centres
from within each study (for example, Boehme 2010a; Boehme 2010b), each of which reported data separately for a distinct population
at a given study site.
Appendix 3. Data extraction form
I. ID
ID substudy (for study centres: a, b, c, etc)
First author
Corresponding author & email
Was author contacted? 1 - Yes
2 - No
If yes, dates(s)
Title
Year (of publication)
Year (study start date)
Language 1 - English
2 - Other
If other, specify:
II. Study details
Country where study was conducted
Country World Bank Classification 1 - Low income
2 - Middle income
3 - High income
4 - Low and high income
5 - Low and middle income
6 - Low, middle, and high
7 - Other combination, describe
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(Continued)
Purpose of testing as described in the study 1 - Diagnosis
2 - Screening in HIV-positive people
9 - Could not tell
Study states:
Objective of study 1 - Detection of PTB only
2 - Detection of rifampicin resistance only
3 - Both, detection of PTB and rifampicin resistance
Study design 1 - Randomized controlled trial
2 - Cross-sectional
3 - Cohort
4 - Other, specify
9 - Could not tell
If other, describe:
IIa. Questions about pre-selection during enrolment
Were patients pre-selected based upon microscopy results? 1 - Yes
2 - No
9 - Unknown/NR
If yes, what was the basis for pre-selection? 1- Primarily or exclusively smear positive
2 - Primarily or exclusively smear negative
8 - Not applicable
Did study include exclusively retreatment patients
upon enrolment? (for example, patients who previously received
first-line drugs and those with nonconverting
pulmonary tuberculosis who were receiving therapy)
1 - Yes
2 - No
9 - Unknown/NR
Participant selection 1 - Consecutive
2 - Random
3 - Convenience
7 - Other
9 - Unknown/NR
Direction of study data collection 1 - Prospective
2 - Retrospective
9 - Unknown/NR
Number included after recruitment by inclusion and exclusion
criteria 9 - Unknown/NR
Number included in analysis (# recruited - # withdrawals)
9 - Unknown/NR
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(Continued)
Unit of analysis 1 - Patient (with a single Xpert per patient)
2 - Specimen (there are more specimens than patients)
9 - Unknown/NR
Describe as in paper, if unclear:
Comments about study design
III. Patient characteristics and setting
Presenting signs and symptoms
Did the study avoid inappropriate exclusions? Please list exclusions
noted in
study, if any (for example, study includes predominantly or exclu-
sively
smear-positive or “difficult-to-diagnose” patients)
1 - Yes
2 - No
9 - Unknonwn/NR
Describe exclusions as stated in study:
Type of specimen (may include expectorated,
induced, bronchial alveolar lavage (BAL), tracheal aspirates)(check
all that
apply). Assume expectorated sputum if not specifically stated
1 - Expectorated sputum
2 - Induced sputum
3 - Bronchial alveolar lavage or bronchial aspirates
4 - Tracheal aspirates
6 - Other
9 - Unknown/NR
If other, describe types and record numbers:
Clinical setting; describe as written in the paper 1 - Outpatient
2 - Inpatient
3 - Both out- and in-patient
4 - Other, specify
5 - Laboratory based
9 - Unknown/NR
Describe as in paper:
Was Xpert testing performed at point of care?
(POCT is diagnostic testing that will result in a
clear and actionable management decision (e.g.
start of treatment, referral, initiation of confirmatory
test) within the same clinical encounter (e.g. same
day). POCT should be mentioned in the study as
it is unlikely if testing takes place in a central
level laboratory.
1 - Yes
2 - No
9 - Could not tell
Level of the laboratory system where Xpert tests
were performed
(Tests generally available at different laboratory
levels, though tests may overlap)
1- Central
2 - Intermediate
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(Continued)
Central: Intermediate laboratory tests and culture
on liquid media and DST (1st and 2nd line
anti-tuberculosis drugs) on solid or in liquid media and LPA
on positive cultures and rapid speciation tests
Intermediate: Peripheral laboratory tests and
culture on solid media and line probe assay (LPA)
from smear positive sputum
Peripheral: AFB (Ziehl-Neelsen, Auramine-rhodamine,
Auramine-O staining) and Xpert MTB/RIF
3 - Peripheral
4- Other, specify
Describe as in paper:
IV. Other demographics
Age (range, mean (SD), median (IQR)) 9 - Unknown/NR
##/total and % female 9 - Unknown/NR
HIV status of participants 0 - HIV -
1 - HIV +
2 - Both HIV+/-
9 - Unknown/NR
If HIV-positive participants included, what is the percentage? % (specify numerator/denominator)
Prior tuberculosis history:Did the study include patients with prior
tuberculosis history?
1 - Yes
2 - No
9 - Unknown/NR
If so, what is the percentage? % (specify numerator/denominator)
9 - Unknown/NR (for data entry write “NR”)
Prior treatment: Did the study include patients with prior tuber-
culosis treatment?
1 - Yes
2 - No
9 - Unknown/NR
If so, what is the percentage? % (specify numerator/denominator)
9 - Unknown/NR (for data entry write “NR”)
Current treatment: Were patients on treatment (defined as tuber-
culosis drugs for
greater than 7 days) for the current tuberculosis episode?
(note: may impact culture results)
1 - Yes
2 - No
9 - Unknown/NR
If so, what is the percentage? % (specify numerator/denominator)
9 - Unknown/NR (for data entry write “NR”)
V. Index test
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(Continued)
Xpert version(s) evaluated 1 - Xpert MTB/RIF only
2 - Xpert Ultra only
3 - Any combination Xpert MTB/RIF and Xpert Ultra
Xpert platform: Was Omni used? Unless Omni explicitely de-
scribed, assume
standard platform
1 - Yes, only Omni used for Xpert tests
2 - Yes, both Omni and standard platform used for Xpert tests
3 - No
Was the index test result interpreted without knowledge of the
result of
the reference standard result?
1-Yes (Since Xpert is automated, we will answer ‘Yes” for all
studies)
VI. Reference standard
For tuberculosis detection, what reference standard(s) was used? 1 - Solid culture (specify 1a)
2 - Liquid culture (specify 2a)
3 - Both solid and liquid culture (specify 1a and 2a)
9 - Unknown/NR
1a - Solid culture
LJ
7H10
7H11
Other
9- Unknown/NR
2a - Liquid culture
MGIT 960
Other (specify):
9- Unknown/NR
For MGIT only, if more than one specimen was inoculated for
culture, were these specimens obtained on different days?
1 - Yes
2 - No
8 - Not applicable
9 - Unknown/NR
For rifampicin resistance detection, what reference standard(s)
was used?
1 - Solid culture (specify 1a)
2 - Liquid culture (specify 2a)
3 - Both solid and liquid culture (specify 1a and 2a)
4 - MTBDRplus
5 - Other, specify
9 - Unknown/NR
1a - Solid culture
LJ
7H10
7H11
Other
Specify method, e.g., proportion
2a - Liquid culture
MGIT 960
Other (specify)
305Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(Continued)
Tuberculosis detection: Was the reference standard result inter-
preted
without knowledge of the index test result?
Answer yes for MGIT and LJ with species confirmation
1 - Yes
2 - No
9 - Unknown/NR
Rifampicin resistance detection: Was the reference standard
result interpreted without knowledge of the index test result?
Answer yes for MGIT
1 - Yes
2 - No
9 - Unknown/NR
VII. Specimen flow
Were Xpert sample and culture obtained from same specimen? 1 - Yes
2 - No
9 - Unknown/NR
What specimen processing procedure was used before testing
with Xpert?
1 - None
2 - NALC-NaOH
3 - NaOH (Petroff )
4 - Other
9 - Unknown/NR
Was microscopy used? 1 - Yes
2 - No
9 - Unknown/NR
Type of microscopy used 1 - Ziehl-Neelsen
2 - Fluorescence microscopy
3 - Both Ziehl-Neelsen and fluorescence microscopy
9 - Unknown/NR
Smear type (if study used both direct and concentrated,
select concentrated)
1 - Direct
2 - Concentrated (processed)
9 - Unknown/NR
For Xpert specimen, what was the condition of the
specimen when tested?
1 - Fresh
2 - Frozen
3 - Both fresh and frozen
9 - Unknown/NR
VIII. Results
Did the study report % contaminated cultures?
(Enter percentage contaminated cultures, if
provided):
# of contaminated cultures/Total # cultures performed = %
1 - Yes -> % contaminated cultures:
2 - No
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(Continued)
Did the study report the number of uninterpretable
results for Xpert for tuberculosis detection? (invalid, error, no re-
sult)
The uninterpretable rate for detection of PTB is the
number of tests classified as “invalid,” “error,” or “no result”
divided by the total number of Xpert tests performed.
1 - Yes -> # Uninterpretable results:
Denominator is total number of Xpert tests performed
(Add total from Table 1 plus # of uninterpretable results):
2 - No
Did the study report the number of indeterminate results for
Xpert for rifampicin resistance detection?
The indeterminate rate for detection of rifampicin resistance
was the number of tests classified as “MTB detected; Rif
resistance INDETERMINATE” divided by the total number
of Xpert-MTB positive results
1 - Yes -># Indeterminate results:
(Enter 0 indeterminate results if the total number in
Table 6 = the number of TPs in Table1)
Denominator is total number of Xpert tests performed
(Total Xpert positive results from Table 1 first row):
2 - No
Did the study report any Xpert rifampicin resistant positive
results in culture negative specimens?
1 - Yes -> Number reported:
2 - No
Did the study report nontuberculous mycobacteria (NTM)?
Record number NTM over the number of cultures performed
1 - Yes -> Number reported:
2 - No
If NTMs were identified, record number of Xpert positive
results among NTMs
#Xpert positive tests among total number NTMs:
9 - Unknown/NR
Abbreviations: HIV: human immunodeficiency virus; LJ: Löwenstein-Jensen; MGIT: mycobacterial growth indicator tube; NR: Not
reported; NTM: Nontuberculous mycobacteria; PTB: pulmonary tuberculosis.
TABLES, examples
Table 1.
Tuberculosisdetection, all partici-
pants
Confirmed tuberculosis Total
Yes No
Xpert MTB/RIF result Positive
Negative
Total
Table 2.
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Tuberculosis detection, smear pos-
itive
Confirmed tuberculosis Total
Yes No
Xpert MTB/RIF result Positive
Negative
Total
Table 3.
Tuberculosisdetection, smear neg-
ative
Confirmed tuberculosis Total
Yes No
Xpert MTB/RIF result Positive
Negative
Total
Table 4.
Rifampicin resistance detection Rifampicin-resistant Total
Yes No
Xpert MTB/RIF result Positive
Negative
Total
Appendix 4. Rules for QUADAS-2
In QUADAS-2, we assessed methodological quality separately for each of the objectives, Xpert for pulmonary tuberculosis (PTB)
detection and Xpert for rifampicin resistance detection.
Domain 1: Patient selection
Xpert MTB/RIF or Xpert Ultra for PTB detection
Risk of bias: Could the selection of patients have introduced bias?
Signalling question 1: Was a consecutive or random sample of patients enrolled? We answered ‘yes’ if the study enrolled a consecutive or
random sample of eligible patients; ‘no’ if the study selected patients by convenience; and ‘unclear’ if the study did not report the
manner of patient selection or we could not tell.
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Signalling question 2: Was a case-control design avoided? Studies using a case-control design were not included in the review because this
study design, especially when used to compare results in severely ill patients with those in relatively healthy individuals, may lead to
overestimation of accuracy in diagnostic studies. We answered ‘yes’ for all studies.
Signalling question 3: Did the study avoid inappropriate exclusions? We answered ‘yes’ if the study included both smear-positive and
smear-negative individuals; ‘no’ if the study included primarily or exclusively smear-positive or smear-negative patients; and ‘unclear’ if
we could not tell. We also answered ‘no’ if the study included primarily or exclusively patients who had undergone previous treatment
(retreatment patients).
Applicability: Are there concerns that the included patients and setting do not match the review question?
We were interested in how Xpert MTB/RIF or Xpert Ultra performed in patients who were evaluated as they would be in routine
practice. We answered ‘low concern’ if patients were evaluated in local hospitals or primary care centres. We answered ‘high concern’
if patients were evaluated exclusively as inpatients in tertiary care centres. We answered ‘unclear concern’ if the clinical setting was not
reported or there was insufficient information to make a decision. We also answered ‘unclear concern’ if Xpert MTB/RIF or Xpert
Ultra testing was done at a central-level laboratory and the clinical setting was not reported for the following reason. It was difficult to
tell if a given reference laboratory provided services mainly to very sick patients.
Xpert MTB/RIF or Xpert ultra for rifampicin resistance detection
Domain 1: Patient selection is the same as for Xpert for PTB detection except for
Signalling question 3: Did the study avoid inappropriate exclusions? We answered ‘yes’ if the study included both smear-positive and
smear-negative individuals; ‘no’ if the study included primarily or exclusively smear-positive or smear-negative patients; and ‘unclear’
if we could not tell. We answered ‘yes’ if the study included primarily or exclusively retreatment patients because the group at risk for
rifampicin resistance includes patients who had undergone previous treatment.
Domain 2: Index test
Xpert for PTB detection
Risk of bias: Could the conduct or interpretation of the index test have introduced bias?
Signallingquestion 1: Were the index test results interpreted without knowledge of the results of the reference standard? We answered this
question ‘yes’ for all studies because Xpert test results were automatically generated and the user was provided with printable test results.
Thus, there is no room for subjective interpretation of test results.
Signallingquestion 2: If a threshold was used, was it prespecified?The threshold was prespecified in all versions of Xpert. We answered this
question ‘yes’ for all studies.
For risk of bias, we judged ‘low concern’ for all studies.
Applicability: Are there concerns that the index test, its conduct, or its interpretation differ from the review question? Variations in
test technology, execution, or interpretation may affect estimates of the diagnostic accuracy of a test. All steps in the Xpert MTB/
RIF and Xpert Ultra assays are completely automated and self-contained following sample loading. We answered ‘low concern’ if the
index test was performed as recommended by the manufacturer, which was true for most studies. We answered ‘unclear concern’ if the
ratio of the Xpert MTB/RIF or Xpert Ultra sample reagent: specimen volume was not 2:1 for a raw specimen or 3:1 for a sediment,
as recommended by the manufacturer. Central-level laboratories use more highly trained staff than peripheral and intermediate-level
laboratories. However, we did not consider this to be a concern about applicability because, in some studies, the reason Xpert MTB/
RIF or Xpert Ultra was performed in a central-level laboratory was the requirement for a sophisticated laboratory infrastructure to
perform culture (reference standard) not to perform Xpert.
Xpert for rifampicin resistance detection
Domain 2: Index test is the same as for Xpert for PTB detection.
Domain 3: Reference standard
Xpert for PTB detection
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Risk of bias: Could the reference standard, its conduct, or its interpretation have introduced bias?
Signallingquestion 1: Is the reference standard likely to correctly classify the target condition?
We answered ‘yes’ for all studies, since culture as a reference standard was a criterion for inclusion in the review.
Signallingquestion 2: Were the reference standard results interpreted without knowledge of the results of the index test?
We answered ‘yes’ if the reference test provided an automated result (for example, MGIT 960), blinding was explicitly stated, or it was
clear that the reference standard was performed at a separate laboratory and/or performed by different people. We answered ‘no’ if the
study stated that the reference standard result was interpreted with knowledge of the Xpert MTB/RIF or Xpert Ultra test result. We
answered ‘unclear’ if we could not tell.
Applicability: Are there concerns that the target condition as defined by the reference standard does not match the question? We
answered ‘high concern’ if included studies did not speciate mycobacteria isolated in culture; ‘low concern’ if speciation was performed;
and ‘unclear concern’ if we could not tell.
Xpert for rifampicin resistance detection
Risk of bias: Could the selection of patients have introduced bias?
Signallingquestion 1: Is the reference standard likely to correctly classify the target condition?
We answered ‘yes’ if either culture-based drug susceptibility testing (DST) or MTBDRplus was used. These were criteria for inclusion
for this objective of the review.
Signallingquestion 2: Were the reference standard results interpreted without knowledge of the results of the index test?
We answered ‘yes’ if the reference test provided an automated result (for example, MGIT 960), blinding was explicitly stated, or it was
clear that the reference standard was performed at a separate laboratory and/or performed by different people. We answered ‘no’ if the
study stated that the reference standard result was interpreted with knowledge of the Xpert MTB/RIF or Xpert Ultra test result. We
answered ‘unclear’ if we could not tell.
Applicability: Are there concerns that the target condition as defined by the reference standard does not match the question? We judged
applicability to be of ‘low concern’ for those studies evaluating Xpert for rifampicin resistance because these specimens had already been
identified as Mycobacterium tuberculosis positive.
Domain 4: Flow and timing
Xpert for PTB detection
Risk of bias: Could the patient flow have introduced bias?
Signallingquestion 1: Was there an appropriate interval between the index test and reference standard? In most included studies, we expected
that specimens for Xpert MTB/RIF or Xpert Ultra and culture would be obtained at the same time, when patients were evaluated
for presumptive PTB. However, even if there were a delay of several days between index test and reference standard, tuberculosis is a
chronic disease and we considered misclassification of disease status to be unlikely, as long as treatment was not initiated in the interim.
We answered ‘yes’ if the index test and reference standard were performed at the same time or if the time interval was less than or equal
to seven days, ‘no’ if the time interval is greater than seven days, and ‘unclear’ if we could not tell.
Signallingquestion 2: Did all patients receive the same reference standard? We answered this question ‘yes’ for all studies as an acceptable
reference standard (either solid or liquid culture) was specified as a criterion for inclusion in the review. However, we acknowledge that
it is possible that some specimens could undergo solid culture and others liquid culture. This could potentially result in variations in
accuracy, but we thought the variation would be minimal.
Signallingquestion 3: Were all patients included in the analysis? We determined the answer to this question by comparing the number of
patients enrolled with the number of patients included in the 2 x 2 tables. We answered ‘yes’ if the numbers matched and ‘no’ if there
were patients enrolled in the study that were not included in the analysis. We answered ‘unclear’ if we could not tell.
Xpert for rifampicin resistance detection
Domain 4: Flow and timing is the same as for Xpert MTB/RIF or Xpert Ultra for PTB detection.
Judgements for ‘risk of bias’ assessments for a given domain
• If we answered all signalling questions for a domain ‘yes’, then we judged risk of bias as ‘low’.
• If we answered all or most signalling questions for a domain ‘no’, then we judged risk of bias as ‘high’.
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• If we answered only one signalling question for a domain ‘no’, we discussed further the ‘Risk of bias’ judgement.
• If we answered all or most signalling questions for a domain ‘unclear’, then we judged risk of bias as ‘unclear’.
• If we answered only one signalling question for a domain ‘unclear’, we discussed further the ‘Risk of bias’ judgement for the
domain.
Appendix 5. Statistical appendix
Bayesian bivariate hierarchical model
The Bayesian bivariate hierarchical model used for the meta-analyses is summarized below. The hierarchical framework took into
account heterogeneity between studies and also between centres within two of the largest studies. The model was derived as an extension
of previously described models (Chu 2009; Reitsma 2005). An OpenBUGS program to fit this model is provided below. Three
independent, dispersed sets of starting values were used to run separate chains. The Gelman-Rubin statistic within the OpenBUGS
program was used to assess convergence. No convergence problems were observed. The first 10,000 iterations were treated as burn-
in iterations and dropped. Summary statistics were obtained based on a total of 150,000 iterations resulting from the three separate
chains.
Notation: From the jth centre in the ith study we extracted the cross-tabulation between the index and reference tests TPij, FPij, TNij,
FNij. The sensitivity in ijth study is denoted by Sij and the specificity by SPij. We denote the Binomial probability distribution with
sample size N and probability p as Binomial(p,N), the Bivariate Normal probability distribution with mean vector µ and variance-
covariance matrix 6 as BVN(µ, 6), the univariate Normal distribution with mean m and variance s by N(m, s) and the Uniform
probability distribution between a and b by Uniform(a,b).
Likelihood Figure 22
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Figure 22. Bayesian bivariate hierarchical model, likelihood.
The pooled sensitivity is given by 1/1+exp (-µ1) and pooled specificity as 1/1+exp (µ2).
Prior distributions Figure 23.
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Figure 23. Bayesian bivariate hierarchical model, prior distributions.
Prior distributions were placed over the coefficients in the linear function: a1 and a2~ N(0,4) and b1 and b2~ N(0,1.39) (Buzoianu
2008).
----------------------------------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------
# BIVARIATE MODEL ASSUMING PERFECT CULTURE REFERENCE TEST
# ALLOWING FOR HETEROGENEITY BETWEEN CENTRES WITHIN TWO OF
# THE STUDIES (BOEHME 2010 and BOEHME 2011)
model {
############################# BOEHME 2010
for(j in 1:5) {
logit(TPR.q[j])<- q1[j,1]
logit(FPR.q[j])<- -q1[j,2]
pos1[j]<-TP1[j]+FN1[j]
neg1[j]<-TN1[j]+FP1[j]
TP1[j] ~ dbin(TPR.q[j],pos1[j])
FP1[j] ~ dbin(FPR.q[j],neg1[j])
se.q[j] <- TPR.q[j]
sp.q[j] <- 1-FPR.q[j]
q1[j,1:2]~ dmnorm(l[1,1:2], T1[1:2,1:2])
}
T1[1:2,1:2]<-inverse(SIGMA1[1:2,1:2])
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SIGMA1[1,1] <- sigma1[1]*sigma1[1]
SIGMA1[2,2] <- sigma1[2]*sigma1[2]
SIGMA1[1,2] <- k1*sigma1[1]*sigma1[2]
SIGMA1[2,1] <- k1*sigma1[1]*sigma1[2]
sigma1[1] <- pow(prec1[1],-0.5) # replaced by sigma1[1] ~ dunif(0,3) in sensitivity analysis to check impact of less informative prior
sigma1[2] <- pow(prec1[2],-0.5) # replaced by sigma1[2] ~ dunif(0,3) in sensitivity analysis to check impact of less informative prior
prec1[1] ~ dgamma(2,0.5) # replaced by prec1[1] <- pow(sigma1[1],-2) in sensitivity analysis to check impact of less informative prior
prec1[2] ~ dgamma(2,0.5) # replaced by prec1[2] <- pow(sigma1[2],-2) in sensitivity analysis to check impact of less informative prior
k1 ~ dunif(-1,1)
se[1]<-1/(1+exp(-l[1,1]))
sp[1]<-1/(1+exp(l[1,2]))
l[1,1:2] ~ dmnorm(mu[1:2], T[1:2,1:2])
############################# BOEHME 2011
for(j in 1:6) {
logit(TPR.r[j])<- r1[j,1]
logit(FPR.r[j])<- -r1[j,2]
pos2[j]<-TP2[j]+FN2[j]
neg2[j]<-TN2[j]+FP2[j]
TP2[j] ~ dbin(TPR.r[j],pos2[j])
FP2[j] ~ dbin(FPR.r[j],neg2[j])
se.r[j] <- TPR.r[j]
sp.r[j] <- 1-FPR.r[j]
r1[j,1:2]~ dmnorm(l[2,1:2], T2[1:2,1:2])
}
T2[1:2,1:2]<-inverse(SIGMA2[1:2,1:2])
SIGMA2[1,1] <- sigma2[1]*sigma2[1]
SIGMA2[2,2] <- sigma2[2]*sigma2[2]
SIGMA2[1,2] <- k2*sigma2[1]*sigma2[2]
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SIGMA2[2,1] <- k2*sigma2[1]*sigma2[2]
sigma2[1] <- pow(prec2[1],-0.5) # replaced by sigma2[1] ~ dunif(0,3) in sensitivity analysis to check impact of less informative prior
sigma2[2] <- pow(prec2[2],-0.5) # replaced by sigma2[2] ~ dunif(0,3) in sensitivity analysis to check impact of less informative prior
prec2[1] ~ dgamma(2,0.5) # replaced by prec2[1] <- pow(sigma2[1],-2) in sensitivity analysis to check impact of less informative prior
prec2[2] ~ dgamma(2,0.5) # replaced by prec2[2] <- pow(sigma2[2],-2) in sensitivity analysis to check impact of less informative prior
k2 ~ dunif(-1,1)
se[2]<-1/(1+exp(-l[2,1]))
sp[2]<-1/(1+exp(l[2,2]))
l[2,1:2] ~ dmnorm(mu[1:2], T[1:2,1:2])
############################# SINGLE CENTRE STUDIES
for(i in 3:70) {
############################# LIKELIHOOD
logit(TPR[i]) <- l[i,1]
logit(FPR[i]) <- -l[i,2]
pos[i]<-TP[i]+FN[i]
neg[i]<-TN[i]+FP[i]
TP[i] ~ dbin(TPR[i],pos[i])
FP[i] ~ dbin(FPR[i],neg[i])
se[i] <- TPR[i]
sp[i] <- 1-FPR[i]
l[i,1:2] ~ dmnorm(mu[1:2], T[1:2,1:2])
}
############################# HYPER PRIOR DISTRIBUTIONS
mu[1] ~ dnomr(0.0.25) # replaced by mu[1] ~ dnorm(0,0.01) in sensitivity analysis to check impact of less informative prior
mu[2] ~ dnomr(0.0.25) # replaced by mu[2] ~ dnorm(0,0.01) in sensitivity analysis to check impact of less informative prior
T[1:2,1:2]<-inverse(TAU[1:2,1:2])
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#### BETWEEN-STUDY VARIANCE-COVARIANCE MATRIX
TAU[1,1] <- tau[1]*tau[1]
TAU[2,2] <- tau[2]*tau[2]
TAU[1,2] <- rho*tau[1]*tau[2]
TAU[2,1] <- rho*tau[1]*tau[2]
tau[1] <- pow(prec[1],-0.5) # replaced by tau[1] ~ dunif(0,3) in sensitivity analysis to check impact of less informative prior
tau[2] <- pow(prec[2],-0.5) # replaced by tau[2] ~ dunif(0,3) in sensitivity analysis to check impact of less informative prior
#### prec = between-study precision in the logit(sensitivity)and logit(specificity)
prec[1] ~ dgamma(2,0.5) # replaced by prec[1] <- powtau[1],-2) in sensitivity analysis to check impact of less informative prior
prec[2] ~ dgamma(2,0.5) # replaced by prec[2] <- powtau[2],-2) in sensitivity analysis to check impact of less informative prior
rho ~ dunif(-1,1)
############################# OTHER PARAMETERS OF INTEREST
#### POOLED SENSITIVITY AND SPECIFICITY
Pooled˙S<-1/(1+exp(-mu[1]))
Pooled˙C<-1/(1+exp(-mu[2]))
#### PREDICTED SENSITIVITY AND SPECIFICITY IN A FUTURE STUDY
l.new[1:2] ~ dmnorm(mu[],T[,])
sens.new <- 1/(1+exp(-l.new[1]))
spec.new <- 1/(1+exp(-l.new[2]))
} #### END OF PROGRAM
############################################################################
############################## DATA #####################################
# DATA WAS READ FROM THREE SEPARATE FILES
# DATA 1 - BOEHME 2010
TP1[] FP1[] FN1[] TN1[]
123 8 24 91
201 1 8 105
136 9 10 188
36 7 7 257
179 1 8 40
END
#row 1 : Azerbaijan
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#row 2 : Peru
#row 3 : South Africa, Cape Town
#row 4 : South Africa, Durban
#row 5 : India
############################################################################
# DATA 2 - FROM BOEHME 2011
TP2[] FP2[] FN2[] TN2[]
203 4 26 303
171 3 6 825
201 2 32 669
121 0 24 144
101 16 0 671
136 5 12 234
END
#row 1 : Azerbaijan
#row 2 : Peru
#row 3 : South Africa
#row 4 : Uganda
#row 5 : India
#row 6 : The Philippines
############################################################################
# DATA 3 - OTHER STUDIES
TP[] FP[] FN[] TN[]
NA NA NA NA
NA NA NA NA
3 2 3 204
8 0 7 110
16 1 17 70
11 1 1 147
81 13 41 677
191 1 44 55
21 2 5 66
27 5 8 155
# ...
# DATA HAVE BEEN TRUNCATED FOR EASE OF PRESENTATION IN THIS APPENDIX
# THE COMPLETE DATA CAN BE FOUND IN Figure 10
# ...
89 5 8 234
11 1 14 475
94 10 29 291
68 15 13 129
111 19 30 320
154 27 31 517
197 6 30 180
84 8 79 1006
31 0 4 68
6 0 1 110
END
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# row 1 Boheme 2010
# row 2 Boheme 2011
# row 3 Adelman 2015
# row 4 Al-darraji 2013
# row 5 Atwebembeire 2016
# row 6 Balcells 2012
# row 7 Balcha 2014
# row 8 Barmankulova 2015
# row 9 Bates 2013
# row 10 Bjerrum 2016
# ...
# DATA HAVE BEEN TRUNCATED FOR EASE OF PRESENTATION IN THIS APPENDIX
# THE COMPLETE DATA CAN BE FOUND IN Figure 10
# ...
# row 60 Sharma 2015
# row 61 Shenai 2016
# row 62 Sohn 2014
# row 63 Ssengooba 2014
# row 64 Tang 2017
# row 65 Theron 2011
# row 66 Theron 2014
# row 67 Tsuyuguchi 2017
# row 68 Yoon 2017
# row 69 Zeka 2011
# row 70 Zmak 2013
Appendix 6. Bayesian bivariate hierarchical model
Figure 22 Bayesian bivariate hierarchical model, likelihood
Figure 23 Bayesian bivariate hierarchical model, prior distributions
F E E D B A C K
Boyles, 7 October 2014
Summary
Name: Tom Boyles
Affiliation: University of Cape Town
I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my
feedback.
In the initial version of Steingart et al’s systematic review of the Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin
resistance in adults (Steingart 2013) includes 15 studies where Xpert MTB/RIF was used as an initial test replacing smear microscopy,
with themajority of patients being drawn from twomajor studies (Boehme 2010, Boehme 2011).My comment relates to the appropriate
reference standard for tuberculosis is these studies. The systematic review appraised the quality of included studies with the Quality
Assessment of Diagnostic Accuracy Studies (QUADAS-2) (Whiting 2011) tool which states that estimates of test accuracy are based
on the assumption that the reference standard is 100% sensitive and that specific disagreements between the reference standard and
index test result from incorrect classification by the index test.
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For each of the studies in question the reference standard for tuberculosis is listed as “Löwenstein-Jensen culture and MGIT 960” and
the review considers that the reference standard is likely to correctly classify the target condition. There is considered to be low risk of
bias or applicability concerns relating to the reference test.
However, in Boehme et al 2010 there were 105 patients with ‘clinical tuberculosis’ who were excluded from the analysis. These patients
were negative by the reference standard of Löwenstein-Jensen culture and MGIT 960 and should have been included in the ‘no
tuberculosis’ group. In Boehme et al 2011 there were 153 similar patients who were excluded from the analysis.
Neither paper gives justification for the exclusion of these patients who according toQUADAS-2were negative by the reference standard
and should be included in the ‘no tuberculosis’ group. Ideally the systematic review should be amended to include these patients but if
the data is unavailable the risk of bias should be acknowledged.
Note from the Editors: In addition to the above feedback, Boyles et al. published a case study in The International Journal of Tuberculosis and
Lung Disease which outlined the above arguments, and illustrates this with a case study (Boyles 2014); which the Cochrane authors respond
to, in the same journal (see below).
Reply
The review authors thank Boyles et al. for this comment. They raise important points about the selective exclusion of culture negative
clinical tuberculosis cases in the Boehme studies.
We considered the published case study (Boyles 2014) in detail, and in response we carried out additional analyses to determine whether
the Boehme studies unduly influenced the overall findings of this Cochrane review. One way we did this was by repeating the meta-
analysis with studies for which we could extract data for all enrolled participants, including patients classified as ‘clinical tuberculosis’
with negative sputum culture. We considered these participants as not having tuberculosis. In the new analysis, we found pooled
sensitivity and specificity estimates to be similar to those we previously reported.
We published our findings as a response to Boyles et al. in The International Journal of Tuberculosis and Lung Disease (Steingart 2015).
In the updated Cochrane Review, for Boehme 2010, we included culture negative results (clinical tuberculosis cases) in determinations
of Xpert MTB/RIF specificity. For Boehme 2011, we did not have data for clinical tuberculosis, and therefore, in the Flow and Timing
domain, we changed our judgement for risk of bias to ‘high’.
WH A T ’ S N E W
Date Event Description
5 June 2019 New citation required but conclusions have not changed The findings in this update are consistent with those re-
ported previously (Steingart 2014).
5 June 2019 New search has been performed The review authors identified 95 unique studies, integrat-
ing 77 new studies since publication of the Cochrane Re-
view (Steingart 2014).
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H I S T O R Y
Protocol first published: Issue 1, 2012
Review first published: Issue 1, 2013
Date Event Description
30 June 2015 Amended Added revised data including (smear positive culture
negatives) for Boehme 2010 and Rachow. Added cor-
rected data for Hanrahan. Added test and analysis for
Hx of TB. Amended patient selection for Boehme
2011 to high risk of bias
16 March 2015 Feedback has been incorporated Feedback from Dr Tom Boyles at University of Cape
Town has been incorporated and responded to
6 May 2014 Amended Following information from one of the trial authors,
details of the version of Xpert MTB/RIF used in
Balcells 2012 have been corrected.
13 February 2014 Amended Sentence moved in abstract; corrected ’pooled median
sensitivity’ to ’median pooled sensitivity’ throughout
30 November 2013 New search has been performed 1. We performed an updated literature search on 7
February 2013.
2. For smearmicroscopy as a comparator test, we added
a descriptive plot showing the estimates of sensitivity
and specificity of Xpert compared with those of smear
microscopy in studies that reported on both tests.
3. We included studies using Xpert version G4 (two
studies) and studies evaluating Xpert in primary care
clinics (two studies). These studies did not change the
overall findings.
4. We improved the QUADAS-2 assessment concern-
ing applicability.
5. For TB detection, we repeated our earlier meta-
regression analyses within subgroups defined by smear
status.
6. For rifampicin resistance detection, we performed
univariate meta-analyses for sensitivity and specificity
separately in order to include studies in which no ri-
fampicin resistance was detected.We also performed a
sensitivity analysis using the bivariate random-effects
model for the subset of studies that provided data for
both sensitivity and specificity.
7.We revised the summary of findings table to include
clinical scenarios with prevalence levels recommended
by the World Health Organization.
8. In the Background, we shortened the section on al-
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(Continued)
ternative tests to include only those tests most relevant
to the review.
9. We added health economic considerations to the
Discussion.
10. We added updated TB surveillance information.
30 November 2013 New citation required but conclusions have not
changed
We conducted a new search and revised the review as
described
17 January 2013 Amended We made some minor edits to the text to correct typo-
graphical errors. In addition, we replaced Figures 6, 8,
11, and 13 with new figures with minor modifications
to the prediction regions
C O N T R I B U T I O N S O F A U T H O R S
MP conceived the original idea for the review.
KRS, MP, and ND wrote the original protocol.
For this updated Cochrane Review, Vittoria Lutje designed the search strategy.
DJH, MK, JSZ, DT, and KRS assessed articles for inclusion and extracted data.
MK and JSZ managed REDCap.
DJH, MK, IS, ND, and KRS analysed the data and interpreted the analyses.
DJH, MK, IS, ND, and KRS drafted the manuscript. In particular, IS and ND drafted the statistical analysis section and the statistical
appendix. EAO drafted the section on patient health outcomes.
SGS and MP provided critical comments to the manuscript.
All authors read and approved the final manuscript draft.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol we stated that we would extract data on industry sponsorship. However, we became aware that FIND had negotiated
a special price for the assay for tuberculosis-endemic countries. As most of the included studies were located in tuberculosis-endemic
countries, we assumed Xpert had been purchased at the negotiated price. We therefore did not consider the included studies to be
sponsored by industry.
We stated we would discuss the consequences when an uninterpretable test result was considered to be a (false) true negative result (may
lead to missed or delayed diagnosis, with potential for increased morbidity, mortality, and tuberculosis transmission), or considered
to be a (false) true positive result (may lead to unnecessary treatment with adverse events and increased anxiety). Since the rate of
uninterpretable results was very low, we did not discuss these consequences.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Drug Resistance, Bacterial; Antibiotics, Antitubercular [∗therapeutic use]; Mycobacterium tuberculosis [∗drug effects; genetics;
∗isolation & purification]; Polymerase Chain Reaction [∗methods]; Rifampin [∗therapeutic use]; Sensitivity and Specificity; Sequence
Analysis, DNA [methods]; Tuberculosis, Pulmonary [diagnosis; ∗drug therapy]
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